CDKL5 Deficiency Disorder

Mendelian MONDO:0100039 Pathograph 66 Show in embeddings browser Epilepsy Neurodevelopmental Disorder Neurological Disease

CDKL5 deficiency disorder (CDD) is an X-linked developmental and epileptic encephalopathy caused by pathogenic variants that reduce CDKL5 function. Severe seizures usually begin in early infancy, accompanied by developmental impairment, hypotonia, cerebral visual impairment, movement abnormalities, and sleep, gastrointestinal and autonomic problems. Rare individuals have milder development or no epilepsy. Females are diagnosed more often than males, but both sexes can be severely affected. Most affected individuals are simplex cases, commonly with a de novo variant; inherited variants and parental or postzygotic mosaicism also occur. CDKL5 has both kinase-dependent and kinase-independent neuronal functions.

Ask OpenScientist

Ask a research question about CDKL5 Deficiency Disorder. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

🏷

Classifications

Harrison's Part

🔗

Mappings

MONDO

MONDO:0100039 CDKL5 disorder

MONDO:0100039 is the current CDKL5 disorder concept, with "CDKL5 Deficiency Disorder" as an exact synonym.

👪

Inheritance

X-linked inheritance HP:0001417

CDD is X-linked. Approximately 99% of reported affected individuals are simplex, meaning the only known affected family member; this is not a measured 99% de novo rate. Most tested variants arise de novo, but transmission from an affected or apparently unaffected heterozygous mother and parental mosaicism are documented. X-inactivation and mosaicism modify expression; blood X-inactivation need not represent brain tissue. A heterozygous mother has a 50% chance of transmitting the variant in each pregnancy. Prenatal and preimplantation testing are possible once the familial variant is known.

X-linked inheritance

Show evidence (4 references)

PMID:38603524 SUPPORT DIRECT REVIEW SYNTHESIS Other

"CDD is inherited in an X-linked manner."

GeneReviews establishes X-linked inheritance.

PMID:38603524 SUPPORT DIRECT REVIEW SYNTHESIS Other

"Approximately 99% of affected individuals represent simplex cases"

Simplex describes family history; it does not demonstrate that every variant arose de novo.

PMID:38603524 SUPPORT DIRECT REVIEW SYNTHESIS Other

"If the mother of the proband has a CDKL5 pathogenic variant, the chance of transmitting it in each pregnancy is 50%."

GeneReviews states the transmission probability for a mother carrying the pathogenic variant.

+ 1 more reference

Discussions and Knowledge Gaps

Which catalytic substrates and kinase-independent scaffold functions account for distinct developmental, visual, movement and seizure outcomes, and which are suitable therapeutic targets?

KNOWLEDGE GAP OPEN gap_cdkl5_substrate_to_phenotype_causality

Attached to

pathophysiology#Loss of CDKL5 Kinase Activity in Neurons pathophysiology#Impaired Dendritic Spine Plasticity

EB2 and MAP1S have physiological phosphorylation evidence; ARHGEF2 remains less secure in vivo. CaV2.3 phosphosite experiments establish a context-dependent channel mechanism but do not reproduce spontaneous human epilepsy. Kinase-independent CLIP170/dynactin assembly and PSD95 condensate organization add distinct candidate pathways. Biomarker restoration, direct substrate validation and rescue of a disease-relevant phenotype are different claims.

Proposed experiments

Substrate-specific rescue in CDKL5-deficient human neurons

substrate-specific rescue experiment

exp_cdkl5_substrate_phenotype_dissection

Compare substrate-specific manipulations and scaffold-selective CDKL5 rescue in patient/isogenic cortically specified neurons. Verify each manipulation biochemically before measuring firing, synchrony and spine plasticity. MAP1S Ser786/812Asp previously failed to mimic phosphorylation, so it is not a validated rescue reagent. Include wild-type CDKL5, kinase-dead CDKL5, phosphorylation-deficient and scaffold-deficient controls, with matched protein abundance.

Readouts

Network excitability versus maturation

pathophysiology#Impaired Dendritic Spine Plasticity

Dendritic spine development GO:0060996 ↓ DECREASED

multielectrode array recording

Direction: POSITIVE

Controls

CDKL5-corrected isogenic neurons

Isogenic CDKL5-restored neurons as the normalization reference.

Biochemically validated substrate and scaffold controls

Measure phosphorylation, binding and expression directly; compare matched kinase-dead and scaffold-deficient constructs rather than presuming any acidic substitution is a valid phosphomimetic.

Decision criterion

A manipulation supports a causal contribution only if it restores the intended biochemical event and reproducibly improves a prespecified functional readout across independent donors and differentiations; rescue of pEB2 alone is insufficient.

Would support

pathophysiology#Impaired Dendritic Spine Plasticity

Show evidence (3 references)

PMID:30266824 SUPPORT In Vitro

"EB2 phosphorylation is reduced in patient-derived human neurons."

Establishes human-relevant CDKL5 substrates but does not resolve which phospho-event causes which clinical feature, which is the open question.

PMID:30266824 SUPPORT DIRECT PRIMARY RESULT In Vitro

"A putative phosphomimetic MAP1S-LC mutant did not act like phosphorylated MAP1S-LC"

A phosphomimetic cannot be assumed to reproduce actual phosphorylation.

PMID:40847610 SUPPORT DIRECT PRIMARY RESULT In Vitro

"the re-expression of both CDKL5-WT and CDKL5-A40V restored the localization of p150glued"

Kinase-dead rescue supports a scaffold branch.

Can restoring CDKL5 after symptom onset reverse established disease, and what is the developmental window during which CDKL5 gene-replacement or reactivation is effective in humans?

KNOWLEDGE GAP OPEN gap_cdkl5_reversibility_treatment_window

Attached to

pathophysiology#Impaired Dendritic Spine Plasticity pathophysiology#Early-Onset Intractable Epilepsy

Post-developmental reversibility has already been demonstrated for several mouse phenotypes. Six-week endogenous restoration improves many behaviors and reduces later female spasms; six-month rescue is less effective, and working memory remains impaired. The unresolved questions are delivery, dose, mosaic coverage and human developmental timing, not whether any postnatal rescue is possible.

Proposed experiments

Delivery and mosaic-coverage comparison across treatment ages

timed gene-reactivation experiment

exp_cdkl5_reactivation_timing

Extend the existing six-week versus six-month endogenous-restoration experiments using clinically relevant delivery, graded neuronal coverage and heterozygous female models. Compare established seizures, EEG, vision and prespecified behavioral endpoints, with vector dose and expression controlled. Include older symptomatic animals rather than interpreting neonatal prevention as reversal.

Readouts

Reversal of deficits by restoration age

pathophysiology#Early-Onset Intractable Epilepsy

electroencephalography behavioral assay

Direction: POSITIVE

Controls

Never-reactivated and wild-type

Matched never-reactivated mutants and wild-type controls.

Decision criterion

An intervention supports translational reversibility only when functional benefit follows verified target engagement after symptom onset, persists longitudinally, and is separable from leaky recombination or nonspecific treatment effects.

Would support

pathophysiology#Impaired Dendritic Spine Plasticity

Show evidence (2 references)

PMID:39855191 SUPPORT DIRECT PRIMARY RESULT Model Organism

"The working memory deficits present in both CDD models are not reversible regardless of the age of rescue or sex."

The full study separates reversible domains from a persistent deficit.

PMID:39855191 SUPPORT DIRECT PRIMARY RESULT Model Organism

"Seizure prevention is more effective with early intervention in heterozygous females but becomes limited after seizure onset."

Timing affects seizure rescue; mouse ages cannot be mapped directly to human treatment windows.

How do sex, mosaicism, age, cell-type-specific deletion and neuronal differentiation affect the epilepsy fidelity of CDKL5 models?

HUMAN MODEL MISMATCH OPEN gap_cdkl5_mouse_model_epilepsy_fidelity

Attached to

pathophysiology#Neuronal Network Hyperexcitability pathophysiology#Early-Onset Intractable Epilepsy

Adult constitutive-null males in early studies lacked spontaneous seizures, whereas older heterozygous females develop spasms and other seizure phenotypes. CaV2.3 phosphosite mice reproduce a selected channel defect without spontaneous epilepsy. Human cortical organoid-derived cultures show transient early hyperexcitability that is absent in NGN2-induced cultures. These comparisons define endpoint-specific model suitability rather than one universally valid or invalid CDD model.

Proposed experiments

Seizure-susceptibility comparison across CDKL5 models

cross-model seizure-susceptibility experiment

exp_cdkl5_seizure_provocation_cross_model

Compare longitudinal spontaneous EEG, age-matched provoked seizure thresholds and independently measured cellular network activity across constitutive males, mosaic females, conditional knockouts and patient-derived cortical cultures. Analyze each endpoint within species and developmental stage; a culture cannot reproduce clinical seizure semiology.

Readouts

Spontaneous and provoked epileptiform activity

pathophysiology#Neuronal Network Hyperexcitability

electroencephalography multielectrode array recording

Direction: POSITIVE

Controls

Wild-type and isogenic-corrected systems

Matched non-mutant references for each model system.

Decision criterion

Validate a model for a specified endpoint when it reproducibly reproduces that endpoint with appropriate controls; distinguish spontaneous epilepsy, provoked susceptibility and cultured network activity, rather than requiring every model to reproduce the full human syndrome.

Would support

pathophysiology#Early-Onset Intractable Epilepsy

Show evidence (3 references)

PMID:24838000 NO_EVIDENCE DIRECT PRIMARY RESULT Model Organism

"did not reveal spontaneous epileptiform activity in hemizygous male Cdkl5 knockout mice"

The negative result is age- and genotype-specific.

PMID:39855191 SUPPORT DIRECT PRIMARY RESULT Model Organism

"female mice with heterozygous loss of Cdkl5 develop myoclonic and tonic-clonic seizures upon aging"

The later female phenotype prevents generalizing the adult male negative finding.

PMID:40930428 NO_EVIDENCE DIRECT PRIMARY RESULT In Vitro

"Induced neurons showed no detectable differences between cases and isogenic controls in network activity using a multielectrode array"

A negative NGN2 result contrasts with the early cortical organoid-derived network phenotype.

What explains the bidirectional association between fever and seizure frequency in CDD?

KNOWLEDGE GAP OPEN gap_cdkl5_fever_association

Attached to

pathophysiology#Early-Onset Intractable Epilepsy

A retrospective Chinese survey reported decreased seizures during fever in 47/84 participants, increased seizures in 19/84 and little change in 18/84. Reporting and selection bias remain, and no mechanistic intervention was performed. This is an association requiring prospective study, not a recommendation to induce fever.

Show evidence (1 reference)

PMID:42644218 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Meanwhile, 19 (22.6%) experienced increased seizure frequency, and 18 (21.4%) showed insignificant change."

The full text documents opposing responses, qualifying the abstract focus on reduction.

⚙

Pathophysiology

CDKL5 Loss-of-Function Variant

Mechanism confidence: Established

Pathogenic coding or splice variants and deletions alter the CDKL5 gene. Some reduce protein abundance, while others impair catalytic or interaction properties without eliminating protein. Variants may be de novo, inherited or mosaic; loss of kinase activity does not by itself test every scaffold function.

CDKL5 hgnc:11411 ⇓ LOSS OF FUNCTION

Downstream

Reduced Functional CDKL5 Protein Protein-truncating or destabilizing alleles can reduce functional protein abundance.

Loss of CDKL5 Kinase Activity in Neurons Catalytic-domain variants can reduce enzymatic activity even when protein remains present.

Show evidence (1 reference)

PMID:38603524 SUPPORT DIRECT REVIEW SYNTHESIS Other

"The diagnosis of CDD is established in a female proband with suggestive clinical findings and a heterozygous CDKL5 pathogenic variant identified by molecular genetic testing."

The molecular diagnosis establishes the initiating genetic cause, with variable downstream biochemical consequences.

CDKL5 Noncoding Exon Deletion

Mechanism confidence: Provisional

Deletions involving noncoding exon 1 or alternative 5-prime exons can remove regulatory or transcript-start sequences. The 15-female series includes unresolved variants; promoter disruption, altered isoform usage and other regulatory effects must be distinguished from proven coding loss.

CDKL5 hgnc:11411

Downstream

Reduced CDKL5 Transcript Abundance Patient fibroblast RNA supports an expression consequence in three tested deletion carriers; the precise regulatory mechanism and neuronal effect remain unresolved.

Show evidence (1 reference)

PMID:39205479 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"We identified 15 females with deletions affecting the 5’ UTR region of CDKL5."

The clinical series identifies noncoding deletions as a distinct physical alteration, with case-specific interpretation.

Reduced CDKL5 Transcript Abundance

Mechanism confidence: Provisional

Fibroblasts from three individuals with noncoding deletions had reduced CDKL5 expression relative to controls. The major coding sequence can be preserved. These assays support a dosage effect but do not establish the same magnitude in neurons or pathogenicity of every 5-prime deletion.

Downstream

Reduced Functional CDKL5 Protein Reduced transcript availability is expected to reduce protein production; protein and neuronal dosage require further validation.

Show evidence (1 reference)

PMID:39205479 SUPPORT DIRECT PRIMARY RESULT In Vitro

"RNA sequencing showed that all three variants were associated with reductions in CDKL5 mRNA levels (normalized expression levels of 25.6%, 17.5% and 56.7% for individuals 1, 2 and 3, respectively, relative to controls)"

RNA measurements in three patient fibroblast lines support reduced transcript abundance.

Reduced Functional CDKL5 Protein

Mechanism confidence: Established

Loss of CDKL5 protein removes catalytic and structural functions. Protein depletion is directly established in knockout models and selected patient cell lines; not every pathogenic missense allele eliminates protein.

Animal models

cdkl5sa21938 Zebrafish Danio rerio perturbs Perturbs the ortholog and measures broad transcriptional consequences.

Downstream

Loss of CDKL5 Kinase Activity in Neurons Loss of the enzyme reduces phosphorylation of its substrates.

Impaired CLIP170-Dynactin Association CDKL5 depletion weakens the CLIP170-dynactin complex independently of catalytic activity.

Altered Postsynaptic Condensate Organization Loss of CDKL5 disrupts its contribution to PSD95-associated condensates.

Increased Postsynaptic NMDA Receptor Abundance Interneuron-specific loss increases postsynaptic NMDAR abundance through an unresolved non-cell-autonomous route.

Reduced Dendritic Arborization Selected mouse ages and neuronal compartments show reduced arborization; this effect is not uniform across models.

Cortical Visual Impairment Knockout models show visual processing deficits, supporting but not fully resolving the human visual phenotype.

Show evidence (1 reference)

PMID:24838000 SUPPORT DIRECT PRIMARY RESULT Model Organism

"confirmed the absence of Cdkl5 protein in hemizygous male and homozygous female knockout mice and intermediate levels in heterozygous females."

Protein abundance follows genotype in the exon-4 deletion model; mutant RNA itself escapes nonsense-mediated decay.

Loss of CDKL5 Kinase Activity in Neurons

Mechanism confidence: Established

Reduced enzymatic activity lowers phosphorylation of validated neuronal substrates. EB2/MAPRE2 and MAP1S phosphorylation are reduced in knockout brain; ARHGEF2 was a chemical-genetic candidate whose physiological phosphorylation was not specifically validated in the same study.

neuron CL:0000540

CDKL5 hgnc:11411 ⇓ LOSS OF FUNCTION

protein serine/threonine kinase activity GO:0004674 ↓ DECREASED

Experimental models

Isogenic R59Ter Neuronal Phosphoproteomics IPSC DERIVED MODEL Maps candidate downstream phosphorylation changes.

Animal models

Neonatal AAV9 CDKL5 Replacement Mus musculus rescues Restores kinase output in a neonatal replacement model.

Downstream

Reduced MAP1S Phosphorylation CDKL5 directly phosphorylates MAP1S, including physiologically validated mouse Ser812.

Reduced EB2 Phosphorylation EB2 is a direct CDKL5 substrate and a useful biochemical readout.

Reduced CaV2.3 Phosphorylation CDKL5 directly phosphorylates CaV2.3 at human Ser14/mouse Ser15.

Show evidence (2 references)

PMID:30266824 SUPPORT DIRECT PRIMARY RESULT Model Organism

"Substrate phosphorylations are greatly reduced in CDKL5 knockout mice, verifying these as physiological substrates."

Full-text antibody validation supports EB2 Ser222 and MAP1S Ser812 in mouse brain; the abstract wording should not be extended to all candidate sites.

PMID:30266824 SUPPORT DIRECT PRIMARY RESULT In Vitro

"EB2 phosphorylation is reduced in patient-derived human neurons."

Patient neuronal lines show a conserved phosphorylation deficit; these comparisons used related parental controls.

Reduced MAP1S Phosphorylation

Mechanism confidence: Established

MAP1S phosphorylation promotes dissociation from microtubules. Loss of phosphorylation favors microtubule association. Ser786 and Ser812 were mapped biochemically, but only Ser812 had specific physiological antibody validation.

Downstream

Prolonged Dendritic Microtubule Growth Increased MAP1S microtubule association contributes to prolonged plus-end growth; MAP1S knockdown rescues this readout.

Show evidence (1 reference)

PMID:30266824 SUPPORT DIRECT PRIMARY RESULT In Vitro

"We show that phosphorylation by CDKL5 is required for MAP1S dissociation from microtubules."

Biochemical and cellular binding assays establish a phosphorylation-dependent change in MAP1S binding.

Reduced EB2 Phosphorylation

Mechanism confidence: Established

Reduced EB2/MAPRE2 phosphorylation at mouse Ser222 or human Ser223 reports loss of CDKL5 activity. EB2 knockdown did not rescue the microtubule growth phenotype, so this biomarker is not established as its causal mediator.

Experimental models

NGN2-Induced Patient Neurons IPSC DERIVED MODEL Provides a biochemical activity readout.

R550Ter Patient iPSC Base-Editing Rescue IPSC DERIVED MODEL Genetic correction restores the substrate readout.

Show evidence (2 references)

PMID:30266824 SUPPORT DIRECT PRIMARY RESULT In Vitro

"EB2 phosphorylation is reduced in patient-derived human neurons."

This establishes a patient-derived biochemical readout without proving that EB2 drives clinical disease.

PMID:30266824 SUPPORT DIRECT PRIMARY RESULT In Vitro

"MAP1S knockdown rescued the increase in comet lifetime in Cdkl5 KO neurons, while EB2 knockdown had no effect"

The rescue comparison distinguishes the MAP1S mechanism from the EB2 readout.

Prolonged Dendritic Microtubule Growth

Mechanism confidence: Provisional

Cdkl5-null cortical neurons have longer EB3-positive growth lifetimes and distances without increased growth velocity. MAP1S knockdown rescues lifetime, supporting a role for MAP1S-mediated microtubule stabilization.

neuron CL:0000540

Experimental models

MAP1S Microtubule Dynamics and Rescue Assays PRIMARY CELL CULTURE Directly measures and manipulates dendritic growth dynamics.

Downstream

Reduced Dendritic TrkB Transport Altered microtubule dynamics provide a candidate explanation for reduced TrkB cargo run length; a transport-specific rescue is needed to establish mediation.

Show evidence (1 reference)

PMID:30266824 SUPPORT DIRECT PRIMARY RESULT In Vitro

"In CDKL5 knockout mouse neurons, dendritic microtubules have longer EB3-labelled plus-end growth duration"

Live-cell imaging directly measures altered microtubule growth dynamics.

Reduced Dendritic TrkB Transport

Mechanism confidence: Provisional

Anterograde TrkB punctum run length is reduced in knockout dendrites. Transport velocity and the anterograde-to-retrograde ratio were not altered. A direct link from this transport defect to particular human manifestations remains unresolved.

neuron CL:0000540

Show evidence (1 reference)

PMID:30266824 SUPPORT DIRECT PRIMARY RESULT In Vitro

"anterograde cargo trafficking is compromised in CDKL5 knockout mouse dendrites."

The full text localizes this defect to TrkB run length, rather than a universal slowing of transport.

Impaired CLIP170-Dynactin Association

Mechanism confidence: Provisional

CDKL5 depletion reduces interaction of CLIP170 with dynactin p150glued and recruitment to microtubule tips. Wild-type and kinase-dead A40V CDKL5 restore localization, supporting a structural function rather than proven phosphorylation of CLIP170.

Experimental models

CLIP170-Dynactin and Cargo Transport Assays PRIMARY CELL CULTURE Tests a kinase-independent structural function.

Downstream

Reduced Axonal Retrograde Cargo Initiation Impaired distal dynactin recruitment reduces initiation of retrograde LAMP1-positive cargo transport.

Show evidence (1 reference)

PMID:40847610 SUPPORT DIRECT PRIMARY RESULT In Vitro

"CLIP170-dynactin complex formation is impaired in the absence of CDKL5"

Co-immunoprecipitation and localization assays support impaired complex assembly; kinase-dead rescue distinguishes this from the catalytic branch.

Reduced Axonal Retrograde Cargo Initiation

Mechanism confidence: Provisional

Embryonic Cdkl5-null hippocampal cultures show reduced distal recruitment and retrograde initiation of LAMP1-positive cargo; anterograde movement is also affected. Pregnenolone rescues these culture readouts, but no patient efficacy is established.

neuron CL:0000540

Show evidence (1 reference)

PMID:40847610 SUPPORT DIRECT PRIMARY RESULT In Vitro

"thus leading to defective retrograde cargo trafficking."

The paper combines complex-formation and neuronal transport assays; clinical consequences remain provisional.

Reduced CaV2.3 Phosphorylation

Mechanism confidence: Provisional

CDKL5 directly phosphorylates CaV2.3 at human Ser14/mouse Ser15. Phosphorylation is reduced in knockout cortex and patient-derived neurons, although residual phosphorylation in knockout brain suggests other kinases can contribute.

Downstream

Prolonged CaV2.3 Current Loss of phosphorylation slows channel inactivation and changes muscarinic modulation.

Show evidence (1 reference)

PMID:38081835 SUPPORT DIRECT PRIMARY RESULT Model Organism

"loss of Cav2.3 phosphorylation leads to channel gain-of-function via slower inactivation and enhanced cholinergic stimulation"

Biochemical, recombinant-channel and mouse experiments connect the phosphosite to channel regulation.

Prolonged CaV2.3 Current

Mechanism confidence: Provisional

Unphosphorylated CaV2.3 has slower inactivation in recombinant channels. Phosphosite-mutant CA1 neurons show enhanced cholinergic depolarization and afterpotentials, while baseline firing and spontaneous excitatory currents are unchanged. This is a state-dependent excitability mechanism.

Animal models

CaV2.3 Ser15Ala Phosphosite Knock-In Mus musculus perturbs Tests one downstream phosphosite without deleting all CDKL5 functions.

Downstream

Neuronal Network Hyperexcitability Enhanced CaV2.3 responses may increase excitability under particular neuromodulatory conditions; S15A mice do not reproduce the full epilepsy syndrome.

Show evidence (1 reference)

PMID:38081835 SUPPORT DIRECT PRIMARY RESULT In Vitro

"Whole-cell patch-clamp recordings of Cav2.3 Ba2+ currents revealed slower decay kinetics (inactivation τ) in S14A mutant channels"

Recombinant current measurements establish altered kinetics; slice responses show dependence on cholinergic stimulation.

Increased Postsynaptic NMDA Receptor Abundance

Mechanism confidence: Provisional

Forebrain GABAergic Cdkl5 deletion increases postsynaptic GluN1/GluN2B and CA1 miniature EPSC frequency without reducing miniature IPSCs. The molecular route from interneuron loss to postsynaptic receptor enrichment is unresolved; R59X knock-in mice show a partly different subunit pattern.

Downstream

Disrupted Cortical Excitation-Inhibition Balance Receptor enrichment accompanies enhanced excitatory transmission after interneuron-specific deletion.

Show evidence (1 reference)

PMID:31201320 SUPPORT DIRECT PRIMARY RESULT Model Organism

"the NMDAR subunits GluN1 and GluN2B were significantly elevated in Dlx-cKO mice."

The full paper shows cell-type-specific receptor enrichment and excitatory transmission changes, not a universal loss of inhibitory current.

Altered Postsynaptic Condensate Organization

Mechanism confidence: Provisional

CDKL5 forms condensates with PSD95 through its intrinsically disordered region and terminal PDZ-binding motif. Kinase-dead CDKL5 retains condensation, while particular disease-associated variants alter capacity or material properties. C291Y and C30W have distinct effects, so loss of phase separation is not a universal allele mechanism.

Experimental models

Postsynaptic Condensate Reconstitution OTHER Reconstitutes and perturbs condensate organization.

Downstream

Impaired Dendritic Spine Plasticity Altered condensate organization impairs Kalirin7 recruitment and activity-dependent spine remodeling.

Show evidence (1 reference)

PMID:41706882 SUPPORT DIRECT PRIMARY RESULT In Vitro

"CDKL5 undergoes liquid–liquid phase separation (LLPS) in vitro and in cultured neurons, forming cocondensates with PSD95."

Reconstitution and cultured-neuron assays establish a scaffold mechanism distinct from substrate phosphorylation.

Impaired Dendritic Spine Plasticity

Mechanism confidence: Provisional

CDKL5-dependent postsynaptic organization supports Kalirin7 recruitment and activity-dependent spine enlargement. Experiments with LLPS-deficient constructs impair these processes; CA1 delivery of wild-type CDKL5 rescues slice long-term potentiation more effectively than the engineered phase-separation mutant.

neuron CL:0000540

dendritic spine development GO:0060996 ↕ DYSREGULATED

Downstream

Impaired Neurodevelopment Impaired synaptic plasticity is a plausible contributor to developmental dysfunction; its contribution to individual clinical domains remains unresolved.

Show evidence (1 reference)

PMID:41706882 SUPPORT DIRECT PRIMARY RESULT In Vitro

"specifically enabling the synaptic recruitment of Kalirin7 to promote dendritic spine enlargement"

The measured intermediate is recruitment of a spine-remodeling factor, not a proven uniform loss of all synapses.

Reduced Dendritic Arborization

Mechanism confidence: Provisional

Two-month-old knockout mice show reduced apical dendritic length and branching in cortical and hippocampal pyramidal neurons, with intermediate or bimodal effects in heterozygous females. Other ages, basal arbors and cultured neuronal protocols show smaller or absent effects.

neuron CL:0000540

Animal models

Constitutive Cdkl5 Exon-4 Knockout Mus musculus partially recapitulates Reproduces selected adult neuronal morphology changes.

Downstream

Impaired Neurodevelopment Reduced neuronal arborization may impair circuit development, but mouse morphology does not directly establish the degree of human disability.

Show evidence (1 reference)

PMID:24838000 SUPPORT DIRECT PRIMARY RESULT Model Organism

"Total length of apical dendritic arbors was significantly reduced"

Morphometric analysis directly supports an arbor phenotype in specified neuronal compartments and ages.

Disrupted Cortical Excitation-Inhibition Balance

Mechanism confidence: Provisional

CDKL5 loss alters excitatory and inhibitory circuitry in a cell-type-, brain-region- and developmental-context-dependent manner. Interneuron-specific deletion can enhance excitatory transmission without reducing inhibition; other conditional models differ. A uniform shift toward excitation in every neuron is not established.

Downstream

Neuronal Network Hyperexcitability Specific combinations of synaptic and channel changes can produce excessive firing and synchrony; this outcome depends on model and maturation.

Show evidence (1 reference)

PMID:31201320 SUPPORT DIRECT PRIMARY RESULT Model Organism

"the NMDAR subunits GluN1 and GluN2B were significantly elevated in Dlx-cKO mice."

Conditional deletion and electrophysiology support a context-specific circuit effect rather than an inference from behavior alone.

Neuronal Network Hyperexcitability

Mechanism confidence: Provisional

Patient-derived cortical organoids dissociated for multielectrode-array assays show increased synchrony and firing during early network maturation. NGN2-induced neurons do not show the same phenotype, and later cortical cultures lose the clear genotype effect. Human epilepsy cannot be inferred from every culture readout.

Experimental models

Patient-Derived Cortical Organoid Neurons IPSC DERIVED MODEL Captures an early cortical network readout.

NGN2-Induced Patient Neurons IPSC DERIVED MODEL The tested NGN2 cultures lack the observed cortical-network phenotype.

Downstream

Early-Onset Intractable Epilepsy Pathological firing and synchrony provide a plausible route to seizures, but the transition from cultured networks to the clinical syndrome remains incompletely resolved.

Show evidence (1 reference)

PMID:40930428 SUPPORT DIRECT PRIMARY RESULT In Vitro

"patient-derived neurons from the organoid differentiation showed increased synchrony and weighted mean firing rate on the multielectrode array within the first month of network maturation"

Electrophysiological evidence is specific to the cortical differentiation and observation window.

Early-Onset Intractable Epilepsy

Mechanism confidence: Established

Epilepsy usually begins in early infancy, often with multiple evolving seizure types and marked treatment resistance. Rare individuals with pathogenic CDKL5 variants remain epilepsy-free, and temporary or prolonged remission occurs in some affected people.

Neuron CL:0000540

Animal models

Constitutive Cdkl5 Exon-4 Knockout Mus musculus fails to recapitulate Does not reproduce the severe early seizure syndrome in the tested adult males.

Timed Endogenous Cdkl5 Restoration Mus musculus rescues Tests age-dependent rescue of the mouse seizure phenotype.

Downstream

Early-Onset Seizures The clinical epilepsy manifests with recurrent seizures.

Epileptic Spasms This seizure phenotype or EEG pattern occurs within the documented evolving epilepsy spectrum; it is not present in every affected individual.

Tonic Seizures This seizure phenotype or EEG pattern occurs within the documented evolving epilepsy spectrum; it is not present in every affected individual.

Focal Seizures This seizure phenotype or EEG pattern occurs within the documented evolving epilepsy spectrum; it is not present in every affected individual.

Myoclonic Seizures This seizure phenotype or EEG pattern occurs within the documented evolving epilepsy spectrum; it is not present in every affected individual.

Generalized Tonic-Clonic Seizures This seizure phenotype or EEG pattern occurs within the documented evolving epilepsy spectrum; it is not present in every affected individual.

Hypsarrhythmia This seizure phenotype or EEG pattern occurs within the documented evolving epilepsy spectrum; it is not present in every affected individual.

Show evidence (1 reference)

PMID:38603524 SUPPORT REVIEW SYNTHESIS Other

"CDKL5 deficiency disorder (CDD) is a developmental and epileptic encephalopathy (DEE) characterized by severe early-onset intractable epilepsy and motor, cognitive, visual, and autonomic disturbances."

GeneReviews documents severe early-onset intractable epilepsy as the defining seizure feature of CDD.

Impaired Neurodevelopment

Mechanism confidence: Established

Developmental impairment affects motor, language and cognitive skills. Underlying neuronal dysfunction and seizure burden may both contribute; controlling seizures has not been shown to normalize development universally. Generalized hypotonia accompanies motor impairment, but its specific causal route is unresolved and is not represented by a directional edge here.

Neuron CL:0000540

Downstream

Global Developmental Delay Impaired acquisition of skills manifests as developmental delay.

Intellectual Disability Cognitive impairment persists as intellectual disability.

Absent Speech Developmental impairment can prevent acquisition of this skill; some affected individuals do acquire it.

Inability to Walk Independently Developmental impairment can prevent acquisition of this skill; some affected individuals do acquire it.

Show evidence (1 reference)

PMID:38603524 SUPPORT REVIEW SYNTHESIS Other

GeneReviews lists motor and cognitive disturbance among the defining features of CDD, which is the developmental outcome this node captures.

Movement Disorder

Mechanism confidence: Established

A complex movement disorder combining chorea, dystonia, and stereotypical hand and leg movements is a characteristic feature of CDD.

Neuron CL:0000540

Downstream

Chorea This movement phenotype occurs within the documented clinical spectrum.

Dystonia This movement phenotype occurs within the documented clinical spectrum.

Motor Stereotypies This movement phenotype occurs within the documented clinical spectrum.

Show evidence (1 reference)

PMID:38603524 SUPPORT REVIEW SYNTHESIS Other

"Movement disorders include chorea, dystonia, and stereotypical hand and leg movements."

GeneReviews documents the characteristic CDD movement disorder.

Cortical Visual Impairment

Mechanism confidence: Established

Cerebral (cortical) visual impairment, reflecting dysfunction of central visual pathways rather than a primary ocular defect, is a common and functionally important feature.

Neuron CL:0000540

Downstream

Cerebral Visual Impairment Central visual dysfunction manifests clinically as cerebral visual impairment.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Other

"Cerebral visual impairment, which affects 80% of individuals, may affect development in each of these areas."

The full GeneReviews chapter explicitly identifies cerebral visual impairment, avoiding inference from generic visual disturbance.

Central Autonomic Dysregulation

Mechanism confidence: Provisional

Autonomic disturbances, including breathing irregularities and gastrointestinal symptoms, contribute to CDD morbidity. The relative contributions of autonomic circuitry, hypotonia and treatment effects remain incompletely defined.

Autonomic neuron CL:0000107

Downstream

Autonomic Dysfunction The proposed circuitry disturbance manifests as the clinical autonomic phenotype.

Constipation Autonomic dysregulation may contribute to this manifestation; relative effects of hypotonia, impaired swallowing, seizures and treatment remain unresolved.

Gastroesophageal Reflux Autonomic dysregulation may contribute to this manifestation; relative effects of hypotonia, impaired swallowing, seizures and treatment remain unresolved.

Apnea Autonomic dysregulation may contribute to this manifestation; relative effects of hypotonia, impaired swallowing, seizures and treatment remain unresolved.

Hypoventilation Autonomic dysregulation may contribute to this manifestation; relative effects of hypotonia, impaired swallowing, seizures and treatment remain unresolved.

Hyperventilation Autonomic dysregulation may contribute to this manifestation; relative effects of hypotonia, impaired swallowing, seizures and treatment remain unresolved.

Show evidence (2 references)

PMID:38603524 SUPPORT REVIEW SYNTHESIS Other

GeneReviews lists autonomic disturbance among the defining features of CDD, which is the manifestation this node captures.

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Other

"Autonomic dysfunction ... Constipation ... Gastroesophageal reflux disease ... Abnormal breathing pattern"

The full GeneReviews chapter explicitly describes this manifestation.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

Digestive 4

Feeding Difficulties HP:0011968

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Other

"the remainder usually have some degree of feeding challenges"

The full GeneReviews chapter explicitly describes this manifestation.

Constipation HP:0002019

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Other

"Constipation and gastroesophageal reflux disease requiring medical management are typically lifelong."

The full GeneReviews chapter explicitly describes this manifestation.

Gastroesophageal Reflux HP:0002020

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Other

"Constipation and gastroesophageal reflux disease requiring medical management are typically lifelong."

The full GeneReviews chapter explicitly describes this manifestation.

Dysphagia HP:0002015

Show evidence (1 reference)

PMID:39205479 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"constipation (12/15), dysphagia (10/15), and sleep disturbance (9/15)."

Ten of fifteen individuals in the noncoding-deletion series had dysphagia; this is a series count, not a whole-disease prevalence estimate.

Endocrine 1

Delayed Puberty HP:0000823

Show evidence (1 reference)

PMID:39205479 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"gastroesophageal reflux, and delayed puberty"

The primary report documents this clinical finding.

Eye 4

Cerebral Visual Impairment VERY_FREQUENT HP:0100704

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Other

"Cerebral visual impairment, which affects 80% of individuals, may affect development in each of these areas."

The full GeneReviews chapter explicitly describes this manifestation.

Context-specific annotations (1)

Ninety-two patients seen at three US CDKL5 Centers of Excellence during 2014–2017; seven had variants of uncertain significance accepted by clinical experts FREQUENT

Use the full-text count 70/92 rather than the rounded 75% in the abstract/discussion. This referral cohort does not estimate population penetrance.

Show evidence (1 reference)

PMID:31313283 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"CVI was diagnosed in 70 patients (76%)."

The primary multicenter study supplies the context-specific frequency.

Nystagmus HP:0000639

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Other

"Abnormal eye movements that include esotropia, exotropia, and horizontal and rotatory nystagmus"

The full GeneReviews chapter explicitly describes this manifestation.

Esotropia HP:0000565

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Other

"Abnormal eye movements that include esotropia, exotropia, and horizontal and rotatory nystagmus"

The full GeneReviews chapter explicitly describes this manifestation.

Exotropia HP:0000577

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Other

"Abnormal eye movements that include esotropia, exotropia, and horizontal and rotatory nystagmus"

The full GeneReviews chapter explicitly describes this manifestation.

Head and Neck 1

Postnatal Microcephaly Secondary microcephaly HP:0005484

Show evidence (1 reference)

PMID:35795799 SUPPORT DIRECT REVIEW SYNTHESIS Other

"Five individuals with CDD were reported to have normal head circumferences at birth and over the subsequent 2 years develop postnatal microcephaly"

The consensus paper summarizes an earlier series documenting postnatal microcephaly.

Limbs 1

Hip Dislocation HP:0002827

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Other

"subluxation/dislocation of hips and knees"

The full GeneReviews chapter explicitly describes this manifestation.

Musculoskeletal 2

Hypotonia Generalized hypotonia HP:0001290

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Other

"Gross motor abnormalities are accompanied by generalized hypotonia."

The full GeneReviews chapter explicitly describes this manifestation.

Scoliosis HP:0002650

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Other

"Musculoskeletal involvement ... may include scoliosis and large joint abnormalities associated with severe hypotonia"

The full GeneReviews chapter explicitly describes this manifestation.

Nervous System 21

Early-Onset Seizures VERY_FREQUENT HP:0001250

Show evidence (3 references)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Other

"Typically beginning within the first two months of life (up to age 12 months)"

The full GeneReviews chapter explicitly describes this manifestation.

PMID:37201242 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"with features of CDD but who never developed epilepsy."

The epilepsy-free case series broadens the recognized clinical spectrum.

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Other

"CDKL5 Deficiency Disorder: Frequency of Select Features ... Epilepsy ... >99%"

The GeneReviews summary estimates epilepsy in more than 99% of affected persons; the separately cited epilepsy-free series shows that this is not obligatory.

Epileptic Spasms HP:0011097

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Other

"Epileptic spasms are the initial seizure type in nearly 25% of individuals"

The full GeneReviews chapter explicitly describes this manifestation.

Context-specific annotations (1)

Ninety-two patients seen at three US CDKL5 Centers of Excellence during 2014–2017; seven had variants of uncertain significance accepted by clinical experts VERY_FREQUENT

75/92 experienced spasms at any time; 21/92 presented with spasms. This referral cohort does not estimate population penetrance.

Show evidence (1 reference)

PMID:31313283 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"The most common seizure at any point in time was epileptic spasms (82% - which typically started in infancy but often persisted at older ages)."

The primary multicenter study supplies the context-specific frequency.

Global Developmental Delay HP:0001263

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Other

"Gross motor, fine motor, and speech-language development are impaired in all affected individuals."

The full GeneReviews chapter explicitly describes this manifestation.

Intellectual Disability HP:0001249

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Other

"Severe developmental delays / intellectual disability ... involving motor, communication (speech and language), and cognitive development"

The full GeneReviews chapter explicitly describes this manifestation.

Chorea HP:0002072

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Other

"Movement disorders include chorea, dystonia, and stereotypical hand and leg movements."

The full GeneReviews chapter explicitly describes this manifestation.

Dystonia HP:0001332

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Other

"Movement disorders include chorea, dystonia, and stereotypical hand and leg movements."

The full GeneReviews chapter explicitly describes this manifestation.

Motor Stereotypies Motor stereotypy HP:0000733

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Other

"Movement disorders include chorea, dystonia, and stereotypical hand and leg movements."

The full GeneReviews chapter explicitly describes this manifestation.

Autonomic Dysfunction Abnormal autonomic nervous system physiology HP:0012332

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Other

"Autonomic dysfunction ... Constipation ... Gastroesophageal reflux disease ... Abnormal breathing pattern"

The full GeneReviews chapter explicitly describes this manifestation.

Sleep Disturbance VERY_FREQUENT HP:0002360

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Other

"CDKL5 Deficiency Disorder: Frequency of Select Features ... Sleep disturbances ... 90%"

GeneReviews Table 2 estimates sleep disturbances in 90%; the narrative describes maintenance insomnia and alternating somnolence.

Tonic Seizures HP:0032792

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Other

"Other seizure types include tonic, focal, myoclonic, and generalized tonic-clonic seizures"

The full GeneReviews chapter explicitly describes this manifestation.

Context-specific annotations (1)

Ninety-two patients seen at three US CDKL5 Centers of Excellence during 2014–2017; seven had variants of uncertain significance accepted by clinical experts FREQUENT

59/92 had tonic seizures and 36/92 myoclonic seizures at any time; percentages reflect this referral cohort.

Show evidence (1 reference)

PMID:31313283 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Tonic seizures were the next most common seizure at any time (64%) with myoclonic (39%) and generalized tonic clonic (34%) also being common."

The primary study reports seizure types over the observed clinical course.

Focal Seizures Focal-onset seizure HP:0007359

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Other

"Other seizure types include tonic, focal, myoclonic, and generalized tonic-clonic seizures"

The full GeneReviews chapter explicitly describes this manifestation.

Myoclonic Seizures HP:0032794

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Other

"Other seizure types include tonic, focal, myoclonic, and generalized tonic-clonic seizures"

The full GeneReviews chapter explicitly describes this manifestation.

Context-specific annotations (1)

Ninety-two patients seen at three US CDKL5 Centers of Excellence during 2014–2017; seven had variants of uncertain significance accepted by clinical experts FREQUENT

59/92 had tonic seizures and 36/92 myoclonic seizures at any time; percentages reflect this referral cohort.

Show evidence (1 reference)

PMID:31313283 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Tonic seizures were the next most common seizure at any time (64%) with myoclonic (39%) and generalized tonic clonic (34%) also being common."

The primary study reports seizure types over the observed clinical course.

Hypsarrhythmia HP:0002521

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Other

"50% of seizures occur without hypsarrhythmia on EEG"

GeneReviews explicitly distinguishes spasms with and without hypsarrhythmia; the percentage applies to the presenting-spasm subgroup.

Absent Speech VERY_FREQUENT HP:0001344

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Other

"Approximately 20% of individuals have spoken language."

The reported spoken-language proportion supports absence of speech in approximately 80%, while alternative communication remains important.

Inability to Walk Independently VERY_FREQUENT HP:0002540

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Other

"Approximately 60% of individuals achieve sitting and approximately 20% achieve independent walking."

Independent walking is achieved by approximately one fifth; this does not imply complete absence of assisted mobility.

Autistic Behavior HP:0000729

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Other

"Occasionally, autistic behaviors including abnormal socialization and repetitive behaviors have been described."

The full GeneReviews chapter explicitly describes this manifestation.

Excessive Daytime Somnolence HP:0001262

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Other

"Parents report lack of sleep overall for several nights followed by excessive somnolence in more severe cases."

The full GeneReviews chapter explicitly describes this manifestation.

Cerebral Atrophy HP:0002059

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Other

"Follow-up MRIs showed progressive cortical and cerebellar atrophy."

The full GeneReviews chapter explicitly describes this manifestation.

Cerebellar Atrophy HP:0001272

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Other

"Follow-up MRIs showed progressive cortical and cerebellar atrophy."

The full GeneReviews chapter explicitly describes this manifestation.

Bruxism HP:0003763

Show evidence (1 reference)

PMID:39205479 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"frequent hand stereotypies, bruxism, intermittent breath holding and hyperventilation"

The primary report documents this clinical finding.

Generalized Tonic-Clonic Seizures Bilateral tonic-clonic seizure with generalized onset HP:0025190

Show evidence (1 reference)

PMID:31313283 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Tonic seizures were the next most common seizure at any time (64%) with myoclonic (39%) and generalized tonic clonic (34%) also being common."

The primary clinical cohort explicitly documents generalized tonic-clonic seizures.

Context-specific annotations (1)

Ninety-two patients seen at three US CDKL5 Centers of Excellence during 2014–2017; seven had variants of uncertain significance accepted by clinical experts FREQUENT

31/92 had generalized tonic-clonic seizures at any time; 20/92 presented with this seizure type. This is a tertiary referral cohort, not a population penetrance estimate.

Show evidence (1 reference)

PMID:31313283 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Tonic seizures were the next most common seizure at any time (64%) with myoclonic (39%) and generalized tonic clonic (34%) also being common."

The full-text results report a 34% frequency over the observed clinical course.

Respiratory 3

Apnea HP:0002104

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Other

"Respiratory problems ... Apnea/hypoventilation ... 20% ... Lower respiratory infections"

The full GeneReviews chapter explicitly describes this manifestation.

Hypoventilation HP:0002791

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Other

"Respiratory problems ... Apnea/hypoventilation ... 20% ... Lower respiratory infections"

The full GeneReviews chapter explicitly describes this manifestation.

Hyperventilation HP:0002883

Show evidence (1 reference)

PMID:39205479 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"intermittent breath holding and hyperventilation"

The primary report documents this clinical finding.

🧬

Genetic Associations

CDKL5

Gene: CDKL5 hgnc:11411 relationship_type: CAUSATIVE

Show evidence (2 references)

PMID:38603524 SUPPORT REVIEW SYNTHESIS Other

"the severity of the phenotype can vary depending on the type and position of the CDKL5 pathogenic variant, pattern of X-chromosome inactivation in females, and presence of postzygotic mosaicism"

GeneReviews documents the genotype and X-inactivation determinants of CDD severity.

PMID:39205479 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"On internal variant reclassification, 5 of the 15 variants identified in this cohort only reached American College of Medical Genetics classification of variant of uncertain significance."

The noncoding deletion series does not justify classifying every overlapping deletion as pathogenic.

💊

Medical Actions

Ganaxolone (Ztalmy)

Action: Pharmacotherapy NCIT:C15986

Agent: Ganaxolone NCIT:C72793

Platform: Small molecule

Ganaxolone is a GABA-A receptor positive allosteric modulator approved in the United States for CDD-associated seizures from age two years. In the 17-week randomized Marigold trial, median major motor seizure frequency fell 30.7% versus 6.9% with placebo (101 randomized; 100 in seizure analyses). The ≥50% responder comparison was not statistically significant and no participant became seizure-free. Somnolence occurred in 36% versus 16%; dosing and interactions require specialist supervision. These findings do not establish disease modification or efficacy against every seizure type.

Mechanism Target:

INHIBITS Neuronal Network Hyperexcitability — GABA-A receptor positive allosteric modulation is expected to reduce excitability. This is a pharmacologic link, not a demonstration that ganaxolone reverses the cited patient-organoid readout or corrects CDKL5 deficiency.

Show evidence (1 reference)

url:https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215904s012lbl.pdf SUPPORT DIRECT PRIMARY RESULT Other

"The precise mechanism by which ganaxolone exerts its therapeutic effects in the treatment of seizures associated with CDD is unknown, but its anticonvulsant effects are thought to result from positive allosteric modulation"

The prescribing information supports the proposed inhibitory mechanism while explicitly stating that the precise therapeutic mechanism is unknown.

Target Phenotypes: Seizure HP:0001250

Show evidence (7 references)

url:https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215904s012lbl.pdf SUPPORT DIRECT PRIMARY RESULT Other

"ZTALMY is indicated for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 years of age and older."

The August 2025 US prescribing information establishes the disease and age indication.

PMID:35429480 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Ganaxolone significantly reduced the frequency of CDD-associated seizures compared with placebo and was generally well tolerated."

The prespecified primary outcome was major motor seizure frequency, not a percentage of patients responding.

url:https://discovery.ucl.ac.uk/10153307/3/Cross_D-21-00849R2_Pestana%20Knight_MARIGOLD_MS_2022-01-26.pdf REFUTE DIRECT PRIMARY RESULT Human Clinical

"The rate of patients with ≥50% reduction from baseline in MMSF ... did not achieve statistical significance."

The full manuscript reports the negative first secondary endpoint; hierarchical testing then stopped.

+ 4 more references

Individualized Antiseizure Medication

Action: Pharmacotherapy NCIT:C15986

Agent: clobazam CHEBI:31413 lamotrigine CHEBI:6367 valproic acid CHEBI:39867 vigabatrin CHEBI:63638

Platform: Small molecule

Conventional antiseizure medications are selected according to seizure type, response and tolerability. Clobazam, lamotrigine, valproate and vigabatrin are used, but durable seizure control is often limited and there is no established universal treatment sequence. Caregiver-reported benefit and medication-use counts must not be interpreted as randomized responder rates. Polytherapy can add sedation and other adverse effects.

Target Phenotypes: Seizure HP:0001250

Show evidence (2 references)

PMID:39060900 NO_EVIDENCE DIRECT PRIMARY RESULT Human Clinical

"Compared with monotherapy, polytherapy had a higher likelihood of reported side effects"

The association supports monitoring treatment burden, with confounding by underlying epilepsy severity.

PMID:40834685 SUPPORT DIRECT REVIEW SYNTHESIS Other

"the most effective were considered to be clobazam, lamotrigine (Lamictal), valproic acid (Depakene) (Depakene), and vigabatrin."

This systematic review identifies commonly studied agents; rankings remain limited by heterogeneous observational evidence.

Ketogenic Diet Therapy

Action: Ketogenic Diet NCIT:C173168

Platform: Behavioral / lifestyle

A supervised ketogenic diet can reduce seizures in some individuals with CDD, but response varies and long-term continuation is often limited. A monogenic-epilepsy meta-analysis reported no seizure freedom among 40 CDKL5 cases; this is not a universal ceiling, because individual reports document temporary or prolonged remission. A review statement of 50% seizure reduction does not mean 50% of patients responded.

Target Phenotypes: Seizure HP:0001250

Show evidence (3 references)

PMID:30928302 SUPPORT DIRECT REVIEW SYNTHESIS Other

"reductions in seizure frequency in 61/104 (58.7%)"

The review summarizes a caregiver-reported cohort; benefit was not defined as a standardized ≥50% response.

PMID:40982721 REFUTE DIRECT REVIEW SYNTHESIS Other

"the lowest seizure-free rates occurred in patients with mutations in the cyclin-dependent kinase-like 5 gene, CDKL5, (n = 40)"

The pooled CDKL5 subgroup had zero observed seizure-free cases, with uncertainty and heterogeneous source studies.

PMID:39205479 NO_EVIDENCE DIRECT PRIMARY RESULT Human Clinical

"patient 3 later became seizure-free and has remained so for the last 17 years."

This individual had received ketogenic diet and antiseizure medication, later discontinued; the observation refutes impossibility of remission but does not isolate diet causality.

Cannabidiol

Action: Pharmacotherapy NCIT:C15986

Agent: cannabidiol CHEBI:69478

Platform: Small molecule

Highly purified cannabidiol has preliminary CDD-specific evidence. In a prospective uncontrolled series of nine females, >50% seizure reduction occurred in 8/9 at three months, 6/9 at six months and 1/8 remaining participants at twelve months. Reported alertness or motor improvements were subjective and potentially confounded by reduction of other medications. Somnolence, rash and a mild transaminase elevation were reported. CDD-specific randomized efficacy is not established.

Target Phenotypes: Seizure HP:0001250

Show evidence (2 references)

PMID:41677102 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"A > 50% seizure reduction was observed in 8/9 patients at 3 months, 6/9 at 6 months, and 1/8 at 12 months."

The response declined markedly with follow-up; the denominator changes after one withdrawal.

PMID:41677102 REFUTE DIRECT PRIMARY RESULT Human Clinical

"Although seizure frequency often returned to baseline by the end of the study, most families chose to continue cannabidiol."

Retention and caregiver preference should not be interpreted as sustained seizure efficacy.

Fenfluramine (Investigational for CDD)

Action: Pharmacotherapy NCIT:C15986

Agent: fenfluramine CHEBI:5000

Platform: Small molecule

The 2026 AAN GEMZ conference abstract reports a positive phase 3 CDD result: median countable motor seizure frequency changed −47.6% with fenfluramine versus −2.8% with placebo in 86 participants in the modified intention-to-treat analysis. These are preliminary conference results, with full trial publication still needed for appraisal. The cached October 2025 US label covers Dravet and Lennox-Gastaut syndromes, not CDD. Valvular heart disease and pulmonary arterial hypertension require echocardiographic monitoring under the prescribing program.

Target Phenotypes: Seizure HP:0001250

Show evidence (3 references)

url:https://index.mirasmart.com/AAN2026/PDFfiles/AAN2026-003281.html SUPPORT DIRECT PRIMARY RESULT Human Clinical

"median percentage CMSF change was −47.6% vs −2.8%, providing an estimated median percentage difference of −52.7% (95% CI: −69.9 to −36.7)"

The conference abstract reports the primary countable-motor-seizure outcome; it is not a peer-reviewed full trial report.

url:https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/212102s017lbl.pdf NO_EVIDENCE DIRECT PRIMARY RESULT Other

"FINTEPLA is indicated for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients 2 years of age and older."

The retrieved US indication does not include CDD.

url:https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/212102s017lbl.pdf NO_EVIDENCE DIRECT PRIMARY RESULT Other

"FINTEPLA can cause valvular heart disease (VHD) and pulmonary arterial hypertension (PAH)."

Absence of these events in a short CDD trial does not remove the known treatment risk.

Ataluren (Negative Clinical Trial)

Action: Pharmacotherapy NCIT:C15986

Agent: Ataluren NCIT:C169791

Platform: Small molecule

Ataluren was tested as a nonsense-codon readthrough strategy in a small randomized crossover trial including eight girls with CDD. It did not improve seizures, cognition, motor function, behavior or quality of life versus placebo. Six completed the blinded phase; brain exposure and restoration of CDKL5 protein were not measured. These results do not establish benefit or rule out all future readthrough approaches.

Target Phenotypes: Seizure HP:0001250

Show evidence (1 reference)

PMID:33538404 REFUTE DIRECT PRIMARY RESULT Human Clinical

"Ataluren was not effective in reducing seizure frequency or improving cognitive, motor, or behavioral function or quality of life in subjects with either DS or CDD due to nonsense variants."

The randomized study provides negative treatment evidence, with small sample size and short treatment periods.

Vagus Nerve Stimulation

Action: Vagus nerve stimulator implantation Ontology label: Surgical Procedure NCIT:C15329

Platform: Device

Implanted vagus nerve stimulation can be considered for medically refractory epilepsy after specialist assessment. Observational caregiver reports suggest seizure reduction in some patients; this is not a reliable route to seizure freedom.

Target Phenotypes: Seizure HP:0001250

Show evidence (1 reference)

PMID:30928302 SUPPORT DIRECT REVIEW SYNTHESIS Other

"Among 220 individuals with CDD with parent-entered data, 17% had a VNS implanted and 69% of parents reported reduced seizure frequency."

The 69% refers to reporting families of VNS recipients, not all 220 individuals, and is uncontrolled.

Corpus Callosotomy

Action: Surgical Procedure NCIT:C15329

Platform: Surgery

Corpus callosotomy may be considered as a palliative procedure for selected refractory seizure patterns. CDD-specific outcome data are sparse and do not establish uniform benefit.

Target Phenotypes: Seizure HP:0001250

Show evidence (1 reference)

PMID:30928302 SUPPORT DIRECT REVIEW SYNTHESIS Other

"Palliative surgeries for refractory epilepsy include vagus nerve stimulation (VNS) and corpus callosotomy."

The clinical review identifies the procedure as palliative; its account includes limited experience and unpublished outcome data.

Multidisciplinary Supportive Care

Action: Supportive Care NCIT:C15747

Coordinated neurological, developmental, nutritional, respiratory, visual, orthopedic and family support addresses the multisystem burden. Surveillance and treatment are individualized to function and comorbidities.

Show evidence (1 reference)

PMID:38603524 SUPPORT DIRECT REVIEW SYNTHESIS Other

"Multidisciplinary care by specialists in the fields of pediatric neurology including pediatric epilepsy, feeding and nutrition, sleep disorders, behavioral disorders, orthopedics, physical therapy, occupational therapy, speech-language disorders, and genetic counseling."

GeneReviews outlines the required multidisciplinary domains.

Physical Therapy

Action: Physical Therapy NCIT:C15302

Physical therapy supports mobility, positioning and prevention of secondary complications, with adaptive equipment as needed.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Other

"Need for PT (to improve gross motor skills)"

The GeneReviews management tables recommend this intervention for the stated clinical need.

Occupational Therapy

Action: Occupational Therapy NCIT:C121351

Occupational therapy supports hand use, daily activities and adaptive equipment.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Other

"OT (to improve fine motor skills)"

The GeneReviews management tables recommend this intervention for the stated clinical need.

Communication Therapy

Action: Speech Language Therapy NCIT:C159273

Speech-language assessment includes augmentative and alternative communication, adapted for motor and cerebral visual limitations.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Other

"Assessment for augmentative communication devices ... strategies"

The GeneReviews management tables recommend this intervention for the stated clinical need.

Nutritional and Feeding Support

Action: Nutritional Support NCIT:C15433

Assessment of swallowing safety, aspiration risk, feeding duration, growth and nutritional intake guides feeding therapy and supplementation.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Other

"Incl eval of aspiration risk ... nutritional status"

The GeneReviews management tables recommend this intervention for the stated clinical need.

Gastrostomy Feeding

Action: Gastrostomy Tube Procedure NCIT:C157864

Platform: Surgery

Gastrostomy is considered for persistent feeding problems, dysphagia, poor growth or unsafe/prolonged oral feeding.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Other

"Gastrostomy tube placement may be required for persistent feeding issues."

The GeneReviews management tables recommend this intervention for the stated clinical need.

Sleep Apnea Support

Action: Continuous Positive Airway Pressure NCIT:C124040

Central or obstructive sleep apnea may require positive airway pressure or oxygen after sleep and respiratory evaluation.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Other

"Interventions (e.g., CPAP or supplemental oxygen) that address central ... obstructive sleep apnea"

The GeneReviews management tables recommend this intervention for the stated clinical need.

Genetic Counseling

Action: Genetic Counseling NCIT:C15240

Counseling addresses X-linked inheritance, parental testing, mosaic recurrence risk and reproductive options.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Other

"To obtain a pedigree ... inform affected persons ... their families"

The GeneReviews management tables recommend this intervention for the stated clinical need.

Baclofen for Movement Symptoms

Action: Pharmacotherapy NCIT:C15986

Agent: baclofen CHEBI:2972

Platform: Small molecule

Baclofen may be considered for clinically significant movement or tone symptoms, with benefit balanced against sedation and functional impact. It is symptomatic treatment rather than CDKL5 restoration.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Other

"May incl therapies such as baclofen, botulinum toxin, or other specific agents to treat movement disorders."

GeneReviews includes baclofen among individualized pharmacological options, without asserting CDD-specific randomized efficacy.

Cerebral Visual Impairment Support

Action: Supportive Care NCIT:C15747

Vision-specific adaptations should be incorporated into early intervention, communication, education and daily activities.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Other

"Incl in early intervention programs ... school district"

The management table recommends incorporating visual impairment into psychoeducational support.

🔬

Diagnosis

CDKL5 Molecular Genetic Testing

Diagnosis requires suggestive clinical findings and a pathogenic or likely pathogenic CDKL5 variant, heterozygous in females or hemizygous in males; mosaic cases also occur. A variant of uncertain significance alone does not establish the diagnosis. Epilepsy panels or genomic testing should assess coding variants, copy-number changes and relevant transcript coverage.

Show evidence (2 references)

PMID:38603524 SUPPORT REVIEW SYNTHESIS Other

"The diagnosis of CDD is established in a female proband with suggestive clinical findings and a heterozygous CDKL5 pathogenic variant identified by molecular genetic testing."

GeneReviews establishes molecular genetic testing for a CDKL5 pathogenic variant as the confirmatory diagnostic method.

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Other

"variant of uncertain significance does not establish or rule out the diagnosis."

Clinical variant interpretation is necessary; finding a rare sequence change is insufficient.

Expanded Genomic and Mosaicism Assessment

If initial testing is unrevealing, review CNV detection, depth for mosaicism, and coverage of the brain-relevant transcript and noncoding regions. Genome sequencing can detect some variants missed by exome or older targeted testing.

Show evidence (2 references)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Other

"Unlike exome sequencing, genome sequencing can identify variants outside of the coding region, large deletions, and rearrangements."

GeneReviews identifies the additional variant classes assessable by genome sequencing.

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Other

"the depth of sequencing may determine the yield of molecular diagnostic testing using these panels."

Low-level mosaicism affects test sensitivity.

Electroencephalographic Assessment

EEG and, when needed, prolonged video EEG characterize evolving seizures and distinguish uncertain spells. Normal early EEG or absence of hypsarrhythmia does not exclude CDD.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Other

"EEG features may be normal in early infancy but subsequently evolve to abnormal background activity that can include a Lennox-Gastaut pattern."

EEG appearance changes with age and is not by itself a definitive molecular diagnosis.

Brain MRI

MRI evaluates alternative causes and associated structural changes. Early scans can be normal, while later cortical or cerebellar atrophy is nonspecific.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Other

"brain MRIs in 64% (n=14/22) of individuals were normal in the first year of life."

The cited series demonstrates limited sensitivity of early MRI.

📊

Prevalence

Scotland, children presenting with seizures before age 3 years, 2014–2017

Birth Prevalence 2.36 per 100,000 (0.805–5.59) 1–9 per 100,000 (births)

Four unrelated CDKL5 cases were identified against an estimated birth denominator of 169,470, corresponding to approximately 1 in 42,400 live births. The bounds are the reported 95% confidence interval. This prospective national early-childhood seizure study gives a minimum birth-based incidence estimate; it can miss mild, mosaic or later-presenting disease and is not a global point prevalence.

Show evidence (1 reference)

PMID:31302675 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"2.36/100 000 (95% CI 0.805–5.59)"

Table 3 reports the CDKL5-specific birth-based rate and confidence interval.

🔀

Differential Diagnoses

Conditions with similar clinical presentations that must be differentiated from CDKL5 Deficiency Disorder:

Rett Syndrome MONDO:0010726

Overlapping Features CDD was historically classified as an early-onset seizure variant of Rett syndrome, but it is a distinct molecular disorder. Developmental impairment and hand stereotypies can overlap.

Distinguishing Features

Very early-onset seizures and cerebral visual impairment favor CDD over classic Rett syndrome.
Hand stereotypies in classic Rett syndrome are generally less distractible and may differ qualitatively from those in CDD.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Other

"In addition, very early-onset seizures and cerebral visual impairment are not generally seen in classic Rett syndrome."

The GeneReviews differential explicitly distinguishes CDD from classic Rett syndrome.

📊

Related Datasets

Base editing restores CDKL5 expression and rescues neuronal deficits in a patient-derived model of CDKL5 deficiency disorder geo:GSE325168

RNA sequencing of female patient-derived R550Ter iPSC neurons, ABE-corrected derivatives and a wild-type-active-X comparator from the same donor. Six samples per condition provide an 18-sample comparison. Shared donor background reduces one source of confounding, but X-inactivation, clone selection and editing effects remain; the lines cannot be claimed to differ only at the CDKL5 nucleotide.

human BULK RNA SEQ n=18

PMID:41963441

Accession, title, organism and sample count verified against the fetched GEO record on 2026-10-01. Interpret expression changes with the study design and model limitations described here.

Excitatory cortical neurons from CDKL5 deficiency disorder patient-derived organoids show early hyperexcitability not identified in neurogenin2 induced neurons [RNA-Seq] geo:GSE319077

RNA sequencing of patient/isogenic neuronal cultures from the cortical organoid differentiation study. The paper also compares NGN2 induction; the organoid cultures were dissociated for functional assays. Early cortical-network hyperexcitability differs from the negative NGN2 result, and RNA-seq findings must not be conflated with electrophysiological measurements. HS3ST1 RNA-seq reduction was not statistically significant by follow-up qPCR.

human BULK RNA SEQ n=18

PMID:40930428

Accession, title, organism and sample count verified against the fetched GEO record on 2026-10-01. Interpret expression changes with the study design and model limitations described here.

Transcriptomic Profiling of Zebrafish Mutant for cdkl5 Reveals Dysregulated Gene Expression Associated with Neuronal and Skeletal Development geo:GSE294284

Whole-animal RNA sequencing of homozygous cdkl5sa21938 zebrafish and wild-type siblings at 5 and 35 days postfertilization, with five pooled biological replicates per genotype and age (20 samples). Pools contain 50 larvae or seven juveniles. These data sample neural and non-neural tissues and cannot localize an expression change to a specific cell type.

zebrafish BULK RNA SEQ n=20

PMID:40649845

Accession, title, organism and sample count verified against the fetched GEO record on 2026-10-01. Interpret expression changes with the study design and model limitations described here. The gene descriptor identifies the human disease gene; the perturbed zebrafish ortholog is cdkl5.

🔬

Clinical Trials

NCT03572933 PHASE_III COMPLETED

Marigold randomized ganaxolone trial with open-label extension; clinical results are summarized under ganaxolone.

Show evidence (1 reference)

clinicaltrials:NCT03572933 SUPPORT DIRECT PRIMARY RESULT Other

"A clinical study to evaluate the efficacy, safety, and tolerability of adjunctive ganaxolone therapy compared to placebo for the treatment of seizures in children and young adults with genetically confirmed CDKL5 gene mutation."

The registry summary establishes the study purpose; status was checked against the live structured registry record.

NCT05064878 PHASE_III ACTIVE_NOT_RECRUITING

GEMZ fenfluramine randomized trial with open-label extension; preliminary 2026 conference efficacy data require distinction from regulatory approval.

Show evidence (1 reference)

clinicaltrials:NCT05064878 SUPPORT DIRECT PRIMARY RESULT Other

"This is a Phase 3 Study to examine the efficacy and safety of ZX008 in children and adults with cyclin-dependent kinase like-5 (CDKL5) deficiency disorder (CDD)."

The registry summary establishes the study purpose; status was checked against the live structured registry record.

NCT05249556 PHASE_III NOT_RECRUITING

Ganaxolone trial planned for children aged six months to under two years. Registry status is NOT_YET_RECRUITING; this does not establish approval below age two.

Show evidence (1 reference)

clinicaltrials:NCT05249556 SUPPORT DIRECT PRIMARY RESULT Other

"This study will assess the efficacy, safety, and tolerability of ganaxolone (GNX) compared with placebo (PBO) as adjunctive therapy to the participant's standard anti-epileptic medication for the treatment of seizures in pediatric patients from 6 months to less than 2 years old with genetically..."

The registry summary establishes the study purpose; status was checked against the live structured registry record.

NCT02758626 PHASE_II COMPLETED

Ataluren crossover study in nonsense-variant CDD and Dravet syndrome; published results show no benefit.

Show evidence (1 reference)

clinicaltrials:NCT02758626 SUPPORT DIRECT PRIMARY RESULT Other

"This is a phase 2, crossover study of Ataluren for the treatment of nonsense mutation Dravet syndrome or cyclin-dependent kinase-like 5 (CDKL5) deficiency, resulting in drug-resistant epilepsy. Patients will receive 12 weeks of ataluren or placebo during each treatment period. Treatment Period 1..."

The registry summary establishes the study purpose; status was checked against the live structured registry record.

NCT03694275 PHASE_II COMPLETED

ARCADE open-label soticlestat study in CDD and Dup15q; trial completion alone does not establish clinical efficacy.

Show evidence (1 reference)

clinicaltrials:NCT03694275 SUPPORT DIRECT PRIMARY RESULT Other

"The purpose of this study is to investigate the effect of soticlestat on the frequency of motor seizures for participants with Dup15q or CDD during the Maintenance Period."

The registry summary establishes the study purpose; status was checked against the live structured registry record.

NCT05558371 NOT_APPLICABLE RECRUITING

International CDKL5 clinical research network natural-history study; observational outcomes are distinct from intervention trials.

Show evidence (1 reference)

clinicaltrials:NCT05558371 SUPPORT DIRECT PRIMARY RESULT Other

"Pathogenic variants in the Cyclin-dependent kinase like 5 (CDKL5) gene cause CDKL5 deficiency disorder (CDD, MIM 300672, 105830), a severe developmental and epileptic encephalopathy associated with cognitive and motor impairments and cortical visual impairment. While capability for disease..."

The registry summary establishes the study purpose; status was checked against the live structured registry record.

🧫

Experimental Models

Patient-Derived Cortical Organoid Neurons IPSC_DERIVED_MODEL

Cortically specified cultures show early increases in firing and synchrony and reduced pEB2. Isogenic comparators came from mosaic or X-inactivation-defined clones; this is not a uniform CRISPR-corrected design. The network phenotype is clearest at days 17–28 and becomes inconsistent after day 30.

Cell source

Three patient/isogenic iPSC pairs, two male and one female, differentiated as guided cortical organoids and dissociated for assays

Publication

PMID:40930428

Pathograph links

Neuronal Network Hyperexcitability partially recapitulates fidelity: moderate observes: cellular Captures an early cortical network readout.

Limitations: Dissociated culture activity is not clinical epilepsy; donor, clone, maturity and protocol influence the result.

Show evidence (1 reference)

PMID:40930428 SUPPORT DIRECT PRIMARY RESULT In Vitro

"patient-derived neurons from the organoid differentiation showed increased synchrony and weighted mean firing rate on the multielectrode array within the first month of network maturation"

MEA shows a time-limited network phenotype.

NGN2-Induced Patient Neurons IPSC_DERIVED_MODEL

pEB2 is reduced, but these cultures have poor cortical specification and show no detected network or neurite-length difference. They remain useful for selected biochemical readouts while failing to reproduce the cortical network phenotype under the tested conditions.

Cell source

Two male patient/isogenic iPSC pairs induced with NGN2

Publication

PMID:40930428

Pathograph links

Neuronal Network Hyperexcitability fails to recapitulate fidelity: low observes: cellular The tested NGN2 cultures lack the observed cortical-network phenotype.

Limitations: Negative results concern this differentiation protocol and maturation window, not every possible use of NGN2 neurons.

Show evidence (1 reference)

PMID:40930428 NO_EVIDENCE DIRECT PRIMARY RESULT In Vitro

"Induced neurons showed no detectable differences between cases and isogenic controls in network activity using a multielectrode array"

A negative functional result limits this protocol for the linked mechanism.

Reduced EB2 Phosphorylation measures fidelity: moderate observes: cellular Provides a biochemical activity readout.

Limitations: A biochemical phenotype alone does not establish network or clinical fidelity.

Show evidence (1 reference)

PMID:40930428 SUPPORT DIRECT PRIMARY RESULT In Vitro

"Patient-derived neurons from both differentiation paradigms had decreased phosphorylated EB2"

The phosphorylation deficit is shared despite differing electrophysiology.

R550Ter Patient iPSC Base-Editing Rescue IPSC_DERIVED_MODEL

Adenine base editing corrected c.1648C>T in 2 of 24 selected iPSC colonies before neuronal differentiation. CDKL5 and pEB2 were restored with partial morphological and transcriptional rescue. Mutant neurons had longer, less-branched neurites. Eight predicted off-target sites were assayed; this does not establish genome-wide safety or editing of mature neurons.

Cell source

Female OR00005 mutant-active-X iPSCs, OR00006 wild-type-active-X comparator and selected ABE-corrected clones, differentiated with NGN2

Publication

PMID:41963441

Pathograph links

Reduced EB2 Phosphorylation rescues fidelity: moderate observes: cellular Genetic correction restores the substrate readout.

Limitations: Clone/X-inactivation differences remain; no clinical seizure efficacy, postmitotic delivery or comprehensive off-target safety was tested.

Show evidence (1 reference)

PMID:41963441 SUPPORT DIRECT PRIMARY RESULT In Vitro

"ABE-correction restored EB2 Ser223 phosphorylation to nearly Control levels"

Correction restores a validated biochemical endpoint.

MAP1S Microtubule Dynamics and Rescue Assays PRIMARY_CELL_CULTURE

EB3 imaging shows prolonged growth lifetime/distance; MAP1S knockdown rescues lifetime whereas EB2 knockdown does not. Putative MAP1S Ser786/812Asp phosphomimetics fail to reproduce phosphorylation-dependent dissociation.

Cell source

Embryonic wild-type and Cdkl5-null cortical neurons, plus recombinant binding assays

Publication

PMID:30266824

Pathograph links

Prolonged Dendritic Microtubule Growth perturbs fidelity: moderate observes: cellular Directly measures and manipulates dendritic growth dynamics.

Limitations: Culture dynamics and TrkB transport do not by themselves establish human seizure or developmental causality.

Show evidence (1 reference)

PMID:30266824 SUPPORT DIRECT PRIMARY RESULT In Vitro

"MAP1S knockdown rescued the increase in comet lifetime in Cdkl5 KO neurons, while EB2 knockdown had no effect"

Selective knockdown discriminates among candidate mediators.

CLIP170-Dynactin and Cargo Transport Assays PRIMARY_CELL_CULTURE

WT and kinase-dead A40V restore dynactin recruitment. Pregnenolone at 1 micromolar rescues complex association and cargo movement in culture; it is distinct from clinical ganaxolone treatment.

Cell source

CDKL5-depleted HeLa/COS7 cells and embryonic Cdkl5-null hippocampal cultures

Publication

PMID:40847610

Pathograph links

Impaired CLIP170-Dynactin Association perturbs fidelity: moderate observes: cellular Tests a kinase-independent structural function.

Limitations: Heterologous-cell complex assembly and embryonic neuron transport have not established clinical pregnenolone efficacy.

Show evidence (1 reference)

PMID:40847610 SUPPORT DIRECT PRIMARY RESULT In Vitro

"the re-expression of both CDKL5-WT and CDKL5-A40V restored the localization of p150glued"

Kinase-dead rescue argues against assigning this result solely to catalytic loss.

Postsynaptic Condensate Reconstitution OTHER

Phase-separation, PSD95 binding and Kalirin7 recruitment assays test structural plasticity. K42R kinase-dead protein retains condensation. Engineered phase-separation-deficient mutants and individual patient-associated variants have different effects.

Cell source

Recombinant CDKL5 C-terminal fragments, transfected HEK293T cells and cultured hippocampal neurons

Publication

PMID:41706882

Pathograph links

Altered Postsynaptic Condensate Organization perturbs fidelity: moderate observes: cellular Reconstitutes and perturbs condensate organization.

Limitations: Recombinant C-terminal fragments and overexpression do not establish that every CDD allele abolishes phase separation; clinical variant interpretation remains separate.

Show evidence (1 reference)

PMID:41706882 SUPPORT DIRECT PRIMARY RESULT In Vitro

"CDKL5 undergoes liquid–liquid phase separation (LLPS) in vitro and in cultured neurons, forming cocondensates with PSD95."

The assay measures condensate formation and recruitment.

Isogenic R59Ter Neuronal Phosphoproteomics IPSC_DERIVED_MODEL

Phosphoproteomic comparison nominated substrates; PPP1R35 Ser52 and GTF2I Ser674 were validated in heterologous assays. Endogenous neuronal antibody validation failed because of background, while GATAD2A and ZNF219 candidates were not equivalently confirmed. Their functional contribution to CDD remains unresolved.

Cell source

Male patient R59Ter neurons and CRISPR-corrected isogenic controls; orthogonal HEK293T validation

Publication

PMID:39136782

Pathograph links

Loss of CDKL5 Kinase Activity in Neurons measures fidelity: moderate observes: cellular Maps candidate downstream phosphorylation changes.

Limitations: Not every differential phosphosite is a direct substrate; function of the validated sites and relevance to clinical phenotypes remain open.

Show evidence (1 reference)

PMID:39136782 SUPPORT DIRECT PRIMARY RESULT In Vitro

"With this antibody we showed highest phosphorylation when GTF2I WT was co-expressed with CDKL5 WT, and phosphorylation levels were significantly lower when co-expressed with CDKL5 K42R"

The study combines neuronal phosphoproteomics with orthogonal substrate assays; downstream clinical causality is not established.

🐁

Animal Models

Constitutive Cdkl5 Exon-4 Knockout

The exon-4 deletion eliminates protein but leaves mutant RNA detectable. Adult mutants show compartment-specific arbor defects, abnormal visual responses and motor behaviors. Home-cage hypoactivity does not imply inability to move in a novel arena. Two-to-four-month-old males lacked spontaneous EEG seizures on the tested backgrounds.

Species

Mus musculus

Genotype

Hemizygous males, homozygous females and heterozygous females

Publication

PMID:24838000

Pathograph links

Reduced Dendritic Arborization partially recapitulates fidelity: moderate observes: cellular Reproduces selected adult neuronal morphology changes.

Limitations: The phenotype depends on age and compartment; P20 basal arbors and other cultures need not reproduce adult apical-arbor findings.

Show evidence (1 reference)

PMID:24838000 SUPPORT DIRECT PRIMARY RESULT Model Organism

"Total length of apical dendritic arbors was significantly reduced"

Morphometry supports the specified neuronal readout.

Early-Onset Intractable Epilepsy fails to recapitulate fidelity: low observes: organism Does not reproduce the severe early seizure syndrome in the tested adult males.

Limitations: This does not extend to neonatal recordings, every conditional genotype, or older heterozygous females.

Show evidence (1 reference)

PMID:24838000 NO_EVIDENCE DIRECT PRIMARY RESULT Model Organism

"did not reveal spontaneous epileptiform activity in hemizygous male Cdkl5 knockout mice"

The adult recording experiment provides a negative seizure result.

Timed Endogenous Cdkl5 Restoration

Re-expression at six weeks reverses multiple behaviors and reduces later spasms in heterozygous females. Restoration at six months has less benefit, including no significant reduction of established female spasms and no male fear-memory rescue. Working-memory deficits persist. The STOP system leaks; the independent FLEX system controls that limitation.

Species

Mus musculus

Genotype

Cdkl5STOP/UBC-CreER and Cdkl5FLEX/CAGG-CreER males and heterozygous females

Publication

PMID:39855191

Pathograph links

Early-Onset Intractable Epilepsy rescues fidelity: moderate observes: organism Tests age-dependent rescue of the mouse seizure phenotype.

Limitations: Older female spasms differ in timing from human infantile epilepsy; genetic recombination is not a clinically deliverable therapy, and early rescue does not abolish all spasms.

Show evidence (1 reference)

PMID:39855191 SUPPORT DIRECT PRIMARY RESULT Model Organism

"Seizure prevention is more effective with early intervention in heterozygous females but becomes limited after seizure onset."

Timed rescue distinguishes prevention from reversal of established spasms.

CaV2.3 Ser15Ala Phosphosite Knock-In

The phosphosite mutant prolongs channel currents and enhances cholinergic responses in slices, with partial, sex-dependent behavioral effects. Females have increased kainate susceptibility, but no spontaneous behavioral seizures were observed through forty weeks.

Species

Mus musculus

Genotype

Homozygous and heterozygous Cacna1e Ser15Ala knock-in

Publication

PMID:38081835

Pathograph links

Prolonged CaV2.3 Current perturbs fidelity: moderate observes: cellular Tests one downstream phosphosite without deleting all CDKL5 functions.

Limitations: The negative seizure result limits translation but does not refute the directly measured channel kinetics.

Show evidence (1 reference)

PMID:38081835 NO_EVIDENCE DIRECT PRIMARY RESULT Model Organism

"We did not observe any spontaneous behavioural seizures in Cav2.3 S15A mice up to 40 weeks of age"

The channel mechanism has limited epilepsy fidelity despite electrophysiological changes.

Neonatal AAV9 CDKL5 Replacement

Intracerebroventricular delivery improved distribution relative to intracisternal delivery. Higher doses restored pEB2 and improved selected behavioral outcomes when at least half of neurons were transduced; lower doses did not produce functional benefit.

Species

Mus musculus

Genotype

Neonatal male Cdkl5 knockout treated with AAV9.Syn.hCDKL5

Publication

PMID:39033321

Pathograph links

Loss of CDKL5 Kinase Activity in Neurons rescues fidelity: moderate observes: cellular Restores kinase output in a neonatal replacement model.

Limitations: Assessment is limited to the available abstract after full-text retrieval failures; neonatal male delivery does not establish efficacy or safety in older mosaic females or humans.

Show evidence (1 reference)

PMID:39033321 SUPPORT DIRECT PRIMARY RESULT Model Organism

"AAV9.Syn.hCDKL5 treatment increased phosphorylation of EB2, a bona fide CDKL5 substrate, demonstrating biological activity in vivo."

The available abstract establishes biochemical rescue and dose-dependent functional effects.

cdkl5sa21938 Zebrafish

Whole-animal RNA-seq at five and thirty-five days shows changes in neuronal, skeletal, muscle and visual gene programs. Three-day Hb9:GFP motor neurons have reduced number and axon length. Transcript enrichment is not proof of direct substrate regulation or of the corresponding human symptom mechanism.

Species

Danio rerio

Genotype

Homozygous nonsense mutant compared with wild-type siblings

Publication

PMID:40649845

Pathograph links

Reduced Functional CDKL5 Protein perturbs fidelity: low observes: organism Perturbs the ortholog and measures broad transcriptional consequences.

Limitations: RNA comes from whole animals, not isolated brain. Tissue proportions and developmental stage can affect enrichment; early heart rate was unchanged despite cardiac pathway enrichment.

Show evidence (1 reference)

PMID:40649845 SUPPORT DIRECT PRIMARY RESULT Model Organism

"cdkl5 was one of the genes found to be differentially expressed between the two groups at both stages of development."

Reduced mutant transcript supports loss of ortholog function; protein abundance was not directly quantified here.

{ }

Source YAML

click to show

name: CDKL5 Deficiency Disorder
creation_date: "2026-07-17T00:00:00Z"
category: Mendelian
description: >-
  CDKL5 deficiency disorder (CDD) is an X-linked developmental and epileptic encephalopathy caused by pathogenic variants that reduce CDKL5 function. Severe seizures usually begin in early infancy, accompanied by developmental impairment, hypotonia, cerebral visual impairment, movement abnormalities, and sleep, gastrointestinal and autonomic problems. Rare individuals have milder development or no epilepsy. Females are diagnosed more often than males, but both sexes can be severely affected. Most affected individuals are simplex cases, commonly with a de novo variant; inherited variants and parental or postzygotic mosaicism also occur. CDKL5 has both kinase-dependent and kinase-independent neuronal functions.
parents:
- Epilepsy
- Neurodevelopmental Disorder
- Neurological Disease
synonyms:
- CDD
- CDKL5 disorder
- CDKL5-related epileptic encephalopathy
- Early infantile epileptic encephalopathy 2
disease_term:
  preferred_term: CDKL5 deficiency disorder
  term:
    id: MONDO:0100039
    label: CDKL5 disorder
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0100039
      label: CDKL5 disorder
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
    mapping_justification: >-
      MONDO:0100039 is the current CDKL5 disorder concept, with "CDKL5 Deficiency Disorder" as an exact synonym.
classifications:
  harrisons_chapter:
  - classification_value: NEUROLOGIC
    evidence:
    - reference: PMID:38603524
      reference_title: "CDKL5 Deficiency Disorder."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "CDKL5 deficiency disorder (CDD) is a developmental and epileptic encephalopathy (DEE) characterized by severe early-onset intractable epilepsy and motor, cognitive, visual, and autonomic disturbances."
      explanation: >-
        GeneReviews defines CDD as a developmental and epileptic encephalopathy, an epilepsy syndrome whose clinical home in Harrison's is the neurologic Part.
      quote_role: REVIEW_SYNTHESIS
  - classification_value: GENETICS_ENVIRONMENT_DISEASE
    evidence:
    - reference: PMID:38603524
      reference_title: "CDKL5 Deficiency Disorder."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "The diagnosis of CDD is established in a female proband with suggestive clinical findings and a heterozygous CDKL5 pathogenic variant identified by molecular genetic testing."
      explanation: >-
        Diagnosis rests on identifying a pathogenic CDKL5 variant, so CDD is also an X-linked single-gene disorder and takes the genetics Part alongside the neurologic one.
      quote_role: REVIEW_SYNTHESIS
inheritance:
- name: X-linked inheritance
  inheritance_term:
    preferred_term: X-linked inheritance
    term:
      id: HP:0001417
      label: X-linked inheritance
  description: >-
    CDD is X-linked. Approximately 99% of reported affected individuals are simplex, meaning the only known affected family member; this is not a measured 99% de novo rate. Most tested variants arise de novo, but transmission from an affected or apparently unaffected heterozygous mother and parental mosaicism are documented. X-inactivation and mosaicism modify expression; blood X-inactivation need not represent brain tissue. A heterozygous mother has a 50% chance of transmitting the variant in each pregnancy. Prenatal and preimplantation testing are possible once the familial variant is known.
  evidence:
  - reference: PMID:38603524
    reference_title: CDKL5 Deficiency Disorder.
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: CDD is inherited in an X-linked manner.
    explanation: GeneReviews establishes X-linked inheritance.
  - reference: PMID:38603524
    reference_title: CDKL5 Deficiency Disorder.
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Approximately 99% of affected individuals represent simplex cases
    explanation: Simplex describes family history; it does not demonstrate that every variant arose de novo.
  - reference: PMID:38603524
    reference_title: CDKL5 Deficiency Disorder.
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: If the mother of the proband has a CDKL5 pathogenic variant, the chance of transmitting it in each pregnancy is 50%.
    explanation: GeneReviews states the transmission probability for a mother carrying the pathogenic variant.
  - reference: PMID:38603524
    reference_title: CDKL5 Deficiency Disorder.
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Once the CDKL5 pathogenic variant has been identified in an affected family member, prenatal and preimplantation genetic testing are possible.
    explanation: Reproductive testing is conditional on identifying the familial pathogenic variant.
pathophysiology:
- name: CDKL5 Loss-of-Function Variant
  description: Pathogenic coding or splice variants and deletions alter the CDKL5 gene. Some reduce protein abundance, while others impair catalytic or interaction properties without eliminating protein. Variants may be de novo, inherited or mosaic; loss of kinase activity does not by itself test every scaffold function.
  biological_scale: MOLECULAR
  mechanism_confidence: ESTABLISHED
  evidence:
  - reference: PMID:38603524
    reference_title: CDKL5 Deficiency Disorder.
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: The diagnosis of CDD is established in a female proband with suggestive clinical findings and a heterozygous CDKL5 pathogenic variant identified by molecular genetic testing.
    explanation: The molecular diagnosis establishes the initiating genetic cause, with variable downstream biochemical consequences.
  role: trigger
  gene:
    preferred_term: CDKL5
    term:
      id: hgnc:11411
      label: CDKL5
    modifier: LOSS_OF_FUNCTION
  downstream:
  - target: Reduced Functional CDKL5 Protein
    description: Protein-truncating or destabilizing alleles can reduce functional protein abundance.
    causal_link_type: DIRECT
  - target: Loss of CDKL5 Kinase Activity in Neurons
    description: Catalytic-domain variants can reduce enzymatic activity even when protein remains present.
    causal_link_type: DIRECT
- name: CDKL5 Noncoding Exon Deletion
  description: Deletions involving noncoding exon 1 or alternative 5-prime exons can remove regulatory or transcript-start sequences. The 15-female series includes unresolved variants; promoter disruption, altered isoform usage and other regulatory effects must be distinguished from proven coding loss.
  biological_scale: MOLECULAR
  mechanism_confidence: PROVISIONAL
  evidence:
  - reference: PMID:39205479
    reference_title: Deletions in the CDKL5 5' untranslated region lead to CDKL5 deficiency disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: We identified 15 females with deletions affecting the 5’ UTR region of CDKL5.
    explanation: The clinical series identifies noncoding deletions as a distinct physical alteration, with case-specific interpretation.
  role: trigger
  gene:
    preferred_term: CDKL5
    term:
      id: hgnc:11411
      label: CDKL5
  downstream:
  - target: Reduced CDKL5 Transcript Abundance
    description: Patient fibroblast RNA supports an expression consequence in three tested deletion carriers; the precise regulatory mechanism and neuronal effect remain unresolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- name: Reduced CDKL5 Transcript Abundance
  description: Fibroblasts from three individuals with noncoding deletions had reduced CDKL5 expression relative to controls. The major coding sequence can be preserved. These assays support a dosage effect but do not establish the same magnitude in neurons or pathogenicity of every 5-prime deletion.
  biological_scale: MOLECULAR
  mechanism_confidence: PROVISIONAL
  evidence:
  - reference: PMID:39205479
    reference_title: Deletions in the CDKL5 5' untranslated region lead to CDKL5 deficiency disorder.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: RNA sequencing showed that all three variants were associated with reductions in CDKL5 mRNA levels (normalized expression levels of 25.6%, 17.5% and 56.7% for individuals 1, 2 and 3, respectively, relative to controls)
    explanation: RNA measurements in three patient fibroblast lines support reduced transcript abundance.
  role: mediator
  downstream:
  - target: Reduced Functional CDKL5 Protein
    description: Reduced transcript availability is expected to reduce protein production; protein and neuronal dosage require further validation.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- name: Reduced Functional CDKL5 Protein
  description: Loss of CDKL5 protein removes catalytic and structural functions. Protein depletion is directly established in knockout models and selected patient cell lines; not every pathogenic missense allele eliminates protein.
  biological_scale: MOLECULAR
  mechanism_confidence: ESTABLISHED
  evidence:
  - reference: PMID:24838000
    reference_title: Mapping pathological phenotypes in a mouse model of CDKL5 disorder.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: confirmed the absence of Cdkl5 protein in hemizygous male and homozygous female knockout mice and intermediate levels in heterozygous females.
    explanation: Protein abundance follows genotype in the exon-4 deletion model; mutant RNA itself escapes nonsense-mediated decay.
  role: mediator
  downstream:
  - target: Loss of CDKL5 Kinase Activity in Neurons
    description: Loss of the enzyme reduces phosphorylation of its substrates.
    causal_link_type: DIRECT
  - target: Impaired CLIP170-Dynactin Association
    description: CDKL5 depletion weakens the CLIP170-dynactin complex independently of catalytic activity.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Altered Postsynaptic Condensate Organization
    description: Loss of CDKL5 disrupts its contribution to PSD95-associated condensates.
    causal_link_type: DIRECT
  - target: Increased Postsynaptic NMDA Receptor Abundance
    description: Interneuron-specific loss increases postsynaptic NMDAR abundance through an unresolved non-cell-autonomous route.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Reduced Dendritic Arborization
    description: Selected mouse ages and neuronal compartments show reduced arborization; this effect is not uniform across models.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Cortical Visual Impairment
    description: Knockout models show visual processing deficits, supporting but not fully resolving the human visual phenotype.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- name: Loss of CDKL5 Kinase Activity in Neurons
  description: Reduced enzymatic activity lowers phosphorylation of validated neuronal substrates. EB2/MAPRE2 and MAP1S phosphorylation are reduced in knockout brain; ARHGEF2 was a chemical-genetic candidate whose physiological phosphorylation was not specifically validated in the same study.
  biological_scale: MOLECULAR
  mechanism_confidence: ESTABLISHED
  evidence:
  - reference: PMID:30266824
    reference_title: Chemical genetic identification of CDKL5 substrates reveals its role in neuronal microtubule dynamics.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: Substrate phosphorylations are greatly reduced in CDKL5 knockout mice, verifying these as physiological substrates.
    explanation: Full-text antibody validation supports EB2 Ser222 and MAP1S Ser812 in mouse brain; the abstract wording should not be extended to all candidate sites.
  - reference: PMID:30266824
    reference_title: Chemical genetic identification of CDKL5 substrates reveals its role in neuronal microtubule dynamics.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: EB2 phosphorylation is reduced in patient-derived human neurons.
    explanation: Patient neuronal lines show a conserved phosphorylation deficit; these comparisons used related parental controls.
  role: mediator
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  molecular_functions:
  - preferred_term: protein serine/threonine kinase activity
    term:
      id: GO:0004674
      label: protein serine/threonine kinase activity
    modifier: DECREASED
  downstream:
  - target: Reduced MAP1S Phosphorylation
    description: CDKL5 directly phosphorylates MAP1S, including physiologically validated mouse Ser812.
    causal_link_type: DIRECT
  - target: Reduced EB2 Phosphorylation
    description: EB2 is a direct CDKL5 substrate and a useful biochemical readout.
    causal_link_type: DIRECT
  - target: Reduced CaV2.3 Phosphorylation
    description: CDKL5 directly phosphorylates CaV2.3 at human Ser14/mouse Ser15.
    causal_link_type: DIRECT
  gene:
    preferred_term: CDKL5
    term:
      id: hgnc:11411
      label: CDKL5
    modifier: LOSS_OF_FUNCTION
- name: Reduced MAP1S Phosphorylation
  description: MAP1S phosphorylation promotes dissociation from microtubules. Loss of phosphorylation favors microtubule association. Ser786 and Ser812 were mapped biochemically, but only Ser812 had specific physiological antibody validation.
  biological_scale: MOLECULAR
  mechanism_confidence: ESTABLISHED
  evidence:
  - reference: PMID:30266824
    reference_title: Chemical genetic identification of CDKL5 substrates reveals its role in neuronal microtubule dynamics.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: We show that phosphorylation by CDKL5 is required for MAP1S dissociation from microtubules.
    explanation: Biochemical and cellular binding assays establish a phosphorylation-dependent change in MAP1S binding.
  role: mediator
  downstream:
  - target: Prolonged Dendritic Microtubule Growth
    description: Increased MAP1S microtubule association contributes to prolonged plus-end growth; MAP1S knockdown rescues this readout.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
- name: Reduced EB2 Phosphorylation
  description: Reduced EB2/MAPRE2 phosphorylation at mouse Ser222 or human Ser223 reports loss of CDKL5 activity. EB2 knockdown did not rescue the microtubule growth phenotype, so this biomarker is not established as its causal mediator.
  biological_scale: MOLECULAR
  mechanism_confidence: ESTABLISHED
  evidence:
  - reference: PMID:30266824
    reference_title: Chemical genetic identification of CDKL5 substrates reveals its role in neuronal microtubule dynamics.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: EB2 phosphorylation is reduced in patient-derived human neurons.
    explanation: This establishes a patient-derived biochemical readout without proving that EB2 drives clinical disease.
  - reference: PMID:30266824
    reference_title: Chemical genetic identification of CDKL5 substrates reveals its role in neuronal microtubule dynamics.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: MAP1S knockdown rescued the increase in comet lifetime in Cdkl5 KO neurons, while EB2 knockdown had no effect
    explanation: The rescue comparison distinguishes the MAP1S mechanism from the EB2 readout.
  role: mediator
- name: Prolonged Dendritic Microtubule Growth
  description: Cdkl5-null cortical neurons have longer EB3-positive growth lifetimes and distances without increased growth velocity. MAP1S knockdown rescues lifetime, supporting a role for MAP1S-mediated microtubule stabilization.
  biological_scale: CELLULAR
  mechanism_confidence: PROVISIONAL
  evidence:
  - reference: PMID:30266824
    reference_title: Chemical genetic identification of CDKL5 substrates reveals its role in neuronal microtubule dynamics.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: In CDKL5 knockout mouse neurons, dendritic microtubules have longer EB3-labelled plus-end growth duration
    explanation: Live-cell imaging directly measures altered microtubule growth dynamics.
  role: mediator
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  downstream:
  - target: Reduced Dendritic TrkB Transport
    description: Altered microtubule dynamics provide a candidate explanation for reduced TrkB cargo run length; a transport-specific rescue is needed to establish mediation.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- name: Reduced Dendritic TrkB Transport
  description: Anterograde TrkB punctum run length is reduced in knockout dendrites. Transport velocity and the anterograde-to-retrograde ratio were not altered. A direct link from this transport defect to particular human manifestations remains unresolved.
  biological_scale: CELLULAR
  mechanism_confidence: PROVISIONAL
  evidence:
  - reference: PMID:30266824
    reference_title: Chemical genetic identification of CDKL5 substrates reveals its role in neuronal microtubule dynamics.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: anterograde cargo trafficking is compromised in CDKL5 knockout mouse dendrites.
    explanation: The full text localizes this defect to TrkB run length, rather than a universal slowing of transport.
  role: mediator
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
- name: Impaired CLIP170-Dynactin Association
  description: CDKL5 depletion reduces interaction of CLIP170 with dynactin p150glued and recruitment to microtubule tips. Wild-type and kinase-dead A40V CDKL5 restore localization, supporting a structural function rather than proven phosphorylation of CLIP170.
  biological_scale: MOLECULAR
  mechanism_confidence: PROVISIONAL
  evidence:
  - reference: PMID:40847610
    reference_title: CDKL5 regulates the initiation of retrograde axonal transport through CLIP170-dynactin complex formation.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: CLIP170-dynactin complex formation is impaired in the absence of CDKL5
    explanation: Co-immunoprecipitation and localization assays support impaired complex assembly; kinase-dead rescue distinguishes this from the catalytic branch.
  role: mediator
  downstream:
  - target: Reduced Axonal Retrograde Cargo Initiation
    description: Impaired distal dynactin recruitment reduces initiation of retrograde LAMP1-positive cargo transport.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
- name: Reduced Axonal Retrograde Cargo Initiation
  description: Embryonic Cdkl5-null hippocampal cultures show reduced distal recruitment and retrograde initiation of LAMP1-positive cargo; anterograde movement is also affected. Pregnenolone rescues these culture readouts, but no patient efficacy is established.
  biological_scale: CELLULAR
  mechanism_confidence: PROVISIONAL
  evidence:
  - reference: PMID:40847610
    reference_title: CDKL5 regulates the initiation of retrograde axonal transport through CLIP170-dynactin complex formation.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: thus leading to defective retrograde cargo trafficking.
    explanation: The paper combines complex-formation and neuronal transport assays; clinical consequences remain provisional.
  role: mediator
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
- name: Reduced CaV2.3 Phosphorylation
  description: CDKL5 directly phosphorylates CaV2.3 at human Ser14/mouse Ser15. Phosphorylation is reduced in knockout cortex and patient-derived neurons, although residual phosphorylation in knockout brain suggests other kinases can contribute.
  biological_scale: MOLECULAR
  mechanism_confidence: PROVISIONAL
  evidence:
  - reference: PMID:38081835
    reference_title: Epilepsy-linked kinase CDKL5 phosphorylates voltage-gated calcium channel Cav2.3, altering inactivation kinetics and neuronal excitability.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: loss of Cav2.3 phosphorylation leads to channel gain-of-function via slower inactivation and enhanced cholinergic stimulation
    explanation: Biochemical, recombinant-channel and mouse experiments connect the phosphosite to channel regulation.
  role: mediator
  downstream:
  - target: Prolonged CaV2.3 Current
    description: Loss of phosphorylation slows channel inactivation and changes muscarinic modulation.
    causal_link_type: DIRECT
- name: Prolonged CaV2.3 Current
  description: Unphosphorylated CaV2.3 has slower inactivation in recombinant channels. Phosphosite-mutant CA1 neurons show enhanced cholinergic depolarization and afterpotentials, while baseline firing and spontaneous excitatory currents are unchanged. This is a state-dependent excitability mechanism.
  biological_scale: MOLECULAR
  mechanism_confidence: PROVISIONAL
  evidence:
  - reference: PMID:38081835
    reference_title: Epilepsy-linked kinase CDKL5 phosphorylates voltage-gated calcium channel Cav2.3, altering inactivation kinetics and neuronal excitability.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: Whole-cell patch-clamp recordings of Cav2.3 Ba2+ currents revealed slower decay kinetics (inactivation τ) in S14A mutant channels
    explanation: Recombinant current measurements establish altered kinetics; slice responses show dependence on cholinergic stimulation.
  role: mediator
  downstream:
  - target: Neuronal Network Hyperexcitability
    description: Enhanced CaV2.3 responses may increase excitability under particular neuromodulatory conditions; S15A mice do not reproduce the full epilepsy syndrome.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- name: Increased Postsynaptic NMDA Receptor Abundance
  description: Forebrain GABAergic Cdkl5 deletion increases postsynaptic GluN1/GluN2B and CA1 miniature EPSC frequency without reducing miniature IPSCs. The molecular route from interneuron loss to postsynaptic receptor enrichment is unresolved; R59X knock-in mice show a partly different subunit pattern.
  biological_scale: MOLECULAR
  mechanism_confidence: PROVISIONAL
  evidence:
  - reference: PMID:31201320
    reference_title: Altered NMDAR signaling underlies autistic-like features in mouse models of CDKL5 deficiency disorder.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: the NMDAR subunits GluN1 and GluN2B were significantly elevated in Dlx-cKO mice.
    explanation: The full paper shows cell-type-specific receptor enrichment and excitatory transmission changes, not a universal loss of inhibitory current.
  role: mediator
  downstream:
  - target: Disrupted Cortical Excitation-Inhibition Balance
    description: Receptor enrichment accompanies enhanced excitatory transmission after interneuron-specific deletion.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
- name: Altered Postsynaptic Condensate Organization
  description: CDKL5 forms condensates with PSD95 through its intrinsically disordered region and terminal PDZ-binding motif. Kinase-dead CDKL5 retains condensation, while particular disease-associated variants alter capacity or material properties. C291Y and C30W have distinct effects, so loss of phase separation is not a universal allele mechanism.
  biological_scale: MOLECULAR
  mechanism_confidence: PROVISIONAL
  evidence:
  - reference: PMID:41706882
    reference_title: CDKL5 modulates the plasticity of excitatory synapses via liquid-liquid phase separation.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: CDKL5 undergoes liquid–liquid phase separation (LLPS) in vitro and in cultured neurons, forming cocondensates with PSD95.
    explanation: Reconstitution and cultured-neuron assays establish a scaffold mechanism distinct from substrate phosphorylation.
  role: mediator
  downstream:
  - target: Impaired Dendritic Spine Plasticity
    description: Altered condensate organization impairs Kalirin7 recruitment and activity-dependent spine remodeling.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
- name: Impaired Dendritic Spine Plasticity
  description: CDKL5-dependent postsynaptic organization supports Kalirin7 recruitment and activity-dependent spine enlargement. Experiments with LLPS-deficient constructs impair these processes; CA1 delivery of wild-type CDKL5 rescues slice long-term potentiation more effectively than the engineered phase-separation mutant.
  biological_scale: CELLULAR
  mechanism_confidence: PROVISIONAL
  evidence:
  - reference: PMID:41706882
    reference_title: CDKL5 modulates the plasticity of excitatory synapses via liquid-liquid phase separation.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: specifically enabling the synaptic recruitment of Kalirin7 to promote dendritic spine enlargement
    explanation: The measured intermediate is recruitment of a spine-remodeling factor, not a proven uniform loss of all synapses.
  role: mediator
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: dendritic spine development
    term:
      id: GO:0060996
      label: dendritic spine development
    modifier: DYSREGULATED
  downstream:
  - target: Impaired Neurodevelopment
    description: Impaired synaptic plasticity is a plausible contributor to developmental dysfunction; its contribution to individual clinical domains remains unresolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- name: Reduced Dendritic Arborization
  description: Two-month-old knockout mice show reduced apical dendritic length and branching in cortical and hippocampal pyramidal neurons, with intermediate or bimodal effects in heterozygous females. Other ages, basal arbors and cultured neuronal protocols show smaller or absent effects.
  biological_scale: CELLULAR
  mechanism_confidence: PROVISIONAL
  evidence:
  - reference: PMID:24838000
    reference_title: Mapping pathological phenotypes in a mouse model of CDKL5 disorder.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: Total length of apical dendritic arbors was significantly reduced
    explanation: Morphometric analysis directly supports an arbor phenotype in specified neuronal compartments and ages.
  role: mediator
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  downstream:
  - target: Impaired Neurodevelopment
    description: Reduced neuronal arborization may impair circuit development, but mouse morphology does not directly establish the degree of human disability.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- name: Disrupted Cortical Excitation-Inhibition Balance
  description: CDKL5 loss alters excitatory and inhibitory circuitry in a cell-type-, brain-region- and developmental-context-dependent manner. Interneuron-specific deletion can enhance excitatory transmission without reducing inhibition; other conditional models differ. A uniform shift toward excitation in every neuron is not established.
  biological_scale: TISSUE
  mechanism_confidence: PROVISIONAL
  evidence:
  - reference: PMID:31201320
    reference_title: Altered NMDAR signaling underlies autistic-like features in mouse models of CDKL5 deficiency disorder.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: the NMDAR subunits GluN1 and GluN2B were significantly elevated in Dlx-cKO mice.
    explanation: Conditional deletion and electrophysiology support a context-specific circuit effect rather than an inference from behavior alone.
  role: mediator
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Excitation-Inhibition Imbalance"
  downstream:
  - target: Neuronal Network Hyperexcitability
    description: Specific combinations of synaptic and channel changes can produce excessive firing and synchrony; this outcome depends on model and maturation.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- name: Neuronal Network Hyperexcitability
  description: Patient-derived cortical organoids dissociated for multielectrode-array assays show increased synchrony and firing during early network maturation. NGN2-induced neurons do not show the same phenotype, and later cortical cultures lose the clear genotype effect. Human epilepsy cannot be inferred from every culture readout.
  biological_scale: TISSUE
  mechanism_confidence: PROVISIONAL
  evidence:
  - reference: PMID:40930428
    reference_title: Excitatory cortical neurons from CDKL5 deficiency disorder patient-derived organoids show early hyperexcitability not identified in neurogenin2 induced neurons.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: patient-derived neurons from the organoid differentiation showed increased synchrony and weighted mean firing rate on the multielectrode array within the first month of network maturation
    explanation: Electrophysiological evidence is specific to the cortical differentiation and observation window.
  role: central_effector
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Neuronal Hyperexcitability and Hypersynchrony"
  downstream:
  - target: Early-Onset Intractable Epilepsy
    description: Pathological firing and synchrony provide a plausible route to seizures, but the transition from cultured networks to the clinical syndrome remains incompletely resolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- name: Early-Onset Intractable Epilepsy
  description: >-
    Epilepsy usually begins in early infancy, often with multiple evolving seizure types and marked treatment resistance. Rare individuals with pathogenic CDKL5 variants remain epilepsy-free, and temporary or prolonged remission occurs in some affected people.
  role: consequence
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Recurrent Unprovoked Seizures"
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:38603524
    reference_title: "CDKL5 Deficiency Disorder."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "CDKL5 deficiency disorder (CDD) is a developmental and epileptic encephalopathy (DEE) characterized by severe early-onset intractable epilepsy and motor, cognitive, visual, and autonomic disturbances."
    explanation: >-
      GeneReviews documents severe early-onset intractable epilepsy as the defining seizure feature of CDD.
    quote_role: REVIEW_SYNTHESIS
  biological_scale: ORGANISM
  mechanism_confidence: ESTABLISHED
  downstream:
  - target: Early-Onset Seizures
    description: The clinical epilepsy manifests with recurrent seizures.
    causal_link_type: DIRECT
  - target: Epileptic Spasms
    description: This seizure phenotype or EEG pattern occurs within the documented evolving epilepsy spectrum; it is not present in every affected individual.
    causal_link_type: DIRECT
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
      reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: OTHER
      quote_role: REVIEW_SYNTHESIS
      directness: DIRECT
      snippet: Epileptic spasms are the initial seizure type in nearly 25% of individuals
      explanation: The full GeneReviews chapter explicitly describes this manifestation.
  - target: Tonic Seizures
    description: This seizure phenotype or EEG pattern occurs within the documented evolving epilepsy spectrum; it is not present in every affected individual.
    causal_link_type: DIRECT
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
      reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: OTHER
      quote_role: REVIEW_SYNTHESIS
      directness: DIRECT
      snippet: Other seizure types include tonic, focal, myoclonic, and generalized tonic-clonic seizures
      explanation: The full GeneReviews chapter explicitly describes this manifestation.
  - target: Focal Seizures
    description: This seizure phenotype or EEG pattern occurs within the documented evolving epilepsy spectrum; it is not present in every affected individual.
    causal_link_type: DIRECT
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
      reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: OTHER
      quote_role: REVIEW_SYNTHESIS
      directness: DIRECT
      snippet: Other seizure types include tonic, focal, myoclonic, and generalized tonic-clonic seizures
      explanation: The full GeneReviews chapter explicitly describes this manifestation.
  - target: Myoclonic Seizures
    description: This seizure phenotype or EEG pattern occurs within the documented evolving epilepsy spectrum; it is not present in every affected individual.
    causal_link_type: DIRECT
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
      reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: OTHER
      quote_role: REVIEW_SYNTHESIS
      directness: DIRECT
      snippet: Other seizure types include tonic, focal, myoclonic, and generalized tonic-clonic seizures
      explanation: The full GeneReviews chapter explicitly describes this manifestation.
  - target: Generalized Tonic-Clonic Seizures
    description: This seizure phenotype or EEG pattern occurs within the documented evolving epilepsy spectrum; it is not present in every affected individual.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:31313283
      reference_title: 'CDKL5 deficiency disorder: Relationship between genotype, epilepsy, cortical visual impairment, and development.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: Tonic seizures were the next most common seizure at any time (64%) with myoclonic (39%) and generalized tonic clonic (34%) also being common.
      explanation: The primary clinical cohort explicitly documents generalized tonic-clonic seizures.
  - target: Hypsarrhythmia
    description: This seizure phenotype or EEG pattern occurs within the documented evolving epilepsy spectrum; it is not present in every affected individual.
    causal_link_type: DIRECT
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
      reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: OTHER
      quote_role: REVIEW_SYNTHESIS
      directness: DIRECT
      snippet: 50% of seizures occur without hypsarrhythmia on EEG
      explanation: GeneReviews explicitly distinguishes spasms with and without hypsarrhythmia; the percentage applies to the presenting-spasm subgroup.
- name: Impaired Neurodevelopment
  description: >-
    Developmental impairment affects motor, language and cognitive skills. Underlying neuronal dysfunction and seizure burden may both contribute; controlling seizures has not been shown to normalize development universally. Generalized hypotonia accompanies motor impairment, but its specific causal route is unresolved and is not represented by a directional edge here.
  role: effector
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:38603524
    reference_title: "CDKL5 Deficiency Disorder."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "CDKL5 deficiency disorder (CDD) is a developmental and epileptic encephalopathy (DEE) characterized by severe early-onset intractable epilepsy and motor, cognitive, visual, and autonomic disturbances."
    explanation: >-
      GeneReviews lists motor and cognitive disturbance among the defining features of CDD, which is the developmental outcome this node captures.
    quote_role: REVIEW_SYNTHESIS
  biological_scale: ORGANISM
  mechanism_confidence: ESTABLISHED
  downstream:
  - target: Global Developmental Delay
    description: Impaired acquisition of skills manifests as developmental delay.
    causal_link_type: DIRECT
  - target: Intellectual Disability
    description: Cognitive impairment persists as intellectual disability.
    causal_link_type: DIRECT
  - target: Absent Speech
    description: Developmental impairment can prevent acquisition of this skill; some affected individuals do acquire it.
    causal_link_type: DIRECT
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
      reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: OTHER
      quote_role: REVIEW_SYNTHESIS
      directness: DIRECT
      snippet: Approximately 20% of individuals have spoken language.
      explanation: The reported spoken-language proportion supports absence of speech in approximately 80%, while alternative communication remains important.
  - target: Inability to Walk Independently
    description: Developmental impairment can prevent acquisition of this skill; some affected individuals do acquire it.
    causal_link_type: DIRECT
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
      reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: OTHER
      quote_role: REVIEW_SYNTHESIS
      directness: DIRECT
      snippet: Approximately 60% of individuals achieve sitting and approximately 20% achieve independent walking.
      explanation: Independent walking is achieved by approximately one fifth; this does not imply complete absence of assisted mobility.
- name: Movement Disorder
  description: >-
    A complex movement disorder combining chorea, dystonia, and stereotypical hand and leg movements is a characteristic feature of CDD.
  role: effector
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:38603524
    reference_title: "CDKL5 Deficiency Disorder."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Movement disorders include chorea, dystonia, and stereotypical hand and leg movements."
    explanation: >-
      GeneReviews documents the characteristic CDD movement disorder.
    quote_role: REVIEW_SYNTHESIS
  biological_scale: ORGANISM
  mechanism_confidence: ESTABLISHED
  downstream:
  - target: Chorea
    description: This movement phenotype occurs within the documented clinical spectrum.
    causal_link_type: DIRECT
  - target: Dystonia
    description: This movement phenotype occurs within the documented clinical spectrum.
    causal_link_type: DIRECT
  - target: Motor Stereotypies
    description: This movement phenotype occurs within the documented clinical spectrum.
    causal_link_type: DIRECT
- name: Cortical Visual Impairment
  description: >-
    Cerebral (cortical) visual impairment, reflecting dysfunction of central visual pathways rather than a primary ocular defect, is a common and functionally important feature.
  role: effector
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
    reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Cerebral visual impairment, which affects 80% of individuals, may affect development in each of these areas.
    explanation: The full GeneReviews chapter explicitly identifies cerebral visual impairment, avoiding inference from generic visual disturbance.
  biological_scale: ORGANISM
  mechanism_confidence: ESTABLISHED
  downstream:
  - target: Cerebral Visual Impairment
    description: Central visual dysfunction manifests clinically as cerebral visual impairment.
    causal_link_type: DIRECT
- name: Central Autonomic Dysregulation
  description: >-
    Autonomic disturbances, including breathing irregularities and gastrointestinal symptoms, contribute to CDD morbidity. The relative contributions of autonomic circuitry, hypotonia and treatment effects remain incompletely defined.
  role: effector
  cell_types:
  - preferred_term: Autonomic neuron
    term:
      id: CL:0000107
      label: autonomic neuron
  evidence:
  - reference: PMID:38603524
    reference_title: "CDKL5 Deficiency Disorder."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "CDKL5 deficiency disorder (CDD) is a developmental and epileptic encephalopathy (DEE) characterized by severe early-onset intractable epilepsy and motor, cognitive, visual, and autonomic disturbances."
    explanation: >-
      GeneReviews lists autonomic disturbance among the defining features of CDD, which is the manifestation this node captures.
    quote_role: REVIEW_SYNTHESIS
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
    reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Autonomic dysfunction ... Constipation ... Gastroesophageal reflux disease ... Abnormal breathing pattern
    explanation: The full GeneReviews chapter explicitly describes this manifestation.
  biological_scale: ORGANISM
  mechanism_confidence: PROVISIONAL
  downstream:
  - target: Autonomic Dysfunction
    description: The proposed circuitry disturbance manifests as the clinical autonomic phenotype.
    causal_link_type: DIRECT
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
      reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: OTHER
      quote_role: REVIEW_SYNTHESIS
      directness: DIRECT
      snippet: Autonomic dysfunction ... Constipation ... Gastroesophageal reflux disease ... Abnormal breathing pattern
      explanation: The full GeneReviews chapter explicitly describes this manifestation.
  - target: Constipation
    description: Autonomic dysregulation may contribute to this manifestation; relative effects of hypotonia, impaired swallowing, seizures and treatment remain unresolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
      reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: OTHER
      quote_role: REVIEW_SYNTHESIS
      directness: DIRECT
      snippet: Autonomic dysfunction ... Constipation ... Gastroesophageal reflux disease ... Abnormal breathing pattern
      explanation: The full GeneReviews chapter explicitly describes this manifestation.
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
      reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: OTHER
      quote_role: REVIEW_SYNTHESIS
      directness: DIRECT
      snippet: Constipation and gastroesophageal reflux disease requiring medical management are typically lifelong.
      explanation: The full GeneReviews chapter explicitly describes this manifestation.
  - target: Gastroesophageal Reflux
    description: Autonomic dysregulation may contribute to this manifestation; relative effects of hypotonia, impaired swallowing, seizures and treatment remain unresolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
      reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: OTHER
      quote_role: REVIEW_SYNTHESIS
      directness: DIRECT
      snippet: Autonomic dysfunction ... Constipation ... Gastroesophageal reflux disease ... Abnormal breathing pattern
      explanation: The full GeneReviews chapter explicitly describes this manifestation.
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
      reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: OTHER
      quote_role: REVIEW_SYNTHESIS
      directness: DIRECT
      snippet: Constipation and gastroesophageal reflux disease requiring medical management are typically lifelong.
      explanation: The full GeneReviews chapter explicitly describes this manifestation.
  - target: Apnea
    description: Autonomic dysregulation may contribute to this manifestation; relative effects of hypotonia, impaired swallowing, seizures and treatment remain unresolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
      reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: OTHER
      quote_role: REVIEW_SYNTHESIS
      directness: DIRECT
      snippet: Autonomic dysfunction ... Constipation ... Gastroesophageal reflux disease ... Abnormal breathing pattern
      explanation: The full GeneReviews chapter explicitly describes this manifestation.
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
      reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: OTHER
      quote_role: REVIEW_SYNTHESIS
      directness: DIRECT
      snippet: Respiratory problems ... Apnea/hypoventilation ... 20% ... Lower respiratory infections
      explanation: The full GeneReviews chapter explicitly describes this manifestation.
  - target: Hypoventilation
    description: Autonomic dysregulation may contribute to this manifestation; relative effects of hypotonia, impaired swallowing, seizures and treatment remain unresolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
      reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: OTHER
      quote_role: REVIEW_SYNTHESIS
      directness: DIRECT
      snippet: Autonomic dysfunction ... Constipation ... Gastroesophageal reflux disease ... Abnormal breathing pattern
      explanation: The full GeneReviews chapter explicitly describes this manifestation.
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
      reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: OTHER
      quote_role: REVIEW_SYNTHESIS
      directness: DIRECT
      snippet: Respiratory problems ... Apnea/hypoventilation ... 20% ... Lower respiratory infections
      explanation: The full GeneReviews chapter explicitly describes this manifestation.
  - target: Hyperventilation
    description: Autonomic dysregulation may contribute to this manifestation; relative effects of hypotonia, impaired swallowing, seizures and treatment remain unresolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
      reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: OTHER
      quote_role: REVIEW_SYNTHESIS
      directness: DIRECT
      snippet: Autonomic dysfunction ... Constipation ... Gastroesophageal reflux disease ... Abnormal breathing pattern
      explanation: The full GeneReviews chapter explicitly describes this manifestation.
    - reference: PMID:39205479
      reference_title: Deletions in the CDKL5 5' untranslated region lead to CDKL5 deficiency disorder.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: intermittent breath holding and hyperventilation
      explanation: The primary report documents this clinical finding.
phenotypes:
- name: Early-Onset Seizures
  description: Seizures usually begin in the first two months and are often drug-resistant. Multiple seizure types evolve with age; rare pathogenic-variant carriers remain epilepsy-free.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
    reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Typically beginning within the first two months of life (up to age 12 months)
    explanation: The full GeneReviews chapter explicitly describes this manifestation.
  - reference: PMID:37201242
    reference_title: CDKL5 Deficiency Disorder Without Epilepsy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: with features of CDD but who never developed epilepsy.
    explanation: The epilepsy-free case series broadens the recognized clinical spectrum.
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
    reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: 'CDKL5 Deficiency Disorder: Frequency of Select Features ... Epilepsy ... >99%'
    explanation: The GeneReviews summary estimates epilepsy in more than 99% of affected persons; the separately cited epilepsy-free series shows that this is not obligatory.
  frequency: VERY_FREQUENT
- name: Epileptic Spasms
  description: Spasms are the initial seizure type in approximately one quarter of affected individuals and may emerge later. About half of those presenting with spasms lack hypsarrhythmia.
  phenotype_term:
    preferred_term: Epileptic spasm
    term:
      id: HP:0011097
      label: Epileptic spasm
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
    reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Epileptic spasms are the initial seizure type in nearly 25% of individuals
    explanation: The full GeneReviews chapter explicitly describes this manifestation.
  phenotype_contexts:
  - population: Ninety-two patients seen at three US CDKL5 Centers of Excellence during 2014–2017; seven had variants of uncertain significance accepted by clinical experts
    frequency: VERY_FREQUENT
    notes: 75/92 experienced spasms at any time; 21/92 presented with spasms. This referral cohort does not estimate population penetrance.
    evidence:
    - reference: PMID:31313283
      reference_title: 'CDKL5 deficiency disorder: Relationship between genotype, epilepsy, cortical visual impairment, and development.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: The most common seizure at any point in time was epileptic spasms (82% - which typically started in infancy but often persisted at older ages).
      explanation: The primary multicenter study supplies the context-specific frequency.
- name: Global Developmental Delay
  description: Gross motor, fine motor and speech-language development are impaired; severity is variable and mild presentations exist.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
    reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Gross motor, fine motor, and speech-language development are impaired in all affected individuals.
    explanation: The full GeneReviews chapter explicitly describes this manifestation.
- name: Intellectual Disability
  description: Intellectual disability is generally severe, but the clinical spectrum includes less severe impairment.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
    reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Severe developmental delays / intellectual disability ... involving motor, communication (speech and language), and cognitive development
    explanation: The full GeneReviews chapter explicitly describes this manifestation.
- name: Cerebral Visual Impairment
  description: Cerebral visual impairment affects approximately 80% in GeneReviews, with impaired tracking, fixation and visually guided tasks; function may improve with age.
  phenotype_term:
    preferred_term: Cerebral visual impairment
    term:
      id: HP:0100704
      label: Cerebral visual impairment
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
    reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Cerebral visual impairment, which affects 80% of individuals, may affect development in each of these areas.
    explanation: The full GeneReviews chapter explicitly describes this manifestation.
  frequency: VERY_FREQUENT
  phenotype_contexts:
  - population: Ninety-two patients seen at three US CDKL5 Centers of Excellence during 2014–2017; seven had variants of uncertain significance accepted by clinical experts
    frequency: FREQUENT
    notes: Use the full-text count 70/92 rather than the rounded 75% in the abstract/discussion. This referral cohort does not estimate population penetrance.
    evidence:
    - reference: PMID:31313283
      reference_title: 'CDKL5 deficiency disorder: Relationship between genotype, epilepsy, cortical visual impairment, and development.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: CVI was diagnosed in 70 patients (76%).
      explanation: The primary multicenter study supplies the context-specific frequency.
- name: Chorea
  description: Choreiform movements may occur as part of the movement disorder.
  phenotype_term:
    preferred_term: Chorea
    term:
      id: HP:0002072
      label: Chorea
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
    reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Movement disorders include chorea, dystonia, and stereotypical hand and leg movements.
    explanation: The full GeneReviews chapter explicitly describes this manifestation.
- name: Dystonia
  description: Dystonia can contribute to impaired motor function.
  phenotype_term:
    preferred_term: Dystonia
    term:
      id: HP:0001332
      label: Dystonia
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
    reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Movement disorders include chorea, dystonia, and stereotypical hand and leg movements.
    explanation: The full GeneReviews chapter explicitly describes this manifestation.
- name: Motor Stereotypies
  description: Stereotypical movements affect the hands, arms or legs, including hand mouthing and leg crossing.
  phenotype_term:
    preferred_term: Motor stereotypy
    term:
      id: HP:0000733
      label: Motor stereotypy
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
    reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Movement disorders include chorea, dystonia, and stereotypical hand and leg movements.
    explanation: The full GeneReviews chapter explicitly describes this manifestation.
- name: Autonomic Dysfunction
  description: Autonomic abnormalities include disturbed breathing and gastrointestinal symptoms; their exact physiology and contribution relative to hypotonia and treatment effects vary.
  phenotype_term:
    preferred_term: Abnormal autonomic nervous system physiology
    term:
      id: HP:0012332
      label: Abnormal autonomic nervous system physiology
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
    reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Autonomic dysfunction ... Constipation ... Gastroesophageal reflux disease ... Abnormal breathing pattern
    explanation: The full GeneReviews chapter explicitly describes this manifestation.
- name: Hypotonia
  description: Generalized hypotonia accompanies motor impairment and can contribute to feeding, respiratory and joint problems.
  phenotype_term:
    preferred_term: Generalized hypotonia
    term:
      id: HP:0001290
      label: Generalized hypotonia
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
    reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Gross motor abnormalities are accompanied by generalized hypotonia.
    explanation: The full GeneReviews chapter explicitly describes this manifestation.
- name: Sleep Disturbance
  description: Sleep initiation or maintenance difficulties and abnormal sleep-wake patterns are common, with possible contributions from seizures and medications.
  phenotype_term:
    preferred_term: Sleep disturbance
    term:
      id: HP:0002360
      label: Sleep disturbance
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
    reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: 'CDKL5 Deficiency Disorder: Frequency of Select Features ... Sleep disturbances ... 90%'
    explanation: GeneReviews Table 2 estimates sleep disturbances in 90%; the narrative describes maintenance insomnia and alternating somnolence.
  frequency: VERY_FREQUENT
- name: Feeding Difficulties
  description: Feeding challenges are frequent; approximately one third require gastrostomy. Swallowing impairment and pharyngeal hypotonia can increase aspiration risk.
  phenotype_term:
    preferred_term: Feeding difficulties
    term:
      id: HP:0011968
      label: Feeding difficulties
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
    reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: the remainder usually have some degree of feeding challenges
    explanation: The full GeneReviews chapter explicitly describes this manifestation.
- name: Constipation
  description: Constipation can persist throughout life and require medical management.
  phenotype_term:
    preferred_term: Constipation
    term:
      id: HP:0002019
      label: Constipation
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
    reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Constipation and gastroesophageal reflux disease requiring medical management are typically lifelong.
    explanation: The full GeneReviews chapter explicitly describes this manifestation.
- name: Gastroesophageal Reflux
  description: Gastroesophageal Reflux can persist throughout life and require medical management.
  phenotype_term:
    preferred_term: Gastroesophageal reflux
    term:
      id: HP:0002020
      label: Gastroesophageal reflux
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
    reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Constipation and gastroesophageal reflux disease requiring medical management are typically lifelong.
    explanation: The full GeneReviews chapter explicitly describes this manifestation.
- name: Postnatal Microcephaly
  description: Head growth can decelerate after birth. This is not obligatory and normal early head size does not exclude CDD.
  phenotype_term:
    preferred_term: Secondary microcephaly
    term:
      id: HP:0005484
      label: Secondary microcephaly
  evidence:
  - reference: PMID:35795799
    reference_title: International Consensus Recommendations for the Assessment and Management of Individuals With CDKL5 Deficiency Disorder.
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Five individuals with CDD were reported to have normal head circumferences at birth and over the subsequent 2 years develop postnatal microcephaly
    explanation: The consensus paper summarizes an earlier series documenting postnatal microcephaly.
- name: Scoliosis
  description: Scoliosis can develop among the musculoskeletal complications; surveillance is guided by growth and mobility.
  phenotype_term:
    preferred_term: Scoliosis
    term:
      id: HP:0002650
      label: Scoliosis
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
    reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Musculoskeletal involvement ... may include scoliosis and large joint abnormalities associated with severe hypotonia
    explanation: The full GeneReviews chapter explicitly describes this manifestation.
- name: Tonic Seizures
  description: This seizure type can occur during the evolving CDD epilepsy phenotype.
  phenotype_term:
    preferred_term: Tonic seizure
    term:
      id: HP:0032792
      label: Tonic seizure
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
    reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Other seizure types include tonic, focal, myoclonic, and generalized tonic-clonic seizures
    explanation: The full GeneReviews chapter explicitly describes this manifestation.
  phenotype_contexts:
  - population: Ninety-two patients seen at three US CDKL5 Centers of Excellence during 2014–2017; seven had variants of uncertain significance accepted by clinical experts
    frequency: FREQUENT
    notes: 59/92 had tonic seizures and 36/92 myoclonic seizures at any time; percentages reflect this referral cohort.
    evidence:
    - reference: PMID:31313283
      reference_title: 'CDKL5 deficiency disorder: Relationship between genotype, epilepsy, cortical visual impairment, and development.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: Tonic seizures were the next most common seizure at any time (64%) with myoclonic (39%) and generalized tonic clonic (34%) also being common.
      explanation: The primary study reports seizure types over the observed clinical course.
- name: Focal Seizures
  description: This seizure type can occur during the evolving CDD epilepsy phenotype.
  phenotype_term:
    preferred_term: Focal-onset seizure
    term:
      id: HP:0007359
      label: Focal-onset seizure
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
    reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Other seizure types include tonic, focal, myoclonic, and generalized tonic-clonic seizures
    explanation: The full GeneReviews chapter explicitly describes this manifestation.
- name: Myoclonic Seizures
  description: This seizure type can occur during the evolving CDD epilepsy phenotype.
  phenotype_term:
    preferred_term: Myoclonic seizure
    term:
      id: HP:0032794
      label: Myoclonic seizure
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
    reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Other seizure types include tonic, focal, myoclonic, and generalized tonic-clonic seizures
    explanation: The full GeneReviews chapter explicitly describes this manifestation.
  phenotype_contexts:
  - population: Ninety-two patients seen at three US CDKL5 Centers of Excellence during 2014–2017; seven had variants of uncertain significance accepted by clinical experts
    frequency: FREQUENT
    notes: 59/92 had tonic seizures and 36/92 myoclonic seizures at any time; percentages reflect this referral cohort.
    evidence:
    - reference: PMID:31313283
      reference_title: 'CDKL5 deficiency disorder: Relationship between genotype, epilepsy, cortical visual impairment, and development.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: Tonic seizures were the next most common seizure at any time (64%) with myoclonic (39%) and generalized tonic clonic (34%) also being common.
      explanation: The primary study reports seizure types over the observed clinical course.
- name: Hypsarrhythmia
  description: Hypsarrhythmia accompanies some early spasms, but its absence does not exclude CDD-associated spasms.
  phenotype_term:
    preferred_term: Hypsarrhythmia
    term:
      id: HP:0002521
      label: Hypsarrhythmia
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
    reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: 50% of seizures occur without hypsarrhythmia on EEG
    explanation: GeneReviews explicitly distinguishes spasms with and without hypsarrhythmia; the percentage applies to the presenting-spasm subgroup.
- name: Absent Speech
  description: Most individuals do not acquire spoken language; simple nonverbal communication may remain possible.
  phenotype_term:
    preferred_term: Absent speech
    term:
      id: HP:0001344
      label: Absent speech
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
    reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Approximately 20% of individuals have spoken language.
    explanation: The reported spoken-language proportion supports absence of speech in approximately 80%, while alternative communication remains important.
  frequency: VERY_FREQUENT
- name: Inability to Walk Independently
  description: Most individuals do not achieve independent walking; approximately 20% do in the GeneReviews synthesis.
  phenotype_term:
    preferred_term: Inability to walk
    term:
      id: HP:0002540
      label: Inability to walk
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
    reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Approximately 60% of individuals achieve sitting and approximately 20% achieve independent walking.
    explanation: Independent walking is achieved by approximately one fifth; this does not imply complete absence of assisted mobility.
  frequency: VERY_FREQUENT
- name: Nystagmus
  description: Abnormal ocular movements or alignment can accompany the central visual phenotype.
  phenotype_term:
    preferred_term: Nystagmus
    term:
      id: HP:0000639
      label: Nystagmus
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
    reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Abnormal eye movements that include esotropia, exotropia, and horizontal and rotatory nystagmus
    explanation: The full GeneReviews chapter explicitly describes this manifestation.
- name: Esotropia
  description: Abnormal ocular movements or alignment can accompany the central visual phenotype.
  phenotype_term:
    preferred_term: Esotropia
    term:
      id: HP:0000565
      label: Esotropia
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
    reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Abnormal eye movements that include esotropia, exotropia, and horizontal and rotatory nystagmus
    explanation: The full GeneReviews chapter explicitly describes this manifestation.
- name: Exotropia
  description: Abnormal ocular movements or alignment can accompany the central visual phenotype.
  phenotype_term:
    preferred_term: Exotropia
    term:
      id: HP:0000577
      label: Exotropia
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
    reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Abnormal eye movements that include esotropia, exotropia, and horizontal and rotatory nystagmus
    explanation: The full GeneReviews chapter explicitly describes this manifestation.
- name: Dysphagia
  description: Swallowing impairment is documented and may necessitate feeding assessment or gastrostomy.
  phenotype_term:
    preferred_term: Dysphagia
    term:
      id: HP:0002015
      label: Dysphagia
  evidence:
  - reference: PMID:39205479
    reference_title: Deletions in the CDKL5 5' untranslated region lead to CDKL5 deficiency disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: constipation (12/15), dysphagia (10/15), and sleep disturbance (9/15).
    explanation: Ten of fifteen individuals in the noncoding-deletion series had dysphagia; this is a series count, not a whole-disease prevalence estimate.
- name: Apnea
  description: Apnea may occur, including sleep-related central or obstructive events; the combined apnea/hypoventilation estimate does not establish the frequency of each subtype.
  phenotype_term:
    preferred_term: Apnea
    term:
      id: HP:0002104
      label: Apnea
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
    reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Respiratory problems ... Apnea/hypoventilation ... 20% ... Lower respiratory infections
    explanation: The full GeneReviews chapter explicitly describes this manifestation.
- name: Hypoventilation
  description: Hypoventilation is reported within the respiratory spectrum; its individual frequency is not separated from apnea in GeneReviews.
  phenotype_term:
    preferred_term: Hypoventilation
    term:
      id: HP:0002791
      label: Hypoventilation
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
    reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Respiratory problems ... Apnea/hypoventilation ... 20% ... Lower respiratory infections
    explanation: The full GeneReviews chapter explicitly describes this manifestation.
- name: Hip Dislocation
  description: Hip subluxation or dislocation can complicate severe hypotonia and impaired mobility.
  phenotype_term:
    preferred_term: Hip dislocation
    term:
      id: HP:0002827
      label: Hip dislocation
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
    reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: subluxation/dislocation of hips and knees
    explanation: The full GeneReviews chapter explicitly describes this manifestation.
- name: Autistic Behavior
  description: Autistic features, including altered socialization and repetitive behavior, are reported; these do not establish a formal autism diagnosis in every affected individual.
  phenotype_term:
    preferred_term: Autistic behavior
    term:
      id: HP:0000729
      label: Autistic behavior
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
    reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Occasionally, autistic behaviors including abnormal socialization and repetitive behaviors have been described.
    explanation: The full GeneReviews chapter explicitly describes this manifestation.
- name: Excessive Daytime Somnolence
  description: Excessive daytime sleepiness can accompany disrupted nocturnal sleep and can also be worsened by medication.
  phenotype_term:
    preferred_term: Excessive daytime somnolence
    term:
      id: HP:0001262
      label: Excessive daytime somnolence
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
    reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Parents report lack of sleep overall for several nights followed by excessive somnolence in more severe cases.
    explanation: The full GeneReviews chapter explicitly describes this manifestation.
- name: Cerebral Atrophy
  description: Progressive atrophy can emerge on follow-up imaging even after normal early MRI. The contribution of primary pathogenesis versus severe epilepsy remains uncertain.
  phenotype_term:
    preferred_term: Cerebral atrophy
    term:
      id: HP:0002059
      label: Cerebral atrophy
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
    reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Follow-up MRIs showed progressive cortical and cerebellar atrophy.
    explanation: The full GeneReviews chapter explicitly describes this manifestation.
- name: Cerebellar Atrophy
  description: Progressive atrophy can emerge on follow-up imaging even after normal early MRI. The contribution of primary pathogenesis versus severe epilepsy remains uncertain.
  phenotype_term:
    preferred_term: Cerebellar atrophy
    term:
      id: HP:0001272
      label: Cerebellar atrophy
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
    reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Follow-up MRIs showed progressive cortical and cerebellar atrophy.
    explanation: The full GeneReviews chapter explicitly describes this manifestation.
- name: Bruxism
  description: Bruxism was documented in the detailed clinical history of an individual with a noncoding CDKL5 deletion.
  phenotype_term:
    preferred_term: Bruxism
    term:
      id: HP:0003763
      label: Bruxism
  evidence:
  - reference: PMID:39205479
    reference_title: Deletions in the CDKL5 5' untranslated region lead to CDKL5 deficiency disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: frequent hand stereotypies, bruxism, intermittent breath holding and hyperventilation
    explanation: The primary report documents this clinical finding.
- name: Hyperventilation
  description: Intermittent hyperventilation and breath holding were described in an individual with a noncoding CDKL5 deletion.
  phenotype_term:
    preferred_term: Hyperventilation
    term:
      id: HP:0002883
      label: Hyperventilation
  evidence:
  - reference: PMID:39205479
    reference_title: Deletions in the CDKL5 5' untranslated region lead to CDKL5 deficiency disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: intermittent breath holding and hyperventilation
    explanation: The primary report documents this clinical finding.
- name: Delayed Puberty
  description: Delayed puberty was recorded in an individual with a noncoding deletion; frequency and mechanism remain uncertain.
  phenotype_term:
    preferred_term: Delayed puberty
    term:
      id: HP:0000823
      label: Delayed puberty
  evidence:
  - reference: PMID:39205479
    reference_title: Deletions in the CDKL5 5' untranslated region lead to CDKL5 deficiency disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: gastroesophageal reflux, and delayed puberty
    explanation: The primary report documents this clinical finding.
- name: Generalized Tonic-Clonic Seizures
  description: Generalized-onset bilateral tonic-clonic seizures are part of the mixed seizure spectrum and may occur at presentation or later.
  phenotype_term:
    preferred_term: Bilateral tonic-clonic seizure with generalized onset
    term:
      id: HP:0025190
      label: Bilateral tonic-clonic seizure with generalized onset
  evidence:
  - reference: PMID:31313283
    reference_title: 'CDKL5 deficiency disorder: Relationship between genotype, epilepsy, cortical visual impairment, and development.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: Tonic seizures were the next most common seizure at any time (64%) with myoclonic (39%) and generalized tonic clonic (34%) also being common.
    explanation: The primary clinical cohort explicitly documents generalized tonic-clonic seizures.
  phenotype_contexts:
  - population: Ninety-two patients seen at three US CDKL5 Centers of Excellence during 2014–2017; seven had variants of uncertain significance accepted by clinical experts
    frequency: FREQUENT
    notes: 31/92 had generalized tonic-clonic seizures at any time; 20/92 presented with this seizure type. This is a tertiary referral cohort, not a population penetrance estimate.
    evidence:
    - reference: PMID:31313283
      reference_title: 'CDKL5 deficiency disorder: Relationship between genotype, epilepsy, cortical visual impairment, and development.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: Tonic seizures were the next most common seizure at any time (64%) with myoclonic (39%) and generalized tonic clonic (34%) also being common.
      explanation: The full-text results report a 34% frequency over the observed clinical course.
genetic:
- name: CDKL5
  gene_term:
    preferred_term: CDKL5
    term:
      id: hgnc:11411
      label: CDKL5
  relationship_type: CAUSATIVE
  notes: >-
    Pathogenic coding missense, truncating, splice and structural variants can reduce CDKL5 abundance or function. Interpretation must use the brain-relevant transcript, including NM_001323289; variants near the C terminus and missense variants outside the kinase domain require particular care. Certain noncoding exon/5-prime UTR deletions reduce expression, but overlap alone does not establish pathogenicity. Female X-inactivation and postzygotic mosaicism modify severity. Kinase activity and scaffold functions need separate functional evaluation.
  evidence:
  - reference: PMID:38603524
    reference_title: "CDKL5 Deficiency Disorder."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "the severity of the phenotype can vary depending on the type and position of the CDKL5 pathogenic variant, pattern of X-chromosome inactivation in females, and presence of postzygotic mosaicism"
    explanation: >-
      GeneReviews documents the genotype and X-inactivation determinants of CDD severity.
    quote_role: REVIEW_SYNTHESIS
  - reference: PMID:39205479
    reference_title: Deletions in the CDKL5 5' untranslated region lead to CDKL5 deficiency disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: On internal variant reclassification, 5 of the 15 variants identified in this cohort only reached American College of Medical Genetics classification of variant of uncertain significance.
    explanation: The noncoding deletion series does not justify classifying every overlapping deletion as pathogenic.
diagnosis:
- name: CDKL5 Molecular Genetic Testing
  description: >-
    Diagnosis requires suggestive clinical findings and a pathogenic or likely pathogenic CDKL5 variant, heterozygous in females or hemizygous in males; mosaic cases also occur. A variant of uncertain significance alone does not establish the diagnosis. Epilepsy panels or genomic testing should assess coding variants, copy-number changes and relevant transcript coverage.
  evidence:
  - reference: PMID:38603524
    reference_title: "CDKL5 Deficiency Disorder."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The diagnosis of CDD is established in a female proband with suggestive clinical findings and a heterozygous CDKL5 pathogenic variant identified by molecular genetic testing."
    explanation: >-
      GeneReviews establishes molecular genetic testing for a CDKL5 pathogenic variant as the confirmatory diagnostic method.
    quote_role: REVIEW_SYNTHESIS
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
    reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: variant of uncertain significance does not establish or rule out the diagnosis.
    explanation: Clinical variant interpretation is necessary; finding a rare sequence change is insufficient.
- name: Expanded Genomic and Mosaicism Assessment
  description: If initial testing is unrevealing, review CNV detection, depth for mosaicism, and coverage of the brain-relevant transcript and noncoding regions. Genome sequencing can detect some variants missed by exome or older targeted testing.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
    reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Unlike exome sequencing, genome sequencing can identify variants outside of the coding region, large deletions, and rearrangements.
    explanation: GeneReviews identifies the additional variant classes assessable by genome sequencing.
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
    reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: the depth of sequencing may determine the yield of molecular diagnostic testing using these panels.
    explanation: Low-level mosaicism affects test sensitivity.
- name: Electroencephalographic Assessment
  description: EEG and, when needed, prolonged video EEG characterize evolving seizures and distinguish uncertain spells. Normal early EEG or absence of hypsarrhythmia does not exclude CDD.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
    reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: EEG features may be normal in early infancy but subsequently evolve to abnormal background activity that can include a Lennox-Gastaut pattern.
    explanation: EEG appearance changes with age and is not by itself a definitive molecular diagnosis.
- name: Brain MRI
  description: MRI evaluates alternative causes and associated structural changes. Early scans can be normal, while later cortical or cerebellar atrophy is nonspecific.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
    reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: brain MRIs in 64% (n=14/22) of individuals were normal in the first year of life.
    explanation: The cited series demonstrates limited sensitivity of early MRI.
treatments:
- name: Ganaxolone (Ztalmy)
  description: Ganaxolone is a GABA-A receptor positive allosteric modulator approved in the United States for CDD-associated seizures from age two years. In the 17-week randomized Marigold trial, median major motor seizure frequency fell 30.7% versus 6.9% with placebo (101 randomized; 100 in seizure analyses). The ≥50% responder comparison was not statistically significant and no participant became seizure-free. Somnolence occurred in 36% versus 16%; dosing and interactions require specialist supervision. These findings do not establish disease modification or efficacy against every seizure type.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: Ganaxolone
      term:
        id: NCIT:C72793
        label: Ganaxolone
  evidence:
  - reference: url:https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215904s012lbl.pdf
    reference_title: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215904s012lbl.pdf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: ZTALMY is indicated for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 years of age and older.
    explanation: The August 2025 US prescribing information establishes the disease and age indication.
  - reference: PMID:35429480
    reference_title: 'Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: Ganaxolone significantly reduced the frequency of CDD-associated seizures compared with placebo and was generally well tolerated.
    explanation: The prespecified primary outcome was major motor seizure frequency, not a percentage of patients responding.
  - reference: url:https://discovery.ucl.ac.uk/10153307/3/Cross_D-21-00849R2_Pestana%20Knight_MARIGOLD_MS_2022-01-26.pdf
    reference_title: https://discovery.ucl.ac.uk/10153307/3/Cross_D-21-00849R2_Pestana%20Knight_MARIGOLD_MS_2022-01-26.pdf
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: The rate of patients with ≥50% reduction from baseline in MMSF ... did not achieve statistical significance.
    explanation: The full manuscript reports the negative first secondary endpoint; hierarchical testing then stopped.
  - reference: url:https://discovery.ucl.ac.uk/10153307/3/Cross_D-21-00849R2_Pestana%20Knight_MARIGOLD_MS_2022-01-26.pdf
    reference_title: https://discovery.ucl.ac.uk/10153307/3/Cross_D-21-00849R2_Pestana%20Knight_MARIGOLD_MS_2022-01-26.pdf
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: No patient in the trial achieved 100% reduction (ie, seizure freedom).
    explanation: No seizure freedom was achieved in the randomized phase.
  - reference: url:https://discovery.ucl.ac.uk/10153307/3/Cross_D-21-00849R2_Pestana%20Knight_MARIGOLD_MS_2022-01-26.pdf
    reference_title: https://discovery.ucl.ac.uk/10153307/3/Cross_D-21-00849R2_Pestana%20Knight_MARIGOLD_MS_2022-01-26.pdf
    supports: NO_EVIDENCE
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: somnolence (36% ... vs 16% ... for ganaxolone and placebo groups, respectively)
    explanation: Somnolence was more frequent on ganaxolone; this is a tolerability finding.
  - reference: PMID:37950390
    reference_title: 'Long-term treatment with ganaxolone for seizures associated with cyclin-dependent kinase-like 5 deficiency disorder: Two-year open-label extension follow-up.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: MMSF was reduced by a median of 48.2% (n = 50)
    explanation: At two years, 50 of 88 extension entrants had evaluable seizure data; attrition and lack of a concurrent control limit inference. Last-observation-carried-forward reduction was 27.4%.
  - reference: PMID:38959712
    reference_title: 'Effects of ganaxolone on non-seizure outcomes in CDKL5 Deficiency Disorder: Double-blind placebo-controlled randomized trial.'
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: The total change in QOL score for children in the ganaxolone group was 2.6 points (95%CI -1.74,7.02) higher (improved) than in the placebo group but without statistical significance.
    explanation: The full secondary analysis found no statistically significant quality-of-life benefit; small nominal behavioral-domain effects do not establish general developmental improvement.
  therapeutic_modality: SMALL_MOLECULE
  target_phenotypes:
  - preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  target_mechanisms:
  - target: Neuronal Network Hyperexcitability
    treatment_effect: INHIBITS
    description: GABA-A receptor positive allosteric modulation is expected to reduce excitability. This is a pharmacologic link, not a demonstration that ganaxolone reverses the cited patient-organoid readout or corrects CDKL5 deficiency.
    evidence:
    - reference: url:https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215904s012lbl.pdf
      reference_title: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215904s012lbl.pdf
      supports: SUPPORT
      evidence_source: OTHER
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: The precise mechanism by which ganaxolone exerts its therapeutic effects in the treatment of seizures associated with CDD is unknown, but its anticonvulsant effects are thought to result from positive allosteric modulation
      explanation: The prescribing information supports the proposed inhibitory mechanism while explicitly stating that the precise therapeutic mechanism is unknown.
- name: Individualized Antiseizure Medication
  description: Conventional antiseizure medications are selected according to seizure type, response and tolerability. Clobazam, lamotrigine, valproate and vigabatrin are used, but durable seizure control is often limited and there is no established universal treatment sequence. Caregiver-reported benefit and medication-use counts must not be interpreted as randomized responder rates. Polytherapy can add sedation and other adverse effects.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: clobazam
      term:
        id: CHEBI:31413
        label: clobazam
    - preferred_term: lamotrigine
      term:
        id: CHEBI:6367
        label: lamotrigine
    - preferred_term: valproic acid
      term:
        id: CHEBI:39867
        label: valproic acid
    - preferred_term: vigabatrin
      term:
        id: CHEBI:63638
        label: vigabatrin
  evidence:
  - reference: PMID:39060900
    reference_title: Caregiver Perspective of Benefits and Side Effects of Anti-Seizure Medications in CDKL5 Deficiency Disorder from an International Database.
    supports: NO_EVIDENCE
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: Compared with monotherapy, polytherapy had a higher likelihood of reported side effects
    explanation: The association supports monitoring treatment burden, with confounding by underlying epilepsy severity.
  - reference: PMID:40834685
    reference_title: Antiseizure medications in CDKL5 encephalopathy- systematic review.
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: the most effective were considered to be clobazam, lamotrigine (Lamictal), valproic acid (Depakene) (Depakene), and vigabatrin.
    explanation: This systematic review identifies commonly studied agents; rankings remain limited by heterogeneous observational evidence.
  therapeutic_modality: SMALL_MOLECULE
  target_phenotypes:
  - preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
- name: Ketogenic Diet Therapy
  description: A supervised ketogenic diet can reduce seizures in some individuals with CDD, but response varies and long-term continuation is often limited. A monogenic-epilepsy meta-analysis reported no seizure freedom among 40 CDKL5 cases; this is not a universal ceiling, because individual reports document temporary or prolonged remission. A review statement of 50% seizure reduction does not mean 50% of patients responded.
  treatment_term:
    preferred_term: Ketogenic Diet
    term:
      id: NCIT:C173168
      label: Ketogenic Diet
  evidence:
  - reference: PMID:30928302
    reference_title: 'Cyclin-Dependent Kinase-Like 5 Deficiency Disorder: Clinical Review.'
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: reductions in seizure frequency in 61/104 (58.7%)
    explanation: The review summarizes a caregiver-reported cohort; benefit was not defined as a standardized ≥50% response.
  - reference: PMID:40982721
    reference_title: 'Efficacy of ketogenic diet therapy for pediatric drug-resistant epilepsy with monogenic etiology: A single-arm meta-analysis.'
    supports: REFUTE
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: the lowest seizure-free rates occurred in patients with mutations in the cyclin-dependent kinase-like 5 gene, CDKL5, (n = 40)
    explanation: The pooled CDKL5 subgroup had zero observed seizure-free cases, with uncertainty and heterogeneous source studies.
  - reference: PMID:39205479
    reference_title: Deletions in the CDKL5 5' untranslated region lead to CDKL5 deficiency disorder.
    supports: NO_EVIDENCE
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: patient 3 later became seizure-free and has remained so for the last 17 years.
    explanation: This individual had received ketogenic diet and antiseizure medication, later discontinued; the observation refutes impossibility of remission but does not isolate diet causality.
  therapeutic_modality: BEHAVIORAL
  target_phenotypes:
  - preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
- name: Cannabidiol
  description: Highly purified cannabidiol has preliminary CDD-specific evidence. In a prospective uncontrolled series of nine females, >50% seizure reduction occurred in 8/9 at three months, 6/9 at six months and 1/8 remaining participants at twelve months. Reported alertness or motor improvements were subjective and potentially confounded by reduction of other medications. Somnolence, rash and a mild transaminase elevation were reported. CDD-specific randomized efficacy is not established.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: cannabidiol
      term:
        id: CHEBI:69478
        label: cannabidiol
  evidence:
  - reference: PMID:41677102
    reference_title: 'Highly purified cannabidiol (CBD) in CDKL5 deficiency disorder (CDD): Open-label prospective study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: A > 50% seizure reduction was observed in 8/9 patients at 3 months, 6/9 at 6 months, and 1/8 at 12 months.
    explanation: The response declined markedly with follow-up; the denominator changes after one withdrawal.
  - reference: PMID:41677102
    reference_title: 'Highly purified cannabidiol (CBD) in CDKL5 deficiency disorder (CDD): Open-label prospective study.'
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: Although seizure frequency often returned to baseline by the end of the study, most families chose to continue cannabidiol.
    explanation: Retention and caregiver preference should not be interpreted as sustained seizure efficacy.
  therapeutic_modality: SMALL_MOLECULE
  target_phenotypes:
  - preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
- name: Fenfluramine (Investigational for CDD)
  description: 'The 2026 AAN GEMZ conference abstract reports a positive phase 3 CDD result: median countable motor seizure frequency changed −47.6% with fenfluramine versus −2.8% with placebo in 86 participants in the modified intention-to-treat analysis. These are preliminary conference results, with full trial publication still needed for appraisal. The cached October 2025 US label covers Dravet and Lennox-Gastaut syndromes, not CDD. Valvular heart disease and pulmonary arterial hypertension require echocardiographic monitoring under the prescribing program.'
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: fenfluramine
      term:
        id: CHEBI:5000
        label: fenfluramine
  evidence:
  - reference: url:https://index.mirasmart.com/AAN2026/PDFfiles/AAN2026-003281.html
    reference_title: 2026 American Academy of Neurology Abstract Website
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: 'median percentage CMSF change was −47.6% vs −2.8%, providing an estimated median percentage difference of −52.7% (95% CI: −69.9 to −36.7)'
    explanation: The conference abstract reports the primary countable-motor-seizure outcome; it is not a peer-reviewed full trial report.
  - reference: url:https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/212102s017lbl.pdf
    reference_title: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/212102s017lbl.pdf
    supports: NO_EVIDENCE
    evidence_source: OTHER
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: FINTEPLA is indicated for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients 2 years of age and older.
    explanation: The retrieved US indication does not include CDD.
  - reference: url:https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/212102s017lbl.pdf
    reference_title: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/212102s017lbl.pdf
    supports: NO_EVIDENCE
    evidence_source: OTHER
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: FINTEPLA can cause valvular heart disease (VHD) and pulmonary arterial hypertension (PAH).
    explanation: Absence of these events in a short CDD trial does not remove the known treatment risk.
  therapeutic_modality: SMALL_MOLECULE
  target_phenotypes:
  - preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
- name: Ataluren (Negative Clinical Trial)
  description: Ataluren was tested as a nonsense-codon readthrough strategy in a small randomized crossover trial including eight girls with CDD. It did not improve seizures, cognition, motor function, behavior or quality of life versus placebo. Six completed the blinded phase; brain exposure and restoration of CDKL5 protein were not measured. These results do not establish benefit or rule out all future readthrough approaches.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: Ataluren
      term:
        id: NCIT:C169791
        label: Ataluren
  evidence:
  - reference: PMID:33538404
    reference_title: Ataluren for drug-resistant epilepsy in nonsense variant-mediated Dravet syndrome and CDKL5 deficiency disorder.
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: Ataluren was not effective in reducing seizure frequency or improving cognitive, motor, or behavioral function or quality of life in subjects with either DS or CDD due to nonsense variants.
    explanation: The randomized study provides negative treatment evidence, with small sample size and short treatment periods.
  therapeutic_modality: SMALL_MOLECULE
  target_phenotypes:
  - preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
- name: Vagus Nerve Stimulation
  description: Implanted vagus nerve stimulation can be considered for medically refractory epilepsy after specialist assessment. Observational caregiver reports suggest seizure reduction in some patients; this is not a reliable route to seizure freedom.
  treatment_term:
    preferred_term: Vagus nerve stimulator implantation
    term:
      id: NCIT:C15329
      label: Surgical Procedure
  evidence:
  - reference: PMID:30928302
    reference_title: 'Cyclin-Dependent Kinase-Like 5 Deficiency Disorder: Clinical Review.'
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Among 220 individuals with CDD with parent-entered data, 17% had a VNS implanted and 69% of parents reported reduced seizure frequency.
    explanation: The 69% refers to reporting families of VNS recipients, not all 220 individuals, and is uncontrolled.
  therapeutic_modality: DEVICE
  target_phenotypes:
  - preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
- name: Corpus Callosotomy
  description: Corpus callosotomy may be considered as a palliative procedure for selected refractory seizure patterns. CDD-specific outcome data are sparse and do not establish uniform benefit.
  treatment_term:
    preferred_term: Surgical Procedure
    term:
      id: NCIT:C15329
      label: Surgical Procedure
  evidence:
  - reference: PMID:30928302
    reference_title: 'Cyclin-Dependent Kinase-Like 5 Deficiency Disorder: Clinical Review.'
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Palliative surgeries for refractory epilepsy include vagus nerve stimulation (VNS) and corpus callosotomy.
    explanation: The clinical review identifies the procedure as palliative; its account includes limited experience and unpublished outcome data.
  therapeutic_modality: SURGERY
  target_phenotypes:
  - preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
- name: Multidisciplinary Supportive Care
  description: Coordinated neurological, developmental, nutritional, respiratory, visual, orthopedic and family support addresses the multisystem burden. Surveillance and treatment are individualized to function and comorbidities.
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:38603524
    reference_title: CDKL5 Deficiency Disorder.
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Multidisciplinary care by specialists in the fields of pediatric neurology including pediatric epilepsy, feeding and nutrition, sleep disorders, behavioral disorders, orthopedics, physical therapy, occupational therapy, speech-language disorders, and genetic counseling.
    explanation: GeneReviews outlines the required multidisciplinary domains.
- name: Physical Therapy
  description: Physical therapy supports mobility, positioning and prevention of secondary complications, with adaptive equipment as needed.
  treatment_term:
    preferred_term: Physical Therapy
    term:
      id: NCIT:C15302
      label: Physical Therapy
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
    reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Need for PT (to improve gross motor skills)
    explanation: The GeneReviews management tables recommend this intervention for the stated clinical need.
- name: Occupational Therapy
  description: Occupational therapy supports hand use, daily activities and adaptive equipment.
  treatment_term:
    preferred_term: Occupational Therapy
    term:
      id: NCIT:C121351
      label: Occupational Therapy
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
    reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: OT (to improve fine motor skills)
    explanation: The GeneReviews management tables recommend this intervention for the stated clinical need.
- name: Communication Therapy
  description: Speech-language assessment includes augmentative and alternative communication, adapted for motor and cerebral visual limitations.
  treatment_term:
    preferred_term: Speech Language Therapy
    term:
      id: NCIT:C159273
      label: Speech Language Therapy
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
    reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Assessment for augmentative communication devices ... strategies
    explanation: The GeneReviews management tables recommend this intervention for the stated clinical need.
- name: Nutritional and Feeding Support
  description: Assessment of swallowing safety, aspiration risk, feeding duration, growth and nutritional intake guides feeding therapy and supplementation.
  treatment_term:
    preferred_term: Nutritional Support
    term:
      id: NCIT:C15433
      label: Nutritional Support
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
    reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Incl eval of aspiration risk ... nutritional status
    explanation: The GeneReviews management tables recommend this intervention for the stated clinical need.
- name: Gastrostomy Feeding
  description: Gastrostomy is considered for persistent feeding problems, dysphagia, poor growth or unsafe/prolonged oral feeding.
  treatment_term:
    preferred_term: Gastrostomy Tube Procedure
    term:
      id: NCIT:C157864
      label: Gastrostomy Tube Procedure
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
    reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Gastrostomy tube placement may be required for persistent feeding issues.
    explanation: The GeneReviews management tables recommend this intervention for the stated clinical need.
  therapeutic_modality: SURGERY
- name: Sleep Apnea Support
  description: Central or obstructive sleep apnea may require positive airway pressure or oxygen after sleep and respiratory evaluation.
  treatment_term:
    preferred_term: Continuous Positive Airway Pressure
    term:
      id: NCIT:C124040
      label: Continuous Positive Airway Pressure
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
    reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Interventions (e.g., CPAP or supplemental oxygen) that address central ... obstructive sleep apnea
    explanation: The GeneReviews management tables recommend this intervention for the stated clinical need.
- name: Genetic Counseling
  description: Counseling addresses X-linked inheritance, parental testing, mosaic recurrence risk and reproductive options.
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
    reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: To obtain a pedigree ... inform affected persons ... their families
    explanation: The GeneReviews management tables recommend this intervention for the stated clinical need.
- name: Baclofen for Movement Symptoms
  description: Baclofen may be considered for clinically significant movement or tone symptoms, with benefit balanced against sedation and functional impact. It is symptomatic treatment rather than CDKL5 restoration.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: baclofen
      term:
        id: CHEBI:2972
        label: baclofen
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
    reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: May incl therapies such as baclofen, botulinum toxin, or other specific agents to treat movement disorders.
    explanation: GeneReviews includes baclofen among individualized pharmacological options, without asserting CDD-specific randomized efficacy.
  therapeutic_modality: SMALL_MOLECULE
- name: Cerebral Visual Impairment Support
  description: Vision-specific adaptations should be incorporated into early intervention, communication, education and daily activities.
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
    reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Incl in early intervention programs ... school district
    explanation: The management table recommends incorporating visual impairment into psychoeducational support.
prevalence:
- population: Scotland, children presenting with seizures before age 3 years, 2014–2017
  measure_type: BIRTH_PREVALENCE
  prevalence_class: BAND_1_9_PER_100000
  rate_per_100000: 2.36
  rate_low: 0.805
  rate_high: 5.59
  notes: Four unrelated CDKL5 cases were identified against an estimated birth denominator of 169,470, corresponding to approximately 1 in 42,400 live births. The bounds are the reported 95% confidence interval. This prospective national early-childhood seizure study gives a minimum birth-based incidence estimate; it can miss mild, mosaic or later-presenting disease and is not a global point prevalence.
  evidence:
  - reference: PMID:31302675
    reference_title: 'Incidence and phenotypes of childhood-onset genetic epilepsies: a prospective population-based national cohort.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: 2.36/100 000 (95% CI 0.805–5.59)
    explanation: Table 3 reports the CDKL5-specific birth-based rate and confidence interval.
datasets:
- accession: geo:GSE325168
  title: >-
    Base editing restores CDKL5 expression and rescues neuronal deficits in a patient-derived model of CDKL5 deficiency disorder
  description: >-
    RNA sequencing of female patient-derived R550Ter iPSC neurons, ABE-corrected derivatives and a wild-type-active-X comparator from the same donor. Six samples per condition provide an 18-sample comparison. Shared donor background reduces one source of confounding, but X-inactivation, clone selection and editing effects remain; the lines cannot be claimed to differ only at the CDKL5 nucleotide.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_count: 18
  genes:
  - preferred_term: CDKL5
    term:
      id: hgnc:11411
      label: CDKL5
  publication: PMID:41963441
  notes: >-
    Accession, title, organism and sample count verified against the fetched GEO record on 2026-10-01. Interpret expression changes with the study design and model limitations described here.
- accession: geo:GSE319077
  title: >-
    Excitatory cortical neurons from CDKL5 deficiency disorder patient-derived organoids show early hyperexcitability not identified in neurogenin2 induced neurons [RNA-Seq]
  description: >-
    RNA sequencing of patient/isogenic neuronal cultures from the cortical organoid differentiation study. The paper also compares NGN2 induction; the organoid cultures were dissociated for functional assays. Early cortical-network hyperexcitability differs from the negative NGN2 result, and RNA-seq findings must not be conflated with electrophysiological measurements. HS3ST1 RNA-seq reduction was not statistically significant by follow-up qPCR.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_count: 18
  genes:
  - preferred_term: CDKL5
    term:
      id: hgnc:11411
      label: CDKL5
  publication: PMID:40930428
  notes: >-
    Accession, title, organism and sample count verified against the fetched GEO record on 2026-10-01. Interpret expression changes with the study design and model limitations described here.
- accession: geo:GSE294284
  title: >-
    Transcriptomic Profiling of Zebrafish Mutant for cdkl5 Reveals Dysregulated Gene Expression Associated with Neuronal and Skeletal Development
  description: >-
    Whole-animal RNA sequencing of homozygous cdkl5sa21938 zebrafish and wild-type siblings at 5 and 35 days postfertilization, with five pooled biological replicates per genotype and age (20 samples). Pools contain 50 larvae or seven juveniles. These data sample neural and non-neural tissues and cannot localize an expression change to a specific cell type.
  organism:
    preferred_term: zebrafish
    term:
      id: NCBITaxon:7955
      label: Danio rerio
  data_type: BULK_RNA_SEQ
  sample_count: 20
  genes:
  - preferred_term: CDKL5
    term:
      id: hgnc:11411
      label: CDKL5
  publication: PMID:40649845
  notes: >-
    Accession, title, organism and sample count verified against the fetched GEO record on 2026-10-01. Interpret expression changes with the study design and model limitations described here. The gene descriptor identifies the human disease gene; the perturbed zebrafish ortholog is cdkl5.
discussions:
- discussion_id: gap_cdkl5_substrate_to_phenotype_causality
  prompt: >-
    Which catalytic substrates and kinase-independent scaffold functions account for distinct developmental, visual, movement and seizure outcomes, and which are suitable therapeutic targets?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Loss of CDKL5 Kinase Activity in Neurons
  - pathophysiology#Impaired Dendritic Spine Plasticity
  rationale: >-
    EB2 and MAP1S have physiological phosphorylation evidence; ARHGEF2 remains less secure in vivo. CaV2.3 phosphosite experiments establish a context-dependent channel mechanism but do not reproduce spontaneous human epilepsy. Kinase-independent CLIP170/dynactin assembly and PSD95 condensate organization add distinct candidate pathways. Biomarker restoration, direct substrate validation and rescue of a disease-relevant phenotype are different claims.
  evidence:
  - reference: PMID:30266824
    reference_title: "Chemical genetic identification of CDKL5 substrates reveals its role in neuronal microtubule dynamics."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "EB2 phosphorylation is reduced in patient-derived human neurons."
    explanation: >-
      Establishes human-relevant CDKL5 substrates but does not resolve which phospho-event causes which clinical feature, which is the open question.
  - reference: PMID:30266824
    reference_title: Chemical genetic identification of CDKL5 substrates reveals its role in neuronal microtubule dynamics.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: A putative phosphomimetic MAP1S-LC mutant did not act like phosphorylated MAP1S-LC
    explanation: A phosphomimetic cannot be assumed to reproduce actual phosphorylation.
  - reference: PMID:40847610
    reference_title: CDKL5 regulates the initiation of retrograde axonal transport through CLIP170-dynactin complex formation.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: the re-expression of both CDKL5-WT and CDKL5-A40V restored the localization of p150glued
    explanation: Kinase-dead rescue supports a scaffold branch.
  proposed_experiments:
  - experiment_id: exp_cdkl5_substrate_phenotype_dissection
    name: Substrate-specific rescue in CDKL5-deficient human neurons
    description: >-
      Compare substrate-specific manipulations and scaffold-selective CDKL5 rescue in patient/isogenic cortically specified neurons. Verify each manipulation biochemically before measuring firing, synchrony and spine plasticity. MAP1S Ser786/812Asp previously failed to mimic phosphorylation, so it is not a validated rescue reagent. Include wild-type CDKL5, kinase-dead CDKL5, phosphorylation-deficient and scaffold-deficient controls, with matched protein abundance.
    experiment_type:
      preferred_term: substrate-specific rescue experiment
    readouts:
    - name: Network excitability versus maturation
      target: pathophysiology#Impaired Dendritic Spine Plasticity
      biological_processes:
      - preferred_term: Dendritic spine development
        term:
          id: GO:0060996
          label: dendritic spine development
        modifier: DECREASED
      assays:
      - preferred_term: multielectrode array recording
      direction: POSITIVE
    controls:
    - name: CDKL5-corrected isogenic neurons
      description: Isogenic CDKL5-restored neurons as the normalization reference.
    - name: Biochemically validated substrate and scaffold controls
      description: Measure phosphorylation, binding and expression directly; compare matched kinase-dead and scaffold-deficient constructs rather than presuming any acidic substitution is a valid phosphomimetic.
    decision_criterion: >-
      A manipulation supports a causal contribution only if it restores the intended biochemical event and reproducibly improves a prespecified functional readout across independent donors and differentiations; rescue of pEB2 alone is insufficient.
    would_support:
    - pathophysiology#Impaired Dendritic Spine Plasticity
- discussion_id: gap_cdkl5_reversibility_treatment_window
  prompt: >-
    Can restoring CDKL5 after symptom onset reverse established disease, and what is the developmental window during which CDKL5 gene-replacement or reactivation is effective in humans?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Impaired Dendritic Spine Plasticity
  - pathophysiology#Early-Onset Intractable Epilepsy
  rationale: >-
    Post-developmental reversibility has already been demonstrated for several mouse phenotypes. Six-week endogenous restoration improves many behaviors and reduces later female spasms; six-month rescue is less effective, and working memory remains impaired. The unresolved questions are delivery, dose, mosaic coverage and human developmental timing, not whether any postnatal rescue is possible.
  evidence:
  - reference: PMID:39855191
    reference_title: Independent genetic strategies define the scope and limits of CDKL5 deficiency disorder reversal.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: The working memory deficits present in both CDD models are not reversible regardless of the age of rescue or sex.
    explanation: The full study separates reversible domains from a persistent deficit.
  - reference: PMID:39855191
    reference_title: Independent genetic strategies define the scope and limits of CDKL5 deficiency disorder reversal.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: Seizure prevention is more effective with early intervention in heterozygous females but becomes limited after seizure onset.
    explanation: Timing affects seizure rescue; mouse ages cannot be mapped directly to human treatment windows.
  proposed_experiments:
  - experiment_id: exp_cdkl5_reactivation_timing
    name: Delivery and mosaic-coverage comparison across treatment ages
    description: >-
      Extend the existing six-week versus six-month endogenous-restoration experiments using clinically relevant delivery, graded neuronal coverage and heterozygous female models. Compare established seizures, EEG, vision and prespecified behavioral endpoints, with vector dose and expression controlled. Include older symptomatic animals rather than interpreting neonatal prevention as reversal.
    experiment_type:
      preferred_term: timed gene-reactivation experiment
    readouts:
    - name: Reversal of deficits by restoration age
      target: pathophysiology#Early-Onset Intractable Epilepsy
      assays:
      - preferred_term: electroencephalography
      - preferred_term: behavioral assay
      direction: POSITIVE
    controls:
    - name: Never-reactivated and wild-type
      description: Matched never-reactivated mutants and wild-type controls.
    decision_criterion: >-
      An intervention supports translational reversibility only when functional benefit follows verified target engagement after symptom onset, persists longitudinally, and is separable from leaky recombination or nonspecific treatment effects.
    would_support:
    - pathophysiology#Impaired Dendritic Spine Plasticity
- discussion_id: gap_cdkl5_mouse_model_epilepsy_fidelity
  prompt: >-
    How do sex, mosaicism, age, cell-type-specific deletion and neuronal differentiation affect the epilepsy fidelity of CDKL5 models?
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - pathophysiology#Neuronal Network Hyperexcitability
  - pathophysiology#Early-Onset Intractable Epilepsy
  rationale: >-
    Adult constitutive-null males in early studies lacked spontaneous seizures, whereas older heterozygous females develop spasms and other seizure phenotypes. CaV2.3 phosphosite mice reproduce a selected channel defect without spontaneous epilepsy. Human cortical organoid-derived cultures show transient early hyperexcitability that is absent in NGN2-induced cultures. These comparisons define endpoint-specific model suitability rather than one universally valid or invalid CDD model.
  evidence:
  - reference: PMID:24838000
    reference_title: Mapping pathological phenotypes in a mouse model of CDKL5 disorder.
    supports: NO_EVIDENCE
    evidence_source: MODEL_ORGANISM
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: did not reveal spontaneous epileptiform activity in hemizygous male Cdkl5 knockout mice
    explanation: The negative result is age- and genotype-specific.
  - reference: PMID:39855191
    reference_title: Independent genetic strategies define the scope and limits of CDKL5 deficiency disorder reversal.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: female mice with heterozygous loss of Cdkl5 develop myoclonic and tonic-clonic seizures upon aging
    explanation: The later female phenotype prevents generalizing the adult male negative finding.
  - reference: PMID:40930428
    reference_title: Excitatory cortical neurons from CDKL5 deficiency disorder patient-derived organoids show early hyperexcitability not identified in neurogenin2 induced neurons.
    supports: NO_EVIDENCE
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: Induced neurons showed no detectable differences between cases and isogenic controls in network activity using a multielectrode array
    explanation: A negative NGN2 result contrasts with the early cortical organoid-derived network phenotype.
  proposed_experiments:
  - experiment_id: exp_cdkl5_seizure_provocation_cross_model
    name: Seizure-susceptibility comparison across CDKL5 models
    description: >-
      Compare longitudinal spontaneous EEG, age-matched provoked seizure thresholds and independently measured cellular network activity across constitutive males, mosaic females, conditional knockouts and patient-derived cortical cultures. Analyze each endpoint within species and developmental stage; a culture cannot reproduce clinical seizure semiology.
    experiment_type:
      preferred_term: cross-model seizure-susceptibility experiment
    readouts:
    - name: Spontaneous and provoked epileptiform activity
      target: pathophysiology#Neuronal Network Hyperexcitability
      assays:
      - preferred_term: electroencephalography
      - preferred_term: multielectrode array recording
      direction: POSITIVE
    controls:
    - name: Wild-type and isogenic-corrected systems
      description: Matched non-mutant references for each model system.
    decision_criterion: >-
      Validate a model for a specified endpoint when it reproducibly reproduces that endpoint with appropriate controls; distinguish spontaneous epilepsy, provoked susceptibility and cultured network activity, rather than requiring every model to reproduce the full human syndrome.
    would_support:
    - pathophysiology#Early-Onset Intractable Epilepsy
- discussion_id: gap_cdkl5_fever_association
  prompt: What explains the bidirectional association between fever and seizure frequency in CDD?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Early-Onset Intractable Epilepsy
  rationale: A retrospective Chinese survey reported decreased seizures during fever in 47/84 participants, increased seizures in 19/84 and little change in 18/84. Reporting and selection bias remain, and no mechanistic intervention was performed. This is an association requiring prospective study, not a recommendation to induce fever.
  evidence:
  - reference: PMID:42644218
    reference_title: Nationwide Survey of Association Between Fever and Epileptic Seizure in CDKL5 Deficiency Disorder Revealed Therapeutic Implications.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: Meanwhile, 19 (22.6%) experienced increased seizure frequency, and 18 (21.4%) showed insignificant change.
    explanation: The full text documents opposing responses, qualifying the abstract focus on reduction.
references:
- reference: PMID:24838000
  title: Mapping pathological phenotypes in a mouse model of CDKL5 disorder.
- reference: PMID:30266824
  title: Chemical genetic identification of CDKL5 substrates reveals its role in neuronal microtubule dynamics.
- reference: PMID:30928302
  title: 'Cyclin-Dependent Kinase-Like 5 Deficiency Disorder: Clinical Review.'
- reference: PMID:31201320
  title: Altered NMDAR signaling underlies autistic-like features in mouse models of CDKL5 deficiency disorder.
- reference: PMID:31302675
  title: 'Incidence and phenotypes of childhood-onset genetic epilepsies: a prospective population-based national cohort.'
- reference: PMID:33538404
  title: Ataluren for drug-resistant epilepsy in nonsense variant-mediated Dravet syndrome and CDKL5 deficiency disorder.
- reference: PMID:35429480
  title: 'Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial.'
- reference: PMID:35795799
  title: International Consensus Recommendations for the Assessment and Management of Individuals With CDKL5 Deficiency Disorder.
- reference: PMID:37201242
  title: CDKL5 Deficiency Disorder Without Epilepsy.
- reference: PMID:37950390
  title: 'Long-term treatment with ganaxolone for seizures associated with cyclin-dependent kinase-like 5 deficiency disorder: Two-year open-label extension follow-up.'
- reference: PMID:38081835
  title: Epilepsy-linked kinase CDKL5 phosphorylates voltage-gated calcium channel Cav2.3, altering inactivation kinetics and neuronal excitability.
- reference: PMID:38603524
  title: CDKL5 Deficiency Disorder.
  tags:
  - GeneReviews
- reference: PMID:38959712
  title: 'Effects of ganaxolone on non-seizure outcomes in CDKL5 Deficiency Disorder: Double-blind placebo-controlled randomized trial.'
- reference: PMID:39033321
  title: Preclinical studies of gene replacement therapy for CDKL5 deficiency disorder.
- reference: PMID:39060900
  title: Caregiver Perspective of Benefits and Side Effects of Anti-Seizure Medications in CDKL5 Deficiency Disorder from an International Database.
- reference: PMID:39136782
  title: Novel CDKL5 targets identified in human iPSC-derived neurons.
- reference: PMID:39205479
  title: Deletions in the CDKL5 5' untranslated region lead to CDKL5 deficiency disorder.
- reference: PMID:39855191
  title: Independent genetic strategies define the scope and limits of CDKL5 deficiency disorder reversal.
- reference: PMID:40649845
  title: Transcriptomic Profiling of Zebrafish Mutant for cdkl5 Reveals Dysregulated Gene Expression Associated with Neuronal, Muscle, Visual and Skeletal Development.
- reference: PMID:40834685
  title: Antiseizure medications in CDKL5 encephalopathy- systematic review.
- reference: PMID:40847610
  title: CDKL5 regulates the initiation of retrograde axonal transport through CLIP170-dynactin complex formation.
- reference: PMID:40930428
  title: Excitatory cortical neurons from CDKL5 deficiency disorder patient-derived organoids show early hyperexcitability not identified in neurogenin2 induced neurons.
- reference: PMID:40982721
  title: 'Efficacy of ketogenic diet therapy for pediatric drug-resistant epilepsy with monogenic etiology: A single-arm meta-analysis.'
- reference: PMID:41677102
  title: 'Highly purified cannabidiol (CBD) in CDKL5 deficiency disorder (CDD): Open-label prospective study.'
- reference: PMID:41706882
  title: CDKL5 modulates the plasticity of excitatory synapses via liquid-liquid phase separation.
- reference: PMID:41963441
  title: Base editing restores CDKL5 expression and rescues neuronal deficits in a patient-derived model of CDKL5 deficiency disorder.
- reference: PMID:42644218
  title: Nationwide Survey of Association Between Fever and Epileptic Seizure in CDKL5 Deficiency Disorder Revealed Therapeutic Implications.
- reference: url:https://discovery.ucl.ac.uk/10153307/3/Cross_D-21-00849R2_Pestana%20Knight_MARIGOLD_MS_2022-01-26.pdf
  title: https://discovery.ucl.ac.uk/10153307/3/Cross_D-21-00849R2_Pestana%20Knight_MARIGOLD_MS_2022-01-26.pdf
- reference: url:https://index.mirasmart.com/AAN2026/PDFfiles/AAN2026-003281.html
  title: 2026 American Academy of Neurology Abstract Website
- reference: url:https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/212102s017lbl.pdf
  title: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/212102s017lbl.pdf
- reference: url:https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215904s012lbl.pdf
  title: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215904s012lbl.pdf
- reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
  title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
  tags:
  - GeneReviews
- reference: PMID:31313283
  title: 'CDKL5 deficiency disorder: Relationship between genotype, epilepsy, cortical visual impairment, and development.'
clinical_trials:
- name: NCT03572933
  phase: PHASE_III
  status: COMPLETED
  description: Marigold randomized ganaxolone trial with open-label extension; clinical results are summarized under ganaxolone.
  notes: Recruitment status checked against ClinicalTrials.gov on 2026-10-01.
  evidence:
  - reference: clinicaltrials:NCT03572933
    reference_title: A Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone Treatment in Children and Young Adults With Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) Followed by Long-term Open-label Treatment
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: A clinical study to evaluate the efficacy, safety, and tolerability of adjunctive ganaxolone therapy compared to placebo for the treatment of seizures in children and young adults with genetically confirmed CDKL5 gene mutation.
    explanation: The registry summary establishes the study purpose; status was checked against the live structured registry record.
- name: NCT05064878
  phase: PHASE_III
  status: ACTIVE_NOT_RECRUITING
  description: GEMZ fenfluramine randomized trial with open-label extension; preliminary 2026 conference efficacy data require distinction from regulatory approval.
  notes: Recruitment status checked against ClinicalTrials.gov on 2026-10-01.
  evidence:
  - reference: clinicaltrials:NCT05064878
    reference_title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Multicenter Study To Examine The Efficacy And Safety Of ZX008 In Subjects With CDKL5 Deficiency Disorder Followed By An Open-Label Extension
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: This is a Phase 3 Study to examine the efficacy and safety of ZX008 in children and adults with cyclin-dependent kinase like-5 (CDKL5) deficiency disorder (CDD).
    explanation: The registry summary establishes the study purpose; status was checked against the live structured registry record.
- name: NCT05249556
  phase: PHASE_III
  status: NOT_RECRUITING
  description: Ganaxolone trial planned for children aged six months to under two years. Registry status is NOT_YET_RECRUITING; this does not establish approval below age two.
  notes: Recruitment status checked against ClinicalTrials.gov on 2026-10-01.
  evidence:
  - reference: clinicaltrials:NCT05249556
    reference_title: Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone in the Treatment of Seizures Associated With Genetically Confirmed Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) in Pediatric Patients From 6 Months to Less Than 2 Years of Age.
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: This study will assess the efficacy, safety, and tolerability of ganaxolone (GNX) compared with placebo (PBO) as adjunctive therapy to the participant's standard anti-epileptic medication for the treatment of seizures in pediatric patients from 6 months to less than 2 years old with genetically confirmed CDD during a 12-week, DB phase. Pharmacokinetic (PK) assessments and population PK analyses will also be performed during this time. The DB phase will be followed by an optional long-term OL phase at which time all participants will receive GNX as an adjunct to their standard anti-seizure medication. Efficacy, safety and tolerability, and PK assessments will continue to be performed.
    explanation: The registry summary establishes the study purpose; status was checked against the live structured registry record.
- name: NCT02758626
  phase: PHASE_II
  status: COMPLETED
  description: Ataluren crossover study in nonsense-variant CDD and Dravet syndrome; published results show no benefit.
  notes: Recruitment status checked against ClinicalTrials.gov on 2026-10-01.
  evidence:
  - reference: clinicaltrials:NCT02758626
    reference_title: A Phase 2 Randomized, Double-Masked Placebo-Controlled Crossover Safety and Tolerability Study of Ataluren for Drug Resistant Epilepsy in Patients With Nonsense Mutation CDKL5 or Dravet Syndrome
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: 'This is a phase 2, crossover study of Ataluren for the treatment of nonsense mutation Dravet syndrome or cyclin-dependent kinase-like 5 (CDKL5) deficiency, resulting in drug-resistant epilepsy. Patients will receive 12 weeks of ataluren or placebo during each treatment period. Treatment Period 1 will be followed by a 4-week Washout Period. Based on ataluren PK and pharmacodynamic data, the 4-week washout period is deemed an appropriate length of time to eliminate any ataluren drug effects. Following the Washout Period, patients will crossover to receive the opposite treatment during Treatment Period 2 as follows: Patients receiving ataluren during Treatment Period 1 will receive placebo during Treatment Period 2. Patients receiving placebo during Treatment Period 1 will receive ataluren during Treatment Period 2.'
    explanation: The registry summary establishes the study purpose; status was checked against the live structured registry record.
- name: NCT03694275
  phase: PHASE_II
  status: COMPLETED
  description: ARCADE open-label soticlestat study in CDD and Dup15q; trial completion alone does not establish clinical efficacy.
  notes: Recruitment status checked against ClinicalTrials.gov on 2026-10-01.
  evidence:
  - reference: clinicaltrials:NCT03694275
    reference_title: A Multicenter, Open-label, Pilot Study of TAK-935 (OV935) in Patients With 15Q Duplication Syndrome or CDKL5 Deficiency Disorder (ARCADE Study)
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: The purpose of this study is to investigate the effect of soticlestat on the frequency of motor seizures for participants with Dup15q or CDD during the Maintenance Period.
    explanation: The registry summary establishes the study purpose; status was checked against the live structured registry record.
- name: NCT05558371
  phase: NOT_APPLICABLE
  status: RECRUITING
  description: International CDKL5 clinical research network natural-history study; observational outcomes are distinct from intervention trials.
  notes: Recruitment status checked against ClinicalTrials.gov on 2026-10-01.
  evidence:
  - reference: clinicaltrials:NCT05558371
    reference_title: Multi-Site Validation of Biomarkers and Core Clinical Outcome Measures for Clinical Trials Readiness in CDKL5 Deficiency Disorder
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: Pathogenic variants in the Cyclin-dependent kinase like 5 (CDKL5) gene cause CDKL5 deficiency disorder (CDD, MIM 300672, 105830), a severe developmental and epileptic encephalopathy associated with cognitive and motor impairments and cortical visual impairment. While capability for disease modifying therapies is accelerating, there is a critical barrier for clinical trial readiness that may result in failure of these therapies, not due to lack of efficacy but due to lack of validated outcome measures and biomarkers. The measures and biomarkers validated here will be adaptable to other developmental and epileptic encephalopathies.
    explanation: The registry summary establishes the study purpose; status was checked against the live structured registry record.
notes: CDD refers here to the loss-of-function developmental disorder; CDKL5 duplications or gain-of-function presentations may have a different clinical spectrum. Clinical severity and epilepsy course do not define established discrete subtypes. Early normal EEG or MRI does not exclude CDD. The ganaxolone full-text evidence URL is the accepted manuscript of PMID:35429480 in UCL Discovery, including supplemental eligibility and outcome tables; URL cache titles retain the generated source identifier. FDA label and AAN abstract URLs identify regulatory guidance and preliminary conference evidence respectively.
experimental_models:
- name: Patient-Derived Cortical Organoid Neurons
  experimental_model_type: IPSC_DERIVED_MODEL
  publication: PMID:40930428
  cell_source: Three patient/isogenic iPSC pairs, two male and one female, differentiated as guided cortical organoids and dissociated for assays
  description: Cortically specified cultures show early increases in firing and synchrony and reduced pEB2. Isogenic comparators came from mosaic or X-inactivation-defined clones; this is not a uniform CRISPR-corrected design. The network phenotype is clearest at days 17–28 and becomes inconsistent after day 30.
  modeled_mechanisms:
  - target: Neuronal Network Hyperexcitability
    description: Captures an early cortical network readout.
    evidence:
    - reference: PMID:40930428
      reference_title: Excitatory cortical neurons from CDKL5 deficiency disorder patient-derived organoids show early hyperexcitability not identified in neurogenin2 induced neurons.
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: patient-derived neurons from the organoid differentiation showed increased synchrony and weighted mean firing rate on the multielectrode array within the first month of network maturation
      explanation: MEA shows a time-limited network phenotype.
    relationship: PARTIALLY_RECAPITULATES
    model_scale: CELLULAR
    limitations: Dissociated culture activity is not clinical epilepsy; donor, clone, maturity and protocol influence the result.
    fidelity: MODERATE
- name: NGN2-Induced Patient Neurons
  experimental_model_type: IPSC_DERIVED_MODEL
  publication: PMID:40930428
  cell_source: Two male patient/isogenic iPSC pairs induced with NGN2
  description: pEB2 is reduced, but these cultures have poor cortical specification and show no detected network or neurite-length difference. They remain useful for selected biochemical readouts while failing to reproduce the cortical network phenotype under the tested conditions.
  modeled_mechanisms:
  - target: Neuronal Network Hyperexcitability
    description: The tested NGN2 cultures lack the observed cortical-network phenotype.
    evidence:
    - reference: PMID:40930428
      reference_title: Excitatory cortical neurons from CDKL5 deficiency disorder patient-derived organoids show early hyperexcitability not identified in neurogenin2 induced neurons.
      supports: NO_EVIDENCE
      evidence_source: IN_VITRO
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: Induced neurons showed no detectable differences between cases and isogenic controls in network activity using a multielectrode array
      explanation: A negative functional result limits this protocol for the linked mechanism.
    relationship: FAILS_TO_RECAPITULATE
    model_scale: CELLULAR
    limitations: Negative results concern this differentiation protocol and maturation window, not every possible use of NGN2 neurons.
    fidelity: LOW
  - target: Reduced EB2 Phosphorylation
    description: Provides a biochemical activity readout.
    evidence:
    - reference: PMID:40930428
      reference_title: Excitatory cortical neurons from CDKL5 deficiency disorder patient-derived organoids show early hyperexcitability not identified in neurogenin2 induced neurons.
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: Patient-derived neurons from both differentiation paradigms had decreased phosphorylated EB2
      explanation: The phosphorylation deficit is shared despite differing electrophysiology.
    relationship: MEASURES
    model_scale: CELLULAR
    limitations: A biochemical phenotype alone does not establish network or clinical fidelity.
    fidelity: MODERATE
- name: R550Ter Patient iPSC Base-Editing Rescue
  experimental_model_type: IPSC_DERIVED_MODEL
  publication: PMID:41963441
  cell_source: Female OR00005 mutant-active-X iPSCs, OR00006 wild-type-active-X comparator and selected ABE-corrected clones, differentiated with NGN2
  description: Adenine base editing corrected c.1648C>T in 2 of 24 selected iPSC colonies before neuronal differentiation. CDKL5 and pEB2 were restored with partial morphological and transcriptional rescue. Mutant neurons had longer, less-branched neurites. Eight predicted off-target sites were assayed; this does not establish genome-wide safety or editing of mature neurons.
  modeled_mechanisms:
  - target: Reduced EB2 Phosphorylation
    description: Genetic correction restores the substrate readout.
    evidence:
    - reference: PMID:41963441
      reference_title: Base editing restores CDKL5 expression and rescues neuronal deficits in a patient-derived model of CDKL5 deficiency disorder.
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: ABE-correction restored EB2 Ser223 phosphorylation to nearly Control levels
      explanation: Correction restores a validated biochemical endpoint.
    relationship: RESCUES
    model_scale: CELLULAR
    limitations: Clone/X-inactivation differences remain; no clinical seizure efficacy, postmitotic delivery or comprehensive off-target safety was tested.
    fidelity: MODERATE
- name: MAP1S Microtubule Dynamics and Rescue Assays
  experimental_model_type: PRIMARY_CELL_CULTURE
  publication: PMID:30266824
  cell_source: Embryonic wild-type and Cdkl5-null cortical neurons, plus recombinant binding assays
  description: EB3 imaging shows prolonged growth lifetime/distance; MAP1S knockdown rescues lifetime whereas EB2 knockdown does not. Putative MAP1S Ser786/812Asp phosphomimetics fail to reproduce phosphorylation-dependent dissociation.
  modeled_mechanisms:
  - target: Prolonged Dendritic Microtubule Growth
    description: Directly measures and manipulates dendritic growth dynamics.
    evidence:
    - reference: PMID:30266824
      reference_title: Chemical genetic identification of CDKL5 substrates reveals its role in neuronal microtubule dynamics.
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: MAP1S knockdown rescued the increase in comet lifetime in Cdkl5 KO neurons, while EB2 knockdown had no effect
      explanation: Selective knockdown discriminates among candidate mediators.
    relationship: PERTURBS
    model_scale: CELLULAR
    limitations: Culture dynamics and TrkB transport do not by themselves establish human seizure or developmental causality.
    fidelity: MODERATE
- name: CLIP170-Dynactin and Cargo Transport Assays
  experimental_model_type: PRIMARY_CELL_CULTURE
  publication: PMID:40847610
  cell_source: CDKL5-depleted HeLa/COS7 cells and embryonic Cdkl5-null hippocampal cultures
  description: WT and kinase-dead A40V restore dynactin recruitment. Pregnenolone at 1 micromolar rescues complex association and cargo movement in culture; it is distinct from clinical ganaxolone treatment.
  modeled_mechanisms:
  - target: Impaired CLIP170-Dynactin Association
    description: Tests a kinase-independent structural function.
    evidence:
    - reference: PMID:40847610
      reference_title: CDKL5 regulates the initiation of retrograde axonal transport through CLIP170-dynactin complex formation.
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: the re-expression of both CDKL5-WT and CDKL5-A40V restored the localization of p150glued
      explanation: Kinase-dead rescue argues against assigning this result solely to catalytic loss.
    relationship: PERTURBS
    model_scale: CELLULAR
    limitations: Heterologous-cell complex assembly and embryonic neuron transport have not established clinical pregnenolone efficacy.
    fidelity: MODERATE
- name: Postsynaptic Condensate Reconstitution
  experimental_model_type: OTHER
  publication: PMID:41706882
  cell_source: Recombinant CDKL5 C-terminal fragments, transfected HEK293T cells and cultured hippocampal neurons
  description: Phase-separation, PSD95 binding and Kalirin7 recruitment assays test structural plasticity. K42R kinase-dead protein retains condensation. Engineered phase-separation-deficient mutants and individual patient-associated variants have different effects.
  modeled_mechanisms:
  - target: Altered Postsynaptic Condensate Organization
    description: Reconstitutes and perturbs condensate organization.
    evidence:
    - reference: PMID:41706882
      reference_title: CDKL5 modulates the plasticity of excitatory synapses via liquid-liquid phase separation.
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: CDKL5 undergoes liquid–liquid phase separation (LLPS) in vitro and in cultured neurons, forming cocondensates with PSD95.
      explanation: The assay measures condensate formation and recruitment.
    relationship: PERTURBS
    model_scale: CELLULAR
    limitations: Recombinant C-terminal fragments and overexpression do not establish that every CDD allele abolishes phase separation; clinical variant interpretation remains separate.
    fidelity: MODERATE
- name: Isogenic R59Ter Neuronal Phosphoproteomics
  experimental_model_type: IPSC_DERIVED_MODEL
  publication: PMID:39136782
  cell_source: Male patient R59Ter neurons and CRISPR-corrected isogenic controls; orthogonal HEK293T validation
  description: Phosphoproteomic comparison nominated substrates; PPP1R35 Ser52 and GTF2I Ser674 were validated in heterologous assays. Endogenous neuronal antibody validation failed because of background, while GATAD2A and ZNF219 candidates were not equivalently confirmed. Their functional contribution to CDD remains unresolved.
  modeled_mechanisms:
  - target: Loss of CDKL5 Kinase Activity in Neurons
    description: Maps candidate downstream phosphorylation changes.
    evidence:
    - reference: PMID:39136782
      reference_title: Novel CDKL5 targets identified in human iPSC-derived neurons.
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: With this antibody we showed highest phosphorylation when GTF2I WT was co-expressed with CDKL5 WT, and phosphorylation levels were significantly lower when co-expressed with CDKL5 K42R
      explanation: The study combines neuronal phosphoproteomics with orthogonal substrate assays; downstream clinical causality is not established.
    relationship: MEASURES
    model_scale: CELLULAR
    limitations: Not every differential phosphosite is a direct substrate; function of the validated sites and relevance to clinical phenotypes remain open.
    fidelity: MODERATE
animal_models:
- name: Constitutive Cdkl5 Exon-4 Knockout
  species: Mus musculus
  genotype: Hemizygous males, homozygous females and heterozygous females
  publication: PMID:24838000
  description: The exon-4 deletion eliminates protein but leaves mutant RNA detectable. Adult mutants show compartment-specific arbor defects, abnormal visual responses and motor behaviors. Home-cage hypoactivity does not imply inability to move in a novel arena. Two-to-four-month-old males lacked spontaneous EEG seizures on the tested backgrounds.
  modeled_mechanisms:
  - target: Reduced Dendritic Arborization
    description: Reproduces selected adult neuronal morphology changes.
    evidence:
    - reference: PMID:24838000
      reference_title: Mapping pathological phenotypes in a mouse model of CDKL5 disorder.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: Total length of apical dendritic arbors was significantly reduced
      explanation: Morphometry supports the specified neuronal readout.
    relationship: PARTIALLY_RECAPITULATES
    model_scale: CELLULAR
    limitations: The phenotype depends on age and compartment; P20 basal arbors and other cultures need not reproduce adult apical-arbor findings.
    fidelity: MODERATE
  - target: Early-Onset Intractable Epilepsy
    description: Does not reproduce the severe early seizure syndrome in the tested adult males.
    evidence:
    - reference: PMID:24838000
      reference_title: Mapping pathological phenotypes in a mouse model of CDKL5 disorder.
      supports: NO_EVIDENCE
      evidence_source: MODEL_ORGANISM
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: did not reveal spontaneous epileptiform activity in hemizygous male Cdkl5 knockout mice
      explanation: The adult recording experiment provides a negative seizure result.
    relationship: FAILS_TO_RECAPITULATE
    model_scale: ORGANISM
    limitations: This does not extend to neonatal recordings, every conditional genotype, or older heterozygous females.
    fidelity: LOW
- name: Timed Endogenous Cdkl5 Restoration
  species: Mus musculus
  genotype: Cdkl5STOP/UBC-CreER and Cdkl5FLEX/CAGG-CreER males and heterozygous females
  publication: PMID:39855191
  description: Re-expression at six weeks reverses multiple behaviors and reduces later spasms in heterozygous females. Restoration at six months has less benefit, including no significant reduction of established female spasms and no male fear-memory rescue. Working-memory deficits persist. The STOP system leaks; the independent FLEX system controls that limitation.
  modeled_mechanisms:
  - target: Early-Onset Intractable Epilepsy
    description: Tests age-dependent rescue of the mouse seizure phenotype.
    evidence:
    - reference: PMID:39855191
      reference_title: Independent genetic strategies define the scope and limits of CDKL5 deficiency disorder reversal.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: Seizure prevention is more effective with early intervention in heterozygous females but becomes limited after seizure onset.
      explanation: Timed rescue distinguishes prevention from reversal of established spasms.
    relationship: RESCUES
    model_scale: ORGANISM
    limitations: Older female spasms differ in timing from human infantile epilepsy; genetic recombination is not a clinically deliverable therapy, and early rescue does not abolish all spasms.
    fidelity: MODERATE
- name: CaV2.3 Ser15Ala Phosphosite Knock-In
  species: Mus musculus
  genotype: Homozygous and heterozygous Cacna1e Ser15Ala knock-in
  publication: PMID:38081835
  description: The phosphosite mutant prolongs channel currents and enhances cholinergic responses in slices, with partial, sex-dependent behavioral effects. Females have increased kainate susceptibility, but no spontaneous behavioral seizures were observed through forty weeks.
  modeled_mechanisms:
  - target: Prolonged CaV2.3 Current
    description: Tests one downstream phosphosite without deleting all CDKL5 functions.
    evidence:
    - reference: PMID:38081835
      reference_title: Epilepsy-linked kinase CDKL5 phosphorylates voltage-gated calcium channel Cav2.3, altering inactivation kinetics and neuronal excitability.
      supports: NO_EVIDENCE
      evidence_source: MODEL_ORGANISM
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: We did not observe any spontaneous behavioural seizures in Cav2.3 S15A mice up to 40 weeks of age
      explanation: The channel mechanism has limited epilepsy fidelity despite electrophysiological changes.
    relationship: PERTURBS
    model_scale: CELLULAR
    limitations: The negative seizure result limits translation but does not refute the directly measured channel kinetics.
    fidelity: MODERATE
- name: Neonatal AAV9 CDKL5 Replacement
  species: Mus musculus
  genotype: Neonatal male Cdkl5 knockout treated with AAV9.Syn.hCDKL5
  publication: PMID:39033321
  description: Intracerebroventricular delivery improved distribution relative to intracisternal delivery. Higher doses restored pEB2 and improved selected behavioral outcomes when at least half of neurons were transduced; lower doses did not produce functional benefit.
  modeled_mechanisms:
  - target: Loss of CDKL5 Kinase Activity in Neurons
    description: Restores kinase output in a neonatal replacement model.
    evidence:
    - reference: PMID:39033321
      reference_title: Preclinical studies of gene replacement therapy for CDKL5 deficiency disorder.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: AAV9.Syn.hCDKL5 treatment increased phosphorylation of EB2, a bona fide CDKL5 substrate, demonstrating biological activity in vivo.
      explanation: The available abstract establishes biochemical rescue and dose-dependent functional effects.
    relationship: RESCUES
    model_scale: CELLULAR
    limitations: Assessment is limited to the available abstract after full-text retrieval failures; neonatal male delivery does not establish efficacy or safety in older mosaic females or humans.
    fidelity: MODERATE
- name: cdkl5sa21938 Zebrafish
  species: Danio rerio
  genotype: Homozygous nonsense mutant compared with wild-type siblings
  publication: PMID:40649845
  description: Whole-animal RNA-seq at five and thirty-five days shows changes in neuronal, skeletal, muscle and visual gene programs. Three-day Hb9:GFP motor neurons have reduced number and axon length. Transcript enrichment is not proof of direct substrate regulation or of the corresponding human symptom mechanism.
  modeled_mechanisms:
  - target: Reduced Functional CDKL5 Protein
    description: Perturbs the ortholog and measures broad transcriptional consequences.
    evidence:
    - reference: PMID:40649845
      reference_title: Transcriptomic Profiling of Zebrafish Mutant for cdkl5 Reveals Dysregulated Gene Expression Associated with Neuronal, Muscle, Visual and Skeletal Development.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: cdkl5 was one of the genes found to be differentially expressed between the two groups at both stages of development.
      explanation: Reduced mutant transcript supports loss of ortholog function; protein abundance was not directly quantified here.
    relationship: PERTURBS
    model_scale: ORGANISM
    limitations: RNA comes from whole animals, not isolated brain. Tissue proportions and developmental stage can affect enrichment; early heart rate was unchanged despite cardiac pathway enrichment.
    fidelity: LOW
differential_diagnoses:
- name: Rett Syndrome
  disease_term:
    preferred_term: Rett syndrome
    term:
      id: MONDO:0010726
      label: Rett syndrome
  description: CDD was historically classified as an early-onset seizure variant of Rett syndrome, but it is a distinct molecular disorder. Developmental impairment and hand stereotypies can overlap.
  distinguishing_features:
  - Very early-onset seizures and cerebral visual impairment favor CDD over classic Rett syndrome.
  - Hand stereotypies in classic Rett syndrome are generally less distractible and may differ qualitatively from those in CDD.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader
    reference_title: CDKL5 Deficiency Disorder - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: In addition, very early-onset seizures and cerebral visual impairment are not generally seen in classic Rett syndrome.
    explanation: The GeneReviews differential explicitly distinguishes CDD from classic Rett syndrome.

📚

References & Deep Research

References

PMID:24838000

Mapping pathological phenotypes in a mouse model of CDKL5 disorder.

No top-level findings curated for this source.

PMID:30266824

Chemical genetic identification of CDKL5 substrates reveals its role in neuronal microtubule dynamics.

No top-level findings curated for this source.

PMID:30928302

Cyclin-Dependent Kinase-Like 5 Deficiency Disorder: Clinical Review.

No top-level findings curated for this source.

PMID:31201320

Altered NMDAR signaling underlies autistic-like features in mouse models of CDKL5 deficiency disorder.

No top-level findings curated for this source.

PMID:31302675

Incidence and phenotypes of childhood-onset genetic epilepsies: a prospective population-based national cohort.

No top-level findings curated for this source.

PMID:33538404

Ataluren for drug-resistant epilepsy in nonsense variant-mediated Dravet syndrome and CDKL5 deficiency disorder.

No top-level findings curated for this source.

PMID:35429480

Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial.

No top-level findings curated for this source.

PMID:35795799

International Consensus Recommendations for the Assessment and Management of Individuals With CDKL5 Deficiency Disorder.

No top-level findings curated for this source.

PMID:37201242

CDKL5 Deficiency Disorder Without Epilepsy.

No top-level findings curated for this source.

PMID:37950390

Long-term treatment with ganaxolone for seizures associated with cyclin-dependent kinase-like 5 deficiency disorder: Two-year open-label extension follow-up.

No top-level findings curated for this source.

PMID:38081835

Epilepsy-linked kinase CDKL5 phosphorylates voltage-gated calcium channel Cav2.3, altering inactivation kinetics and neuronal excitability.

No top-level findings curated for this source.

PMID:38603524

CDKL5 Deficiency Disorder.

No top-level findings curated for this source.

PMID:38959712

Effects of ganaxolone on non-seizure outcomes in CDKL5 Deficiency Disorder: Double-blind placebo-controlled randomized trial.

No top-level findings curated for this source.

PMID:39033321

Preclinical studies of gene replacement therapy for CDKL5 deficiency disorder.

No top-level findings curated for this source.

PMID:39060900

Caregiver Perspective of Benefits and Side Effects of Anti-Seizure Medications in CDKL5 Deficiency Disorder from an International Database.

No top-level findings curated for this source.

PMID:39136782

Novel CDKL5 targets identified in human iPSC-derived neurons.

No top-level findings curated for this source.

PMID:39205479

Deletions in the CDKL5 5' untranslated region lead to CDKL5 deficiency disorder.

No top-level findings curated for this source.

PMID:39855191

Independent genetic strategies define the scope and limits of CDKL5 deficiency disorder reversal.

No top-level findings curated for this source.

PMID:40649845

Transcriptomic Profiling of Zebrafish Mutant for cdkl5 Reveals Dysregulated Gene Expression Associated with Neuronal, Muscle, Visual and Skeletal Development.

No top-level findings curated for this source.

PMID:40834685

Antiseizure medications in CDKL5 encephalopathy- systematic review.

No top-level findings curated for this source.

PMID:40847610

CDKL5 regulates the initiation of retrograde axonal transport through CLIP170-dynactin complex formation.

No top-level findings curated for this source.

PMID:40930428

Excitatory cortical neurons from CDKL5 deficiency disorder patient-derived organoids show early hyperexcitability not identified in neurogenin2 induced neurons.

No top-level findings curated for this source.

PMID:40982721

Efficacy of ketogenic diet therapy for pediatric drug-resistant epilepsy with monogenic etiology: A single-arm meta-analysis.

No top-level findings curated for this source.

PMID:41677102

Highly purified cannabidiol (CBD) in CDKL5 deficiency disorder (CDD): Open-label prospective study.

No top-level findings curated for this source.

PMID:41706882

CDKL5 modulates the plasticity of excitatory synapses via liquid-liquid phase separation.

No top-level findings curated for this source.

PMID:41963441

Base editing restores CDKL5 expression and rescues neuronal deficits in a patient-derived model of CDKL5 deficiency disorder.

No top-level findings curated for this source.

PMID:42644218

Nationwide Survey of Association Between Fever and Epileptic Seizure in CDKL5 Deficiency Disorder Revealed Therapeutic Implications.

No top-level findings curated for this source.

url:https://discovery.ucl.ac.uk/10153307/3/Cross_D-21-00849R2_Pestana%20Knight_MARIGOLD_MS_2022-01-26.pdf

https://discovery.ucl.ac.uk/10153307/3/Cross_D-21-00849R2_Pestana%20Knight_MARIGOLD_MS_2022-01-26.pdf

No top-level findings curated for this source.

url:https://index.mirasmart.com/AAN2026/PDFfiles/AAN2026-003281.html

2026 American Academy of Neurology Abstract Website

No top-level findings curated for this source.

url:https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/212102s017lbl.pdf

https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/212102s017lbl.pdf

No top-level findings curated for this source.

url:https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215904s012lbl.pdf

https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215904s012lbl.pdf

No top-level findings curated for this source.

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK602610/?report=reader

CDKL5 Deficiency Disorder - GeneReviews® - NCBI Bookshelf

No top-level findings curated for this source.

PMID:31313283

CDKL5 deficiency disorder: Relationship between genotype, epilepsy, cortical visual impairment, and development.

No top-level findings curated for this source.

Deep Research

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (1)

Create: CDKL5 Deficiency Disorder · 2026-07-18T02:01:03Z · View source

De-novo curation of CDKL5 deficiency disorder (MONDO:0100039), an X-linked developmental and epileptic encephalopathy, with granular unbundled pathophysiology (CDKL5 LoF variant -> loss of kinase activity -> impaired dendritic spine/synapse development -> E/I imbalance -> network hyperexcitability -> early-onset intractable epilepsy; parallel effector nodes for impaired neurodevelopment, movement disorder, cortical visual impairment, autonomic dysfunction) with three conforms_to links to the epilepsy_excitation_inhibition_imbalance module. GeneReviews baseline (PMID:38603524) used and tagged. Deep research provider: claude_code. Evidence snippet-verified: 38603524 (GeneReviews), 30266824 (CDKL5 substrates MAP1S/EB2/ARHGEF2, patient-neuron relevance), 35429480 (ganaxolone Marigold phase 3 RCT), 24838000 (Cdkl5-KO mouse), 39033321 (preclinical gene replacement). Discussions section: substrate-to-phenotype causality gap, gene-replacement reversibility/treatment-window gap, and Cdkl5-mouse epilepsy HUMAN_MODEL_MISMATCH. All snippets manually confirmed as exact substrings; schema/term/reference/folded-hyphen validation pass.

Claude Code ▸

CDKL5 Deficiency Disorder — Comprehensive Research Report

claude-haiku-4-5-20251001, claude-opus-4-8 15 citations 2026-07-17T21:52:04.184210

CDKL5 Deficiency Disorder — Comprehensive Research Report

sup Harry. Pulled this one together from GeneReviews, the 2022 Lancet Neurology clinical review, the Marigold trial, the international consensus recommendations, and the mechanism/mouse-model literature, cross-checked identifiers against the repo's local MONDO. CDD is one of those disorders where the genetics are clean (one X-linked kinase, mostly de novo) but the downstream biology is a sprawling delta — a single busted enzyme upstream, and the river fans out into seizures, blindness, gut trouble, and movement disorder downstream. Here's the whole map.

1. Disease Information

Overview. CDKL5 Deficiency Disorder (CDD) is a rare, X-linked, monogenic developmental and epileptic encephalopathy (DEE) caused by loss-of-function variants in CDKL5 (cyclin-dependent kinase-like 5). The core clinical picture is a triad: early-onset, treatment-refractory epilepsy (usually beginning in the first 2–3 months of life), severe global developmental impairment, and cerebral/cortical visual impairment (CVI). It was historically lumped under "early-onset seizure variant of Rett syndrome" but is now recognized as an independent clinical entity — the developmental impairment is present from the earliest months and is not a regression after normal development the way classic Rett is (Fehr et al. 2013, PMID:23443029; Leonard et al. 2022, PMID:35483386).

Key identifiers. - MONDO: MONDO:0100039 "CDKL5 disorder" (exact synonym: CDKL5 Deficiency Disorder) — the gene-anchored umbrella term. The narrower phenotype term is MONDO:0010396 "developmental and epileptic encephalopathy, 2" (DEE2). For a dismech entry I'd anchor on MONDO:0100039 as the primary disease_term, since the KB uses CDD as the disease-level entity. - OMIM: #300672 — Developmental and Epileptic Encephalopathy 2 (DEE2); older aliases EIEE2 / "Epileptic encephalopathy, early infantile, 2." - Orphanet: ORPHA:505652 (CDKL5-deficiency disorder). - ICD-11: 8A62 (developmental and epileptic encephalopathy) grouping; ICD-10 usually coded under G40.4 / G40.89. - MeSH: C564064; UMLS: C4750718; DOID: DOID:0080467; GARD: 0018617; NORD: 904. - Gene: CDKL5, hgnc:11411, cytoband Xp22.13.

Synonyms / alternative names. CDKL5 disorder; CDKL5 encephalopathy; early-onset seizure variant of Rett syndrome (historical/deprecated); "atypical Rett syndrome, Hanefeld variant" (historical); early infantile epileptic encephalopathy type 2 (EIEE2, deprecated); DEE2; STK9 deficiency (STK9 is the old gene symbol).

Data source type. Almost everything here is disease-level aggregated knowledge from patient registries (the International CDKL5 Disorder Database / ICDD, the US CDKL5 Centers of Excellence, the Italian and other national cohorts) and case series — not single-patient EHR. The largest natural-history datasets come from these registries plus the Marigold trial cohort.

2. Etiology

Primary cause — genetic. CDD is a monogenic disorder: pathogenic/likely-pathogenic loss-of-function variants in CDKL5, a serine/threonine protein kinase. There is no environmental or infectious cause; environment is not thought to trigger disease onset (though catabolic/illness stress and photic/other triggers can precipitate individual seizures, as in any epilepsy). MONDO definition: "A monogenic disease that has material basis in mutation in the CDKL5 gene."

Genetic risk factors. - The causal variant in CDKL5 is the disease. The vast majority (>90–95%) are de novo; rare familial recurrences occur via parental germline (gonadal) mosaicism or, uncommonly, X-linked transmission from a mildly/asymptomatic carrier mother (skewed X-inactivation) (GeneReviews, NBK602610). - Sex as a modifier of expression: because CDKL5 is X-linked, males (hemizygous) and females (heterozygous, subject to X-inactivation) differ. Females are affected ~12:1 over males in ascertained cohorts, but affected males often have an equally severe or more severe course (no second normal allele), except mosaic males who can be milder.

Protective factors. - X-inactivation skewing toward the mutant allele can act protectively (or deleteriously, depending on direction) in heterozygous females — cellular mosaicism means some neurons retain wild-type CDKL5. Somatic mosaicism for the variant (in either sex) is associated with milder phenotypes, including reported cases without epilepsy (MacKay et al. 2020; "CDKL5 Deficiency Disorder Without Epilepsy," S0887899423001248). - No dietary or lifestyle protective factor is established. No protective germline variant at another locus is known.

Gene–environment interactions. Not a meaningful axis for CDD — it is a highly penetrant monogenic disorder. The relevant "interaction" is genotype × X-inactivation × mosaicism, i.e., an intrinsic genomic modifier landscape rather than gene × environment.

3. Phenotypes

CDD is a multi-system neurodevelopmental disorder. Frequencies below are from registry cohorts (ICDD, Fehr et al. 2016 PMID:27884167; Leonard et al. 2022 PMID:35483386; Olson et al. 2019 PMID:30928302) — treat percentages as cohort-derived, and per dismech policy, cite the association separately from the frequency band.

Neurological / seizures (near-universal, the defining feature). - Early-onset epilepsy — >90% by 3 months; median onset ~6 weeks; ~90% seizing by 12 months. HP:0011097 (epileptic spasms), HP:0011145 (Tonic seizure), HP:0002069 (bilateral tonic-clonic seizure), HP:0032794 (hypermotor seizure). Suggest umbrella HP:0001250 (Seizure), plus HP:0011451 (infantile onset). A characteristic multi-stage pattern is described: early tonic/spasm seizures → a "honeymoon" remission period in some → later refractory epilepsy with mixed types (mean ~2.8 seizure types at once). Frequency: Very frequent/obligate. - Refractory / drug-resistant epilepsy — HP:0002133 (Status epilepticus can occur); HP:0032807 (Drug-resistant epilepsy). Frequent. - A distinctive "hypermotor–tonic–spasms" (HTS) seizure sequence has been reported as characteristic of CDD.

Developmental / cognitive. - Severe global developmental delay / intellectual disability — HP:0011344 (Severe global developmental delay), HP:0010864 (Intellectual disability, severe/profound). Present from earliest months (not a regression). Nearly universal. - Absent or severely limited speech — HP:0001344 (Absent speech). Frequent. - Motor: only ~25% of girls (fewer boys) achieve independent walking; <75% of girls sit independently by age 5. HP:0002540 (Inability to walk), HP:0001260 (Dysarthria), HP:0001263 (Global developmental delay).

Tone & movement. - Hypotonia — HP:0001252 (Hypotonia), central, early. Very frequent. - Later spasticity / hypertonia — HP:0001276; dystonia HP:0001332; chorea HP:0002072; stereotypies including hand stereotypies (Rett-like hand-wringing/mouthing) HP:0000733 (Abnormal repetitive mannerisms). Frequent. - Bruxism HP:0003763.

Visual. - Cerebral/cortical visual impairment (CVI) — HP:0100704 (Cerebral visual impairment). Very frequent (~majority) and correlates with developmental achievement — vision is being explored as an outcome measure (Olson et al. 2021, PMID:34028805; PMID:34547934). Poor eye contact/abnormal visual tracking noted from infancy. HP:0000496 (Abnormality of eye movement), HP:0000618 (Blindness) in severe cases. - Strabismus HP:0000486; roving eye movements.

Autonomic / GI / respiratory. - Gastrointestinal dysfunction — constipation HP:0002019, gastroesophageal reflux HP:0002020, feeding difficulties HP:0011968, some needing gastrostomy. Frequent. - Sleep disturbance / dysregulation — HP:0002360 (Sleep disturbance). Frequent. - Breathing abnormalities (irregular breathing, breath-holding) HP:0002793. - Autonomic dysfunction — temperature dysregulation, cold extremities HP:0012332.

Growth / skeletal / other. - Acquired microcephaly — HP:0005484 (Postnatal microcephaly) in a subset (head circumference often normal at birth). More variable than in Rett. - Feeding difficulty → growth issues / short stature HP:0004322. - Scoliosis HP:0002650; hip dysplasia HP:0001385; osteopenia/low bone density HP:0000938 (from immobility + AEDs). - Subtle dysmorphic features in some (broad forehead, deep-set eyes, tapered fingers) — non-specific.

Behavioral. - Autistic features / autistic-like behavior — HP:0000717 (Autism), HP:0000729 (Autistic behavior). HP:0000718 irritability. Frequent, particularly notable given the mouse-model NMDAR data below.

Quality-of-life impact. Profound. Most individuals are non-verbal, non-ambulatory or minimally ambulatory, fully dependent for ADLs, with lifelong care needs. Caregiver burden is very high; refractory seizures, sleep disruption, GI problems, and CVI each independently degrade daily functioning. Registry-based QoL work uses caregiver-reported and disease-specific measures (the CDKL5 Developmental Score, the Marigold trial's caregiver global impression) rather than generic EQ-5D/SF-36, which don't capture this population well.

4. Genetic / Molecular Information

Causal gene. CDKL5 (cyclin-dependent kinase-like 5; old symbol STK9), Xp22.13, hgnc:11411, OMIM gene 300203. Encodes a ~115 kDa serine/threonine protein kinase of the CMGC kinase family (related to CDKs and MAPKs). Structure: an N-terminal catalytic kinase domain (roughly aa 13–297, containing the ATP-binding site and the TEY activation-loop motif) and a large C-terminal regulatory domain that controls localization (nuclear/cytoplasmic shuttling) and autoinhibition. Multiple transcript isoforms exist (hCDKL5_1 and the brain-predominant hCDKL5_5 being the clinically dominant ones).

Pathogenic variants. - >300 pathogenic/likely-pathogenic variants catalogued (ClinVar, the LOVD CDKL5 database, HGMD). Full allelic spectrum: missense, nonsense, frameshill/frameshift (indels), splice-site, and large intragenic/whole-gene deletions & duplications plus complex rearrangements. Roughly: truncating (nonsense/frameshift/splice) ~50–60%, missense ~20–30%, large CNV/deletion ~10–15%. - Missense variants cluster in the catalytic kinase domain (they disrupt folding/ATP binding/catalysis). Arg178 is a recognized missense mutational hotspot; other recurrent residues include Ala40, Arg59, Cys152, Arg134. p.Thr288 and the activation loop matter for catalytic activity. - Variant classification follows ACMG/AMP; ClinGen has a CDKL5-specific variant curation expert panel. Most de novo LoF in a well-established haploinsufficient/hemizygous-lethal gene meet PVS1/PS2 criteria. - Somatic vs germline: overwhelmingly germline de novo; somatic/germline mosaicism occurs and predicts milder phenotype. - Functional consequence: loss of function (haploinsufficiency in females via X-linked mosaicism; complete loss in hemizygous males). Kinase-dead missense = LoF at the catalytic level. No convincing gain-of-function or dominant-negative mechanism is established; the disorder is a kinase-deficiency state.

Allele frequency. Pathogenic variants are absent from population databases (gnomAD) — consistent with de novo, highly deleterious, non-inherited variants under strong selection. CDKL5 is strongly loss-of-function-intolerant (high pLI / low LOEUF in gnomAD constraint metrics).

Genotype–phenotype correlations. Real but imperfect: - More severe: missense variants within the catalytic kinase domain, and truncations after aa ~781 (disrupting the far C-terminus). Higher seizure burden, more profound motor disability. - Milder: missense affecting the ATP-binding region and truncations located between aa ~172 and ~781, and mosaic cases. - Even so, substantial intra-genotype variability exists (the "clinical variability is probably genetically determined" caveat from Leonard 2022), implying modifier effects.

Modifier genes. No specific trans-acting modifier gene is validated in humans. The dominant modifiers are X-inactivation pattern and mosaicism. This is a good candidate spot for a dismech Inheritance/genetic note rather than a hard modifier-gene claim.

Epigenetics. CDKL5 itself is subject to X-chromosome inactivation (the central epigenetic phenomenon here). CDKL5 protein also feeds back onto chromatin/nuclear signaling (it interacts with MeCP2 and DNMT1 and influences the methyl-CpG machinery — the mechanistic bridge to Rett), but CDD is not primarily an imprinting/methylation disease.

Chromosomal abnormalities. Large Xp22 deletions encompassing CDKL5 (sometimes contiguous-gene deletions involving NHS, ARX neighbors), and the historically described balanced X;autosome translocations disrupting CDKL5/STK9 (Kalscheuer et al. 2003, PMID:14508708) that first implicated the gene. Detected by chromosomal microarray / MLPA when sequencing is negative.

5. Environmental Information

Environmental factors: none causal. CDD is genetic and highly penetrant. No toxin, radiation, pollution, or occupational exposure is implicated in causation.

Lifestyle factors: not applicable to disease causation. Downstream management touches on nutrition (feeding, ketogenic diet as a seizure therapy) but these are treatments, not risk factors.

Infectious agents: none. No pathogen causes or triggers CDD. (Intercurrent infection/fever can lower seizure threshold, as in any epilepsy, but that's a nonspecific precipitant, not etiology.)

6. Mechanism / Pathophysiology

CDD is fundamentally a kinase-deficiency disorder: loss of CDKL5 catalytic activity removes phosphorylation of a small set of neuronal substrates, degrading cytoskeletal dynamics, synapse formation, and activity-dependent circuit regulation during a critical early-postnatal window.

The upstream lesion → substrate phosphorylation failure. CDKL5 is a serine/threonine kinase with an RPXS* consensus phosphorylation motif. Chemical-genetic substrate mapping (Baltussen et al. 2018, EMBO J, PMID:30266824) identified three high-confidence neuronal substrates, all microtubule-associated proteins: - MAP1S (Ser786), - EB2/MAPRE2 (Ser222), - ARHGEF2 (Ser122).

Quote: "CDKL5 phosphorylates three microtubule-associated proteins: MAP1S, EB2 and ARHGEF2… all phosphorylation sites contained an RPXS* consensus motif." Crucially, these phospho-events are reduced in patient iPSC-derived neurons, confirming human relevance. Other proposed/context-dependent substrates: CDKL5 phosphorylates EB2 to regulate microtubule plus-end dynamics; additional literature implicates NGL-1 (LRRTM/netrin-G ligand), PSD-95, Shootin1, HDAC4, and AMPA/GluA2 trafficking.

Cellular processes affected (the causal chain): 1. Microtubule dynamics dysregulation — in Cdkl5-KO neurons, dendritic microtubules show longer EB3-labelled plus-end growth duration; this is rescued by lowering MAP1S, pinning the defect on failed MAP1S phosphorylation. (GO:0000226 microtubule cytoskeleton organization, GO:0031117 positive regulation of microtubule depolymerization.) 2. Impaired neuronal morphogenesis — reduced dendritic arborization of cortical neurons, abnormal axon outgrowth, and reduced dendritic spine density/maturation. (GO:0048667 cell morphogenesis involved in neuron differentiation, GO:0007409 axonogenesis, GO:0048813 dendrite morphogenesis, GO:0050768 regulation of neurogenesis.) 3. Synaptic dysfunction & E/I imbalance — CDKL5 is enriched at excitatory postsynaptic densities; its loss impairs synapse formation/stability. Cell-type-specific KO shows selective loss in GABAergic interneurons → excessive glutamatergic transmission, hyperexcitability, and increased postsynaptic NMDA receptors (Tang et al. 2019, Nat Commun, s41467-019-10689-w) — a mechanistic link to both seizures and autistic-like behavior. (GO:0050804 modulation of chemical synaptic transmission, GO:0007268 chemical synaptic transmission, GO:0051966 regulation of synaptic transmission, glutamatergic.) 4. Altered activity-dependent signaling — EB2 phosphorylation is suppressed by NMDA-receptor activity, implicating CDKL5 in activity-dependent circuit tuning. Downstream Akt/mTOR/rpS6 and ERK/MAPK signaling are dysregulated in KO brain.

Protein dysfunction. Missense variants cause kinase-dead or misfolded CDKL5 (loss of catalytic output, sometimes destabilized protein); truncating variants delete catalytic and/or C-terminal regulatory regions. Net effect = loss of enzymatic function, not aggregation.

Molecular pathways / GO. Microtubule cytoskeleton regulation; Rho-GEF (ARHGEF2) signaling; NMDA-receptor / glutamatergic synaptic signaling; Akt-mTOR-rpS6 translational control; MAPK/ERK. Reactome/KEGG anchors: neuronal system, axon guidance, glutamatergic synapse.

Immune involvement. Not a primary feature; CDD is not autoimmune/inflammatory. (Some late-stage neurodegenerative mouse data invoke reactive changes — see below — but this is secondary.)

Tissue-damage mechanism / neurodegenerative angle. Predominantly a neurodevelopmental (wiring) disorder rather than a degenerative one, but aging Cdkl5-KO mice show age-related cognitive/motor decline with increased neuronal senescence and death (MacKay et al. 2021, PMC8139207), suggesting a secondary progressive component. GO:0090398 cellular senescence; GO:0008219 cell death.

Cell types (CL) & subcellular (GO CC). Cortical glutamatergic projection neurons (CL:0000679), GABAergic interneurons (CL:0000617), hippocampal neurons (CL:0002608), Purkinje/cerebellar neurons; cellular compartments — postsynaptic density (GO:0014069), dendrite (GO:0030425), axon (GO:0030424), microtubule (GO:0005874), cytoplasm and nucleus (CDKL5 shuttles; GO:0005634).

Molecular profiling. Transcriptomic/proteomic work in KO mouse brain and patient iPSC-neurons/cortical organoids shows dysregulated synaptic and cytoskeletal gene programs and reduced substrate phosphorylation; CDD cortical organoids display neuronal-maturation and network-activity deficits (frontier gene-therapy organoid work, 2025). CRISPR/knockout functional genomics underpins the substrate and cell-type-specific studies. No single validated fluid transcriptomic/metabolomic biomarker exists yet.

Upstream vs downstream summary: CDKL5 LoF (upstream trigger) → failed phosphorylation of MAP1S/EB2/ARHGEF2 and synaptic substrates → microtubule/dendrite/synapse defects + GABAergic E-I imbalance → cortical circuit hyperexcitability and maldevelopment → seizures, developmental impairment, CVI (downstream clinical manifestations).

7. Anatomical Structures Affected

Organ / system level. - Central nervous system — primary target. UBERON:0000955 (brain), UBERON:0001851 (cerebral cortex), UBERON:0002037 (cerebellum), UBERON:0001954 (hippocampus/Ammon's horn). Cortex and hippocampus dominate the epilepsy/cognitive phenotype; cerebellum contributes to tone/coordination. - Visual pathway / occipital cortex — CVI is cortical, so the lesion is in UBERON:0004128 (visual cortex) / posterior visual pathways, not the eye itself (eyes are structurally normal). UBERON:0000970 (eye) involved only functionally (gaze, tracking). - Secondary system involvement: gastrointestinal tract (UBERON:0000160 intestine — constipation/dysmotility, reflux), musculoskeletal (UBERON:0001434 skeletal system — scoliosis, hip dysplasia, low bone density from immobility), autonomic/respiratory control (brainstem-mediated breathing/temperature dysregulation).

Tissue & cell level. Neural tissue — cortical pyramidal (glutamatergic) neurons, cortical/hippocampal GABAergic interneurons, cerebellar neurons; glia secondarily. CVI reflects dysfunction of visual-cortical neurons and their networks.

Subcellular. Neuronal microtubule cytoskeleton, dendrites and dendritic spines, axons/growth cones, excitatory postsynaptic density; CDKL5 localizes to cytoplasm and nucleus (shuttling).

Localization / lateralization. Bilateral, diffuse CNS involvement (generalized/multifocal epilepsy, global developmental impairment). Not a focal/lateralized lesion, though individual seizures may have focal onset. Structural MRI is often normal or shows nonspecific findings (mild cortical/cerebellar atrophy, thin corpus callosum, or delayed myelination in a subset) — CDD is largely a "microstructural/functional" rather than gross-malformation disorder.

8. Temporal Development

Onset. Early infantile. Seizures typically begin in the first 2–3 months (median ~6 weeks; can be first days–weeks of life). Onset pattern is subacute–chronic — seizures emerge, developmental impairment is apparent essentially from the start (not a post-onset regression).

Progression / disease course. A frequently described three-stage epilepsy trajectory: 1. Stage 1 (early): onset of tonic/spasm seizures in infancy, often with initially normal or near-normal interictal EEG. 2. Stage 2 ("honeymoon"): a period of partial seizure improvement/remission in a subset (weeks–months). 3. Stage 3 (later): refractory, multifocal epilepsy with epileptic spasms/tonic seizures and hypsarrhythmia-like or multifocal EEG; the mixed, drug-resistant chronic phase.

Developmental course is static-to-slowly-progressive impairment — milestones are severely delayed and often never attained; there is no true regression as in classic Rett, though some plateau or mild loss of skills can occur, especially with heavy seizure burden. Emerging natural-history-into-adulthood data (medRxiv 2025) describe persistent severe disability, ongoing epilepsy in most, and added adult comorbidities (scoliosis, osteoporosis, dysautonomia).

Disease duration. Chronic, lifelong. Not self-limited.

Remission patterns. True seizure freedom is uncommon and usually not durable; partial, treatment-associated reduction is the realistic goal. The stage-2 "honeymoon" is a spontaneous partial remission in some.

Critical periods. The early postnatal window (when CDKL5 normally peaks and drives synaptogenesis/dendritic maturation) is the presumed window of both maximal vulnerability and maximal therapeutic opportunity — a key rationale for pushing gene/protein-replacement therapy as early as possible.

9. Inheritance and Population

Epidemiology. - Incidence ~1:40,000–1:60,000 live births. A Scottish study estimated ~2.36 per 100,000 livebirths and a birth prevalence around 1/42,400. CDD is among the most common monogenic causes of early-life epilepsy / infantile epileptic encephalopathy. - Prevalence: rare (Orphanet class). For a dismech Prevalence record: measure_type: BIRTH_PREVALENCE, prevalence_class: BAND_1_9_PER_100000, rate_per_100000 ≈ 2.0 (from the ~1:42,400–1:60,000 range), with notes capturing the 1:40,000–1:60,000 verbatim source phrasing.

Inheritance (genetic). - X-linked (HP:0001417), functionally X-linked dominant in expression (HP:0001423). Bind inheritance_term to HP:0001423 (X-linked dominant) or HP:0001417 as appropriate. - >90–95% de novo. Familial recurrence is rare and occurs through parental germline mosaicism (HP:0001470 sex-limited/gonadal mosaicism concept) or inheritance from a mildly-affected/carrier mother. - Penetrance: effectively complete for a bona fide LoF variant (with severity modulated by X-inactivation/mosaicism). - Expressivity: variable, partly genotype-determined (see §4), strongly modulated by mosaicism and X-inactivation. - Genetic anticipation: not applicable (not a repeat-expansion disorder). - Founder effects / consanguinity: none relevant (de novo dominant X-linked, not recessive). - Carrier frequency: not a carrier-screening disorder in the classic recessive sense; recurrence risk counseling centers on germline mosaicism (empirically low but non-zero, ~1% quoted).

Population demographics. - Sex ratio: ascertained ~12:1 female:male (females far more commonly diagnosed; affected males are under-ascertained and often severe or embryonic-lethal at the severe end, with mosaic males milder). - Geographic distribution: panethnic, worldwide, no endemic clustering; reported across all studied populations (US, European, Italian, Slovak, Chinese, etc.). - Variant-specific geography: no strong founder/geographic variant clustering — de novo origin scatters variants across populations. - Age distribution: presents in infancy; the prevalent population skews pediatric but a growing adult cohort exists as survival is generally into adulthood.

10. Diagnostics

Genetic testing is definitive. Diagnosis = identification of a pathogenic/likely-pathogenic CDKL5 variant. - First-line: multigene epilepsy/DEE panel or exome/genome sequencing (WES/WGS) — high yield in early-onset epileptic encephalopathy; CDKL5 is on all standard early-infantile epilepsy panels. - Single-gene CDKL5 sequencing when clinically targeted. - Chromosomal microarray (CMA) and MLPA/del-dup analysis to catch large deletions/duplications missed by sequencing; karyotype/FISH historically caught the X-autosome translocations. - Not a mitochondrial-DNA or repeat-expansion disorder — those tests are not indicated. - GTR/ClinGen list clinical CDKL5 tests; a ClinGen VCEP curates variant pathogenicity.

Clinical diagnostic criteria. Olson et al. 2019 minimal criteria (PMID:30928302): (1) a pathogenic CDKL5 variant, plus supporting clinical features — severe global psychomotor impairment and epilepsy onset in the first year of life (typically first 3 months). The 2022 International Consensus Recommendations (Amin/Leonard et al., PMC9251467) standardize assessment and management.

Supporting (non-genetic) tests. - EEG (electrophysiology): often normal early, evolving to multifocal epileptiform discharges, hypsarrhythmia-like patterns, or attenuation; documents the epileptic encephalopathy but is not specific. - Visual electrophysiology: pattern-reversal VEP and structured CVI assessment (used both diagnostically and as an emerging outcome measure). - Brain MRI: usually normal or nonspecific (mild atrophy, thin corpus callosum, delayed myelination) — used to exclude structural/other causes. - Metabolic workup / biomarkers: no specific fluid biomarker; metabolic labs are normal and serve to exclude metabolic epilepsies in the differential.

Differential diagnosis. Rett syndrome (MECP2) and FOXG1 disorder (the "Rett spectrum"); other early-infantile DEEs — STXBP1, KCNQ2, SCN2A/SCN8A, ARX, SPTAN1, PCDH19; Ohtahara syndrome and West syndrome (infantile spasms) as syndromic descriptions that CDD can present as; pyridoxine-dependent and other metabolic/vitamin-responsive epilepsies (important to exclude because treatable). Distinguishing feature: very early seizures with developmental impairment from the outset + CVI + a CDKL5 variant.

Screening. CDD is not currently on newborn screening panels (no established presymptomatic intervention yet — though this may change if gene/protein therapies mature). Cascade/carrier screening is limited to the germline-mosaicism recurrence-risk scenario. Prenatal/PGT is available for families with a known variant (mainly recurrence via mosaicism).

11. Outcome / Prognosis

Survival / mortality. Most individuals survive into adulthood; CDD is not typically rapidly fatal, but there is elevated mortality vs the general population, including risk of SUDEP (sudden unexpected death in epilepsy), aspiration/respiratory complications, and status epilepticus. Precise life-expectancy figures are not well established; adult cohorts are only now being characterized.

Morbidity / function. Severe, lifelong disability is the norm: most are non-verbal, most do not achieve independent ambulation (~25% of girls walk, fewer boys), and essentially all require full support for daily living. High morbidity from refractory seizures, CVI, GI dysfunction, scoliosis, osteoporosis/fractures, and sleep/autonomic problems.

Disease course / complications. Refractory epilepsy (incl. status epilepticus), aspiration pneumonia and feeding failure (often → gastrostomy), progressive scoliosis and hip dysplasia, osteopenia/fractures, dysautonomia, and (in aging cohorts) possible neurodegenerative decline.

Prognostic factors. Genotype (catalytic-domain missense and far-C-terminal truncation = worse; mosaicism and certain milder truncations = better), seizure burden/refractoriness, degree of CVI (correlates with developmental achievement), and early developmental attainment. No validated molecular prognostic biomarker yet; vision (VEP/CVI status) and disease-specific developmental scores are the practical prognostic/outcome tools.

12. Treatment

There is no cure; management is symptomatic and multidisciplinary (seizure control, developmental/rehab support, and complication management), with disease-modifying gene/protein therapies in preclinical–early development.

Pharmacotherapy — seizures (MAXO:0000058-family antiepileptic drug therapy; anchor NCIT:C15986 Pharmacotherapy + CHEBI/NCIT therapeutic_agent). - Ganaxolone (ZTALMY) — the flagship, FDA-approved (March 18, 2022) specifically for seizures associated with CDD in patients ≥2 years (label later expanded younger). A neuroactive steroid, positive allosteric modulator of GABA_A receptors (synaptic and extrasynaptic), oral suspension TID. Approval based on the Phase 3 Marigold trial (Pestana Knight et al., Lancet Neurol 2022, PMID:35429480): median 30.7% reduction in 28-day major motor seizure frequency vs 6.9% placebo; open-label extension showed ~49.6% median reduction at ≥12 months. therapeutic_agent: ganaxolone (CHEBI:31642 / NCIT term); consider therapeutic_modality note as small-molecule GABA_A PAM. First drug approved specifically for CDD. - Broad-spectrum AEDs used empirically (variable, often partial response): valproate, clobazam/benzodiazepines, vigabatrin (esp. for spasms), levetiracetam, lamotrigine, topiramate, felbamate, corticosteroids/ACTH (for infantile spasms), cannabidiol (Epidiolex) and fenfluramine (used off-label / in trials for DEEs including CDD). - Ketogenic diet (MAXO:0000088 dietary intervention) — used for refractory seizures with reported benefit in a subset.

Supportive / rehabilitative (broadly applicable, high-value). - Physical, occupational, and speech/AAC therapy (MAXO:0000011 physical therapy; NCIT:C15315 Rehabilitation) — mobility, contracture prevention, communication devices. - Vision/CVI intervention and low-vision support. - GI/nutrition management (MAXO:0000088) — reflux/constipation treatment, gastrostomy feeding when needed. - Orthopedic care (MAXO:0000004 / NCIT:C16186) — scoliosis bracing/surgery, hip surveillance; bone-health management (vitamin D, bisphosphonates for osteoporosis). - Sleep and autonomic management; supportive/palliative care (MAXO:0000950). - Genetic counseling (MAXO:0000079) — recurrence-risk counseling centered on germline mosaicism.

Advanced / disease-modifying therapeutics (investigational). - AAV gene replacement therapy — e.g., AAV9.Synapsin.hCDKL5 delivering CDKL5 to neurons; preclinical proof-of-concept in KO mice (Molecular Therapy 2024, PMID:39033321). - Cell-penetrating "cross-correction" protein-replacement gene therapy — Igk-TATk-CDKL5 fusion (secretable, TAT-domain cell-penetrating CDKL5) improves brain-wide distribution and efficacy in mosaic KO mice and in CDD patient-derived cortical organoids (Neurotherapeutics 2025; Frontiers Bioeng 2025) — addresses the mosaicism challenge of X-linked delivery. - Downstream/mechanistic approaches — targeting NMDA-receptor hyperfunction (given the GABAergic-interneuron E/I-imbalance data), IGF-1/mTOR-axis modulation, and other synaptic strategies are under study.

Treatment strategy. Seizure-focused algorithm (ganaxolone now a first-in-class option; combine with broad-spectrum AEDs / ketogenic diet per refractoriness) layered on comprehensive multidisciplinary supportive care per the 2022 International Consensus Recommendations. Personalized/genotype-guided care is aspirational — the near-term precision play is early gene/protein replacement timed to the critical developmental window.

Pharmacogenomics: no CDD-specific PGx guidance; standard AED metabolism considerations (e.g., CYP-mediated) apply generically.

13. Prevention

Primary prevention: not preventable — CDD arises from de novo genetic variants; no vaccine, exposure, or lifestyle modification prevents it. The realistic reproductive-prevention avenue for at-risk families (prior affected child = germline-mosaicism recurrence risk) is prenatal diagnosis or preimplantation genetic testing for the known variant, alongside genetic counseling (NSGC/ACMG framework).
Secondary prevention (early detection): early genetic diagnosis of infants with early-onset epilepsy enables early symptomatic management and trial access; not on newborn screening currently (no presymptomatic treatment yet — a target if gene therapy matures).
Tertiary prevention (complication avoidance): the practical core — SUDEP-risk reduction via seizure control, aspiration/nutrition management, scoliosis and hip surveillance, bone-health monitoring (fracture prevention), sleep/autonomic care, and proactive multidisciplinary follow-up per consensus guidelines.
Immunization / public-health / environmental / prophylaxis: not applicable to a monogenic non-infectious disorder (routine childhood vaccination is still recommended as general pediatric care).

14. Other Species / Natural Disease

Taxonomy / orthologs. CDKL5 is conserved across vertebrates. Mouse Cdkl5 (NCBITaxon:10090; MGI gene), rat Cdkl5 (NCBITaxon:10116), zebrafish cdkl5 (NCBITaxon:7955) orthologs all exist and are used experimentally. Human gene NCBI Gene ID 6792.
Naturally occurring disease in other species. No well-characterized spontaneous CDKL5 disease in companion animals or wildlife is documented in OMIA; CDD in non-human animals is essentially engineered (knockout/knock-in), not natural. So no meaningful VBO breed association or veterinary natural-disease entry.
Comparative biology. Mouse models recapitulate substantial parts of the human phenotype (see §15), supporting evolutionary conservation of CDKL5's neurodevelopmental role and its substrate biology (the MAP1S/EB2/ARHGEF2 phospho-events are conserved and reduced in human patient neurons). A notable cross-species divergence: the seizure phenotype is milder/less consistent in mice than in humans — a translational caveat (candidate HUMAN_MODEL_MISMATCH discussion in a dismech entry).
Transmission / zoonosis: not applicable (non-infectious, genetic).

15. Model Organisms

Mouse (primary model). Constitutive Cdkl5-knockout mice (Wang et al. 2012; Amendola et al. 2014, PLoS One, PMID:24838000 "Mapping pathological phenotypes in a mouse model of CDKL5 disorder") recapitulate: - limb clasping, hypoactivity, abnormal eye tracking/visual responses (decreased VEPs), autistic-like behaviors, motor-coordination and memory deficits, altered EEG responses to convulsants, reduced dendritic arborization of cortical neurons, and Akt/rpS6 signaling alterations. - Heterozygous female Cdkl5⁺/⁻ mice (the genotype-matched model for the female-predominant human disorder) reliably show autistic-like behaviors, motor/memory deficits, and breathing abnormalities (PMC5994305) — a valuable, translationally relevant model. - Knock-in patient-variant models, e.g., the E364X knock-in (PMC11584566) and R59X, model specific truncations for genotype–phenotype and therapy testing. - Conditional/cell-type-specific KO: GABAergic-neuron-restricted deletion produces autistic-like phenotypes with glutamatergic hyperexcitability and increased NMDA receptors (Tang et al. 2019) — dissecting the interneuron contribution. - Aging KO mice show progressive cognitive/motor decline with neuronal senescence and death (PMC8139207).

Model limitations. The epilepsy phenotype is under-recapitulated in mice (spontaneous seizures are mild/inconsistent), limiting the KO as a seizure-efficacy model — a key human-model mismatch. Mouse brains also lack some human-specific cortical features.

Other systems. - Zebrafish cdkl5 morphants/mutants — neurodevelopmental and behavioral readouts, useful for higher-throughput screening. - Patient iPSC-derived neurons and cortical organoids — the most human-relevant in vitro systems; show reduced substrate phosphorylation, neuronal-maturation and network-activity deficits, and are the testbed for cross-correction protein/gene therapy (Frontiers Bioeng 2025). - Cellular/biochemical: heterologous kinase-activity assays for variant functional classification.

Applications. Substrate/mechanism discovery, E/I-imbalance and circuit studies, natural-history/aging modeling, and — increasingly — gene- and protein-replacement therapy efficacy/biodistribution testing (AAV9-hCDKL5, Igk-TATk-CDKL5).

Resources. MGI (mouse), RGD (rat), ZFIN (zebrafish), IMPC/IMSR for KO alleles, Cellosaurus for iPSC lines; the International CDKL5 Disorder Database (ICDD) and the Loulou Foundation / IFCR research infrastructures anchor the human/translational side.

Key Citations (PMID-anchored, for evidence items)

Claim area	Reference	PMID / ID
Clinical review (features, onset, kinase role)	Leonard, Downs, Benke et al., Lancet Neurol 2022	PMID:35483386
Ganaxolone Phase 3 Marigold trial	Pestana Knight et al., Lancet Neurol 2022;21:417-427	PMID:35429480
CDKL5 substrates / microtubule dynamics	Baltussen et al., EMBO J 2018	PMID:30266824
Interneuron NMDAR / autistic-like features	Tang et al., Nat Commun 2019	s41467-019-10689-w
Mouse model pathological phenotypes	Amendola et al., PLoS One 2014	PMID:24838000
First gene implication (X translocation)	Kalscheuer et al., Am J Hum Genet 2003	PMID:14508708
CDD as independent entity (registry)	Fehr et al., 2013	PMID:23443029
Diagnostic criteria	Olson et al., 2019	PMID:30928302
CVI as outcome measure	Olson et al., 2021	PMID:34028805 / 34547934
Aging KO neurodegeneration/senescence	MacKay et al., 2021	PMC8139207
"20 years lessons learned" review	2024	PMID:38411242
Preclinical AAV gene replacement	2024 (Mol Ther)	PMID:39033321
International consensus recommendations	Amin/Leonard et al., 2022	PMC9251467
GeneReviews	CDKL5 Deficiency Disorder	NBK602610

dismech curation caveats (per project SOP): every snippet above must be re-verified as an exact substring of the fetched abstract via just fetch-reference PMID:XXXX + just validate-references before it goes into YAML — I pulled these from search summaries and one PMC fetch, so treat them as leads, not ground truth. Anchor the entry on MONDO:0100039 (gene-level CDD), keep MONDO:0010396/OMIM:300672 as the DEE2 phenotype xref, gene hgnc:11411 (lowercase, Xp22.13). Watch the two HUMAN_MODEL_MISMATCH flags — (1) mouse seizure phenotype under-recapitulates human epilepsy, (2) organoid therapy data not yet confirmed in human tissue — those are worth discussions blocks rather than hard evidence claims.

Sources: - GeneReviews: CDKL5 Deficiency Disorder (NBK602610) - Leonard et al. 2022, Lancet Neurol clinical review (PMC9788833) - Pestana Knight et al. 2022, Marigold trial (PMID:35429480) - Baltussen et al. 2018, CDKL5 substrates (PMC6293278) - Tang et al. 2019, NMDAR/autistic-like features (Nat Commun) - Amendola et al. 2014, mouse model (PMC4023934) - International Consensus Recommendations 2022 (PMC9251467) - Cortical/Cerebral Visual Impairment in CDD (PMC8825365) - Preclinical AAV gene replacement (PMID:39033321) - Igk-TATk-CDKL5 cross-correction gene therapy (PMC12664459) - OMIM #300672 DEE2 - Orphanet: CDKL5-deficiency disorder (ORPHA:505652) - ZTALMY (ganaxolone) FDA approval — Marinus - MedlinePlus Genetics: CDKL5 deficiency disorder - 20 Years Lessons Learned (PMID:38411242)

Ask OpenScientist

OpenScientist Report

Classifications

Mappings

Inheritance

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Diagnosis

Prevalence

Differential Diagnoses

Related Datasets

Clinical Trials

Experimental Models

Animal Models

Source YAML

References & Deep Research

References

Deep Research

CDKL5 Deficiency Disorder — Comprehensive Research Report

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic / Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome / Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Key Citations (PMID-anchored, for evidence items)